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Abstract 
Cancer cachexia is responsible for one third of cancer-related deaths and 
contributes to the death of many others. More than 80% of cancer patients are 
cachectic towards the end of life. Despite intensive research, the mechanisms of 
cancer cachexia are still poorly understood. It is our hypothesis that identification of 
early changes in gene expression in cachexia will lead to an improved 
understanding of the mechanism that trigger this important problem In cancer 
patients. 
Thus, to shed light on the mechanisms involved in the major cachexia target tissues, 
we investigated the entire transcriptome in muscle and fat to identify altered 
expression of genes in cancer patients with and without cachexia. 
Samples of rectus abdominis muscle and visceral fat were collected at surgery from 
patients exhibiting 5-10% weight loss prior to surgery, compared with stable-weight 
patients. Analysis of all expressed genes was carried out using next generation 
sequencing (iliumina HiSeq 2500). Also, selected differentially expressed genes 
were confirmed using real time RT-PCR. 
In muscle, 30 genes showed highly significant changes in expression (25 
downregulated and 5 upregulated: P<0.0005 - P<0.00001, FOR 0.2). Analysis of the 
25 downregulated genes involved included 7 that are involved with metabolism (5 of 
which are mitochondrial); 4 with signaling; 4 with ubiquitination; and 3 with 
intracellular trafficking. There was marked downregulation of multiple genes involved 
in glycogen metabolism which correlates with the lack of glycogen, muscle 
weakness, and fatigue; characteristic of cachexia. The 5 upregulated genes include 
2 involved with calcium signaling and 2 with cell matrix interactions. Expression of 
genes previously thought to be important in cachexia, including several inflammatory 
cytokines, was not significantly different. FBX032, which encodes atrogin-1, 
upregulated in an in vitro cachexia model, was actually downregulated. No 
transcripts for the dermicidin gene, which contains the sequence that codes for the 
backbone peptide of proteolysis-inducing factor, were detected. Expression of 
myostatin was significantly decreased as was its receptor (ACVR2B), possibly 
reflecting end organ adaptation to tumor produced myostatin. 
vii 
In visceral fat, expression of 6 genes were downregulated and 10 upregulated with 
high statistical significance (P<0.001-0 0002). Several of these encode metabolic 
enzymes. Of genes In fat previously implicated in cachexia, such as hormone 
sensitive lipase and adipose tissue triglyceride lipase, were unchanged. In contrast, 
leptin was significantly downregulated and the zinc-a-2-glycoprotein (lipid mobilizing 
factor) was significantly upregulated as expected. 
These studies confirmed that for a multifactorial condition, genome wide 
transcriptome analysis is the method of choice to explore the disease complexity. 
They explain some documented evidence in cachexia pathogenesis, highlight 
ambiguous data from animal models, and reveal unexpected changes in gene 
expression that underlie the pathophysiology of the cachectic state in cancer. These 
results bring reliable, representable, and consistent data from the clinic and back to 
the bench with more focused insights to be investigated and verified. 
Keywords: Cancer cachexia, wasting, skeletal muscle, adipose tissue, RNA 
sequencing, real-time RT-PCR. 
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1.1 Overview 
Chapter 1: Introduction 
1.1.1 H isto ry, E tymo logy, a n d  Defi n ition 
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Cachexia is known for centuries. The earl iest l ink of cachexia to chronicity of a i lment 
dates back 2400 years to the classical Greece and the school of medicine of 
H ippocrates [ 1 ] . I t was described by H ippocrates as: 
"The flesh is  consumed and becomes water, . . .  the abdomen fi l l s  with 
water, the feet and legs swe l l ,  the shoulders, clavicles, chest, and 
th ighs melt away . . .  The i l lness is fataL" [ 1 ] . 
H ippocrates,  460-377 BC 
The first t ime cachexia was used to describe involuntary weight loss in  the context of 
chronic i l lness is u nknown. However, "card iac" cachexia was fi rst documented by 
Cha rles Mauriac, a French physician ,  back in  1 860 when it was described as a :  
"commonly observed secondary phenomenon i n  pat ients affected with 
diseases of the heart . . .  a pecu l iar  state of cachexia wh ich is . . .  
convent ional ly designated card iac cachexia" [2] .  
Cachexia was a lso acknowledged by Herta M u l ler ,  a 2009 Nobel Prize winner for 
l iterature ,  who wrote in  her novel "Atemschaukel" ,  which was trans lated to Engl ish 
"The H unger Angel"[3] as: 
" . . .  once the flesh has d isappeared from the body, carry ing the bones 
becomes a burden ;  it draws you down i nto the earth" 
Mu l ler ,  2009 
Cachexia is a term orig i nat ing from the G reek " kak6s" and "hexis";  meaning "bad 
condit ion or appearance" [2] . Cachexia or the "Wasting Syndrome" is evident in  
many d iseases and condit ions such as :  cancer, chronic heart fa i l u re ,  chronic k idney 
d isease, chronic obstruct ive pu lmonary d isease , cyst ic f ibrosis ,  rheumatoid arthrit is ,  
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m ult iple sclerosis ,  Alzheimer's disease, infectious d iseases such as acquired 
immune deficiency syndrome,  and tubercu losis, fami l ia l  amyloid polyneuropathy, 
gadol in ium poison ing ,  mercury poison ing ,  hormonal deficiency, and many other 
chronic i l lnesses [4J . 
Defin it ion of cancer cachexia has changed several t imes in  the last few years 
despite the slow-paced understanding of its etiopathogenesis. U p  t i l l  2008, cachexia 
had no operational defin it ion that can adequately and reasonably val idate i t  in  terms 
of its existence and pathological processes. This had h indered ,  for years, properly 
designed a nd conducted cl in ica l and basic sciences research . Thus ,  many efforts 
were taken to reach a consensus defin it ion for the syndrome [5-7]. However, many 
cachexia definit ions share two main themes; weight  loss and i nflammation [8J  with 
many other associated symptoms: anorex ia ,  fatigue,  insu l in  resistance, and 
increased m uscle prote in breakdown . Cachexia is d ifferent from starvat ion,  age-
re lated loss of muscle mass, primary depression ,malabsorption ,  hyperthyroid ism, 
and a l l  other metabol ic  d iseases and condit ions. The latest defin it ion of cancer 
cachexia states that i t  is a:  
"mult ifactoria l  syndrome characterized by an  ongoing loss of skeleta l 
m uscle mass (with or  without loss of fat mass) that can not be fu l ly 
reversed by convent iona l  nutrit ional  support and leads to progressive 
funct ional impa i rment" [7]. 
None of the defin it ions of cachexia suggested so far are f inal. However, the most 
recent systemic review ind icated that in c l in ica l  pract ice ,  muscle wasti ng is assumed 
in  re lation to weight l oss i n  cancer patients, provided the patients have no fl u id 
retention or a large tumor mass [9] .  Keeping in  mind that th is thesis wishes to 
ident ify mechan isms of early cachexia, we operational ly defi ned early cancer 
cachexia to gu ide our  patients' selection as: cancer patients with documented or 
self-reported weight loss of 5- 1 0% of tota l body weight in  the past 6 months. 
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1 . 1 . 2 E p id emiology 
Cachexia is  one of the most ser ious and h igh ly prevalent, however, underest imated 
and under-d iagnosed syndrome. Cachexia is a major unmet health chal lenge . 
Despite of the scarce resources about the extent of cachexia ,  it is bel ieved that the 
overa l l  prevalence of cachexia is g rowing worldwide. I t  is estimated to constitute 
around 1 % of the total  populat ion in the developed world [4] and a possibly 
comparable number in the rest of the world .  Cachexia prevalence is general ly high 
and variable amongst d ifferent patholog ical condit ions .  For example, it ranges from 
5% to 1 5% in congestive heart fa i lure and chronic obstructive pulmonary d isease 
[4] , whi le it reaches 60% to 80% in advanced cancer [4, 1 0] .  Data about preva lence 
of cachexia in the cancer patients varies considerably depending on the cancer type 
and stage,  and also d iffered depending on the criteria used for its d iagnosis [ 1 1 ] . 
The incidence of cachexia a mong cancer patients is very h igh ,  but it is dependent 
on tumor type and the stage of the disease. For example, the incidence in  patients 
with gastric or pancreatic cancer is more than 80%, whi le i t  is around 50% in lung,  
prostate or colon cancer patients, and approximate ly 40% of patients with breast 
cancer or some leukemias [ 1 2 , 1 3] .  However, tumor type was not found to have a 
d i rect corre lation to extent of cachexia .  For example ,  some lymphomas can weigh 
severa l k i lograms and cause no cachexia, whi le pancreatic tumors as smal l  as <2 
cm3and weighing one or two grams may cause profound cachexia .  
1 . 1 . 3 C l ass ifi cation of C ancer Cachexia 
Cancer cachexia is classif ied to three cl in ical stages; precachexia ,  cachexia, and 
refractory cachexia. Each of these stages has d isti nguish ing c l in ical features agreed 
on via consensus panel of experts in the f ield [7] . Stages are d istinguished primari ly 
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on body mass index (8M I) as an Ind ication of body energy stores In addit ion to the 
genera l  overa l l  condit ion. I n  precachexia ,  patients demonstrate substantial 
involuntary weight loss ( i .e .  :55%) in addit ion to early cl in ical and metabol ic signs 
(e.g. anorexia) .  In cachexia stage,  weight loss exceeds 5% of stable body weight 
over the past 6 months, or  a body mass index (8M I )  less than 20 kg/m2 and ongoing 
weight loss of more than 2%. On the other hand , refractory cachexia is  a stage 
reached at the very advanced cancer when patients are c l in ical ly "term ina l" ( l ife 
expectancy of less than 3 months) and it is d istinguished by the presence of rapidly 
progressive cancer unresponsive to antineoplastic therapy, active catabol ism, 
and/or the presence of factors that render active management of weight-loss no 
longer possible or  appropriate [7] .  In refractory cachexia,  patients a lso demonstrate 
low performance status.  Whi le there are three identif iable stages of cachexia, 
patients wi l l  not necessari ly exhibit the a l l  three phases. 
The r isk of developing cachexia ,  the stage of cachexia ,  and the rate of progression 
of cachexia varies depending on the cancer type and stage, the presence of 
systemic inf lammation, food i ntake, and response to ant icancer therapy [7] .  Cancer 
cachexia is  further compl icated by anticancer treatment (e .g .  chemotherapy and 
radiotherapy) which themselves induce anorexia ,  and malabsorption that exacerbate 
the effects of the cancer itself. Also, obstruction of the gastrointest ina l  t ract by the 
tumor wi l l  a lso cause anorexia ,  nausea and vomit ing and reduct ion in d igestion and 
absorpt ion .  Al l  these can even fu rther  compl icate cachexia .  
1 . 1 .4 S i g n i ficance of Wei g h t  Loss i n  Ca ncer Patients 
Cachexia is known since a ncient Greek t imes as a label  for 'signummal iomin is' 
( indicating end stage and poor q ua l ity of l ife) in various ,  mostly fata l ,  d iseases. 
Weight loss (the most prominent feature of cachexia) is a positive risk factor for 
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death for cancer patients. Its presence is a lways associated with h igh-mortality and 
d im in ish ing qual ity of l ife [ 1 4] .  Morta l ity rates of patients with cachexia are h ighest in 
cancer patients . More than 30% of cancer patients d ie  due to cachexia and i t  
reaches around 80% in  some cancer cases, and more than 50% of patients with 
cancer die with cachexia being present [4, 1 5] .  In cancer patients, death normal ly 
happens when weight loss exceeds 30% of total body weight [ 1 6]. Whi le in 
starvation ,  weight loss exceeding 40% of body weight usual ly leads to death [ 1 7] .  
Consider ing cancer  as a d isease of o ld age ,  weight loss is a wel l -documented factor 
for a s ign ificant increasing mortal ity among elderly patients whether they are 
d ischarged home [ 1 8] or residing at nursing homes [ 1 9] .  
On the other hand ,  weight loss a s  a primary measure of cachexia is  important d u e  to 
u navai labi l ity of data on body composit ion .  Atta inment and accurate measurement 
of basel ine data on body composit ion is  cl in ica l ly  hard to perform and isn 't yet 
considered as an acceptable cl in ical standard .  Also, changes in body weight can be 
accurately and easi ly assessed and fol lowed up. 
On the other hand, however, weight loss is sti l l  debated as a mono measure of 
diagnosing the cachect ic state . Weight loss a lone cannot fu l ly expla in  the associated 
physical symptoms that accompany cachexia .  Nevertheless, the prepondera nce of 
evidence is in favor for the importance of weight loss as the main c l in ical 
manifestat ion of cachexia and that i t  is  highly predictive of morbid ity and mortal ity in 
cachectic patients. 
1 . 1 . 5 D iagnos ing Cancer Cachexia  
Cancer cachexia is  ra rely screened a nd a lways under-diagnosed due to its 
complexity in nature ,  and the lack of general ly acceptable defin it ion or d iagnostic 
gu ide l ines.  However, c l in ical ly, m ult iple definit ions of cachexia been ut i l ized to 
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examine the presence or absence of cachectic state in  cancer patients. Fox et . a l .  
(2009) conducted a study to  est imate the cachect ic state amongst cancer patients 
based on four different cachexia defin it ions;  ICO-9 d iagnostic code of 799.4 
(cachexia) ,  ICO-9 d iagnosis of cachexia ,  anorexia ,  abnormal  weight loss, or feedi ng 
d ifficu lt ies, prescription for megestro l acetate, oxandrolone, somatropin ,  or 
dronabinol ,  and �5% weight loss in  patients with d ifferent mal ignancies [ 1 1 ] . The 
eye opening f indings of the study was the h uge d iscrepancy in  cachexia prevalence 
in cancer patients under each of these categories depending u pon the employed 
defin it ion For example,  in breast cancer patients, prevalence of cachexia was 8 .8%, 
1 3 .9%,  20.5%, and 3 1 . 3% for the fou r  categories respective ly .  That  is around 3 .6  
fo ld i ncrease between the first and the forth defin it ion [ 1 1 ] . Thus ,  un less we 
operat ional ly define cachexia based on more educated ins ig hts about its 
etiopathogenicity, deve loping a specific/sensit ive/accurate d iagnostic measure/s is 
an unatta inable goal .  
The two gold standard measures for d iagnosing cachexia should be computed 
tomography and the magnetic resonance imaging .  The two measures are expensive 
and not used rout inely .  However, s ince cachexia is a t ime-dependent process, it is 
h ighly un l ikely that these methods could be routinely appl ied to the c l in ical d iagnosis 
of cachexia, because of the absence of a basel ine comparison . 
1 . 2 M a nagement of C a ncer Cachexia  
Patients with cancer  cachexia have l im ited treatment options. Current ava i lable 
options basica l ly  treat symptoms of cachexia, such as anorexia ,  and not cachexia 
itself . 
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1 . 2 . 1  N utrit i onal  Treatme nt 
Many attempts were made to reverse cachexia via nutrit ional  management ( i .e .  
entera l ,  parentera l ,  and nutrit ional  supplements) . However, none of  these achieve 
improvement in lean body mass [20] . A meta-ana lysis evaluat ing the effect of 
enteral nutr it ional supplementat ion fa i led to demonstrate any survival benefit in  
cancer patients but  was ab le  to  decrease some post operative ly  risks and to  
reduces the overa l l  hospital stay [2 1 ] . Furthermore, parentera l  n utr it ion was found to  
be associated with net  negat ive consequences in  cancer patients [22] and does not 
a lone affect the overa l l  survival or qual ity of l i fe [23] . 
Supplements tested in  cachexia include m inerals ,  v i tamins,  omega-3fats, prote in­
enriched nutrit ion ,  a nd ant ioxidants [24] .  Omega-3fats ,  have been extensively 
i nvestigated in  cachexia and found to have a min ima l  posit ive effect on weight ,  
appetite and qual ity of l ife in  advanced cancer  patients[25]. Taken together, the 
complex mix of d ifferent mediators involved i n  the pathophysiology of cancer 
cachexia renders nutrit ional  intervention a strategy un l ikely to succeed complete ly ,  
a lthough of course overa l l  n utrit ion needs to be adequate [26] . 
1 . 2 . 2  N o n - P h a rmacologica l  T reatments 
Non-pharmacological treatments inc lude d ifferent measures such as: 
counsel ing/educat ion,  psychotherapeutic intervent ions, and physical tra in ing (or 
therapeut ic exercise) .  Psychotherapeutic interventions such as the creation of a 
pleasant environment for meals ,  encourag ing patients to eat with adequate attention 
to the food preferences of the patient show some promise [27]. The 
pathophysiologic changes in cachexia inc lude:  insu l in  resistance, a decrease in  the 
rate of protei n  synthesis ,  and a systemic inflammatory response. Physical exercise 
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exerts beneficia l documented evidence in  I ncreasing insu l in  sensitivity, prote in  
synthesIs rate , and suppression of  the inflammatory response [28]. However, most 
research has not found a conclusive evidence for its effectiveness [29]. 
1 . 2.3 Drug Thera py 
Many drugs have undergone cl in ical t ria ls that attempt to reverse cachexia .  
Thal idomide was used in  c l in ical tr ia l with advanced pancreatic cancer patients and 
found to be wel l  tolerated and effective at attenuat ing loss of weight ,  arm muscle 
mass and physica l function [30]. Nevertheless, no study has provided information on 
long-term weight ga in  in a larger tria l ,  or in end stage disease, or in advanced 
cachexia. On the other  hand ,  cannabis extract of tetrahydrocannabinol did not result 
in  any d i fferences in  appetite or  qual ity of l i fe in patients with cancer cachexia [31 ] .  
Whi le cannabinoids m a y  increase appetite i n  selected patients, there is not enough 
evidence to support the ir  use. In a systematic review, megestro l ;  an appetite 
stimu lant ,  was found to improve appetite and weight ga in  in cancer cachexia [32] ,  
but  it i ncreased mortal ity without a s ignificant increase of  body-weight [33] .  
Short-term treatment with steroids improved a ppetite and activity in  term inal ly i l l  
cancer pat ients [34] whi le in longer treatment duration did not resu lt in  weight ga in 
[35-37]. On the other hand ,  the long-term use of non-stero ida l  anti- inflammatory 
d rugs showed reduct ion i n  the resti ng energy expenditure and preservat ion of total 
body fat, whi le lean body mass was not i nfl uenced [38] . F ina l ly ,  prokinetics d id not 
improve the nutrit ional  status of patients with cachexia [39] .  
1 .2.4 M u lt imodal  Th erapy 
Considering the mu lt i -factoria l  nature of cancer cachexia pathogenesis,  treating the 
u nderly ing neoplasm that tr igger its in it iat ion is the treatment gold standard .  The 
9 
best way to treat cancer cachexia is to cure the cancer. Anticancer treatment wil l  
not ,  per se , a l leviate cachexia through target ing the metabolic changes and the 
other documented et iologies. Metabolic changes such as reduced energy intake, in 
turn, can be supported by targeting more than one of the contributing factors despite 
the a bsence of properly tested combination therapy in cancer  cachexia. For 
exa m ple ,  combination of megestrol with tetrahydrocannabinol [40] and 
elcosapentaenoic acid [4 1 ]  d id  not provide any benefits compared with megestrol 
a lone but was more effective when combined with ibuprofen [42]. Another large 
study comparing medroxyprogesterone, megestrol acetate, e icosapentaenoic acid, 
L-carnit ine and thal idomide found that the combinat ion of all drugs was superior to 
any of the other treatment arms with s ingle drug treatment leading to increased lean 
body m ass, decreased rest ing energy expenditure and improved appetite [43]. 
Therefore, mu lt imodal therapy for cancer cachexia should be presented as opposed 
to monotherapy.  Also, early pal l iative care should be in itiated to manage the 
ind ividua l  symptoms associated with refractory cachexia and that research in  th is 
domain should be promoted . 
1 .3 Prevention of C a c h e x ia 
Many intervent ion been tested for l ikel i hood to prevent cachexia . Relaxation tra in ing 
with deep a bdominal  breath ing ,  a utosuggest ion , control led tension and relaxation of 
body parts and voluntary image control are some of these tested interventions. 
Relaxation ,  for example ,  was found to have posit ive effects on body weight and 
performance status in  a g roup of cancer patients [44] .  However, th is study did not 
separate the cachect ic from the non-cachect ic patients and its resu lts have not been 
reproduced. 
1 .4 Etiopathogenesis of C a n ce r  Cachexia 
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Cancer cachexia is a mu ltifactor ia l ,  so far, i rrevers ible syndrome. Symptoms of 
cachexia i nvolve loss of muscle, with or without fat, frequently associated with 
anorexia, i nflammation and insu l in  resistance. Cachexia has its un ique pathology 
that sets it un ique compared to starvation .  Cachexia has a preferent ia l  muscle loss 
for an equivalent amount of weight loss compared to starvat ion [45] . In cachexia, the 
visceral protein compartments are preserved [46] . Muscle loss occurs predominantly 
in  ske leta l m uscles rather than visceral muscle [47]. Even more interest ing ly ,  the 
volume of the l iver and other viscera may increase in  cancer cachexia as opposed 
to the decrease observed in  sta rvation [45] . However, the mechanisms of that 
increase are unknown. As in  sepsis, patients with advanced cancer have an 
e levated rate of whole-body tracer fl ux and depressed non-export (structura l )  
hepatic protein  synthesis rate [46] .  Th is brings cance r  cachexia in  proxim ity to 
sepsis. Yet, cancer cachexia develops slowly and is not associated with the 
tremendous increase i n  basal metabol ism due to the surge of d ifferent inflammatory 
cytoki nes in sepsis [48] . 
On the other hand ,  patients with anorexia have the majority of weight lost from fat 
compared to lung cancer  patients, who lose weight from both ,  total body fat and 
skeleta l muscle prote in  mass [49] .  I n  summary ,  the changes in  body composit ion 
seen in  cachexia resemble those found in  infection  and i nju ry rather than those in 
starvat ion .  During prolonged sta rvation ,  ketone bodies produced by fat metabol ism 
in the l iver replace g lucose as an  energy  source for the bra in ,  thus prevent ing loss of 
muscle through g lucogenesis from amino acids. However in  cachexia ,  th is does not 
occur, probably because the e nergy demands on the host are sufficiently h igh to 
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prevent the bu i ldup of acetyl CoA i n  the l iver and Its subsequent conversion to 
acetoacetate and -hydroxybutyrate [50] . 
1 .4. 1 E ne rg y  Bala nce a n d  E ne rg y  Expend itu re 
Body mass is contro l led by the balance between the amount of energy i ntake and 
energy expenditure Therefore, a major  contributor to the cachexia can be attributed 
to the increased energy expenditure .  Since the majority of energy intake is spent on 
the resting energy  expenditure (REE) ,  determ in ing the leve l of REE in  cancer patient 
can be the start ing point to uncover the etiology of cancer cachexia. The rate of REE 
in  cancer patients I S  strongly determi ned by  the  type of  tumor. For  example, patients 
with lung [38] a nd pancreatic [5 1 ]  cancer have an e levated REE ,  whi le gastric and 
colon cancer patients have no increase in  REE [38]. This can, at least in  part, 
expla in  the h igher mortal ity rates of l ung and pancreatic cancer patients. I n  
pancreatic cancer patients, for example ,  t h e  increase i n  REE is proportional with the 
i ncrease in  the acute phase response (APR) [5 1 ] . APR proteins have long been 
known to be a measure of underly ing t issue inj u ry ,  infection , or inflammation . In 
APR, the l iver red irects prote in  synthesis from albumin to acute phase proteins 
(APP) ,  such as C-reactive prote in  (CRP), fibri nogen, serum amyloid A, a-2-
macrog lobu l in ,  and anda1 -antit ryps in .  E levated levels of APP,  in  turn, are correlated 
with shorter surv ival in pancreatic cancer patients [5 1 ] .  The l i nk between the 
development of an  APR and the rate of loss of body mass is a lso establ ished in  l ung 
and gastrointest ina l  cancers [52]. Furthermore, serum leve ls of interleukin6 ( I L-6) 
was found to corre late with level of CRP in patients with non-smal l  ce l l  lung [53]. 
Despite of the above evidence , pancreatic cancer patients were found to have 
reduced total energy expenditure (TEE)  due to a reduction in their  physical activity 
leve l (PAL) [54] .  
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Recently, research on  the  l i nk  between brown adipose t issue ( BAT) and cachexia 
has been brought to the surface. The history of th is l i nk goes back to the study 
which examined autopsy samples of peri-adrenal t issue that showed BAT to be 
present in  80% of cachectic cancer patients, compared with only 1 3% of age 
matched contro ls [55] .  BAT has a wel l-establ ished ro le i n  contro l l ing body 
thermostasis and energy  balance despite its scarcity in adult humans.  
Thermogenesis i n  BAT and i ts possible l ink to cachexia was studied in  the context of 
REE .  Thethermogenic effect of BAT and skeleta l muscle is probably due to the 
function of uncoupl ing prote ins (UCP) .  UCPs are mitochondria l  inner membrane 
proteins that can d iss ipate the proton g radient before it can be used to provide the 
energy for oxidative phosphorylat ion by decreasing the level of coupl ing of 
respiration to ADP phosphorylat ion [56] .  There are five types of UCPs: UCP1  found 
only in BAT, UCP2 found in  most t issues,  UCP3 found on ly i n  BAT and skeletal 
m uscle, UCP4 fou nd in  bra in  tissue, and UCP5 found in bra in ,  testis and others 
[57] .Of these five, U C P 1  is considered to be most important, a lthough UCP3 a lso 
plays an important role in energy balance and l ipid metabol ism .  In a murine model of 
cachexia ,  mRNA expression levels of UCP 1 , but not UCP2 a nd 3, in BAT was 
s ign ificantly elevated over controls [58] . However, expression of UCP2 and 3 were 
Sign ificantly increased in skeleta l m uscle [58]. I n  cachectic cancer patients , UCP3 
expression level in  rectus abdominis muscle was five t imes h igher than controls [59]. 
This increased expression level might be the mechanism by which R E E  is increased 
in skeletal muscles of cachect ic patients. Therefore , the increase in REE is not 
merely the main cause of cachexia. 
Another way of which energy balance can be a cause of cachexia is the "futi le 
energy cycle". This fut i le cycle, a phenomenon termed 'Warburg effect", is used by 
most cancer cel ls to generate ATP.  Warburg effect ut i l ized g lycolysis fol lowed by 
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lact ic acid fermentation in  the cytoso l ,  rather than b y  a comparatively low rate of 
g lycolysis fo l lowed by oxidation of pyruvate in m itochondria  in most normal ce l ls as 
the principal method to generate energy [60] . Mal ig nant cel ls  typica l ly have 
g lycolyt ic rates up to 200 times higher than those of their normal t issues of orig in 
even with the presence of oxygen .Several reasons are attributed to th is 
phenomenon. However, regard less of the possible reasons, the Warburg effect 
resu lts in a net yield of two A TP molecules as opposed to oxidative phosphorylat ion 
that yields a tota l of approximately 30-32 A TP molecules. Thus, the conversion of 
g lucose into lactic acid is  an  energy- inefficient process, which means that g rowth of 
tumors requ i res 40 t imes more g lucose than if it was ful ly oxid ized through the 
tricarboxyl ic  acid cycle .  In order for the lactate to be recycled by l iver, a net of 4 ATP 
molecules are needed.  Hence ,  the Warburg effect resu lts in a negat ive balance of 2 
ATP molecules; which is  another energy inefficient process [6 1 ] . I n  weight losing 
colorecta l cancer patients, the rates of g lucose product ion a nd recycl ing were 
s ign ificant ly h igher than that in controls [62] . Th is complete fut i le p rocess account for 
an  a pproximately addit ional  loss of energy in  cancer  patients of 300 kcallday [63] . 
Regardless of these evidence ,  fast progressing cachexia such that evident in  
pancreatic cancer patients, cannot be attributed merely to th is  futi le cycle .  
Pancreatic tumors are relat ive ly smal l  i n  s ize and requ i re a long period to develop 
which is d isproport iona l  to the degree and i ntensity of weight loss observed i n  these 
patients. 
1 .4.2 A norexia and Cachexia  
Anorexia ,  or loss of  appetite, is one of  the symptoms of cachexia and is common in  
cancer patients. Cancer patients report early satiety. Th is may be the result of  many 
factors such as: the mechan ical obstruct ion of the gastro intest ina l  tract which may 
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h i nder the passage of food , the funct ional abnormal it ies of the gastro intestina l  
mucosa result ing in malabsorpt ion,  or chemical triggers that suppresses appetite 
center in  the bra in .  If anorexia ,  regard less of the cause, is the main reason of weight 
loss In  cancer patients, one should expect a d i rect corre lation between reduced food 
Intake and the degree of weight loss. Surpris ing ly ,  the opposite is true! A large study 
of 297 cancer patients found that weight loss could not be accounted for by a 
d im in ished dietary intake, s ince the absolute amounts of energy intake did not diffe r, 
and the intake per ki logram of body weight was actua l ly  h igher in  the weight-losing 
patients com pared with the weight-stable patients [64] .  
Also, if anorexia is a d i rect and essentia l  etiology for cachexia ,  nutrit ional 
supplementation to compensate for the deficiency in  calor ic i ntake would be 
expected to promptly reverse cachectic state. However, c l in ical  tria ls showed that 
the wasting process in  cancer patients cannot be reversed by al l  means of 
nutnt ional supplementation such as dietary counsel ing [65] , total  parentera l  nutrit ion 
[66] ,  or appetite stimu lants such as cryoheptadine [67] .  or dronabino l .  In addit ion, 
weight ga in due to the tota l parenteral nutrit ion was trans ient and translated into an 
i ncrease i n  fat and water rather than lean body mass [66] .  This effect is not only 
l im ited to weight loss i n  cancer patients, but was also observed in  patients with 
human immunodeficiency virus [68] , and sepsis [69]. However, nutritional  
supplementation i n  pancreatic cancer patients has some survival advantage despite 
of its inabi l ity to reverse body weight loss [70] . These results show that anorexia is  
an  i mportant symptom of cachexia but is not the so le suspect for the loss of body 
mass. 
1.4 .3  Cachexia  a s  a Cata b o l i c  State 
15 
In  the a bsence of stimu l i ,  adu lt muscle mass remains constant with relatively equal 
rates of prote in  synthesis and degradation . However, an  imbalance via depression 
in  protein synthesis, an increase in  protein  degradation , or a combination of both 
should occur for cachexia to develop; research evidence is ava i lable for all the 
possib i l i t ies. For example,  one study suggested that cachexia is primari ly a result of 
a lterat ions in prote in  synthesis rather than protein  degradation [7 1 ] . Other study 
suggested the high protei n  tu rnover rates in patients with hepatocel lu lar  carcinoma 
to be the resu lt of an elevated rate of prote in  breakdown , with oxidation of the 
released amino acids [72] .  However, the majority of studies suggest that both 
processes are occurring s imu ltaneously.  There are three major proteolytic pathways 
responsible for the degradation  of prote ins in skeletal muscle; the lysosomal  system,  
the calc ium-activated system ,  and the ubiquit in-proteasome pathway [73]. 
The lysosomal system includes the acid opt imal  cysteine proteases cathepsins B ,  H ,  
a n d  L as wel l  as t h e  aspartate protease cathepsin D. This system is main ly 
responsible for the degradat ion of extrace l lu lar  prote ins ,  cel l  receptors, endocytosed 
prote ins ,  and phagocytosed bacteria rather than i nfluencing the normal turnover of 
cytosol ic  prote ins [74 , 75] .  This degradation system is accelerated by g lucagon in  
the l iver and the lack of insu l in  or essent ia l  am ino acids [76] . The second 
degradation system is the ATP-independent, calcium-activated , cytosol ic cysteine 
proteases system that are activated by an  i ncrease in  cytosol ic calciu m  which is 
main ly involved i n  t issue i nju ry ,  necrosis ,  and autolysis. These proteases include 
calpains I and I I  [77-79]. The th i rd degradation system is the ATP- and ubiquit in­
dependent proteasome pathway.  The function of the u biqu it in-proteasome pathway 
is to degrade defective prote in  products produced from errors in translat ion or from 
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oxidative stress [80, 8 1 ] . I t  works in  harmony with the calpain system to disassemble 
and degrade m uscle myofi laments [82]. The defective prote in  is targeted by the 
addit ion of mu lt iple u biqu it in molecules and the subsequent recognit ion and 
degradation by the 26S proteasome [83] . Polyubiquit ination of the prote in  is  a 
process that not only tag prote ins for degradation ,  but a lso ensures the specificity of 
the process that is normal ly handled by the proteasome. For polyubiqu it i nation to 
occur, ub iqu it in is activated by an activati ng enzyme (E 1 )  in two steps. F i rstly, an  
intermediate is formed by  A TP hydrolysis connect ing adenosine monophosphate 
(AMP) with the carboxy-termina l  carboxyl g roup of g lycine in ubiquit i n .  Secondly,  a 
th ioester l inkage with a cysteine residue in  E is formed [8 1 ] . Then , the u biquit in 
carr ier protei n  (E2) accepts th is u biqui t in to its active site at a cysteine res idue.  This 
is fol lowed by E2 carrier prote in  recogn iz ing the u biqu it in protein l igase (E3) .  Then, 
the E3 l igase transfers u biqui t in from the E2 th ioester intermediate either to a 
specific ub iqu i t in  b inding site or  to an isopeptide l inkage with some degree of 
substrate specificity [73]. After mu lt i ple rounds of E3 ,  ubiqu it in l igat ion creates a 
polyubiqu it in  cha in on the target prote in .  Once the prote ins are marked with a 
polyubiqu it in  cha in ,  they are degraded i nto ol igopeptides (peptides conta in ing s ix to 
n ine amino acid residues) by the 26S proteasome [84] . These are then degraded by 
the g iant protease tripeptidyl peptidase I I  (TPP I I )  and various aminopept idases. 
TPPI I cleaves peptides generated by the proteasome into tr ipeptides [85]. In normal 
situations ,  th is process is not rate- l im it ing for proteolysis.  However, it i s  important 
because the accumulat ion of abnormal  peptides may be i njurious to the cel l .  
1 .4. 3.1  U b i q u it i n  P roteasome Pathway System a n d  C a c h e x i a  
The ubiq uit in proteasome pathway system is responsible for  the majority of  skeleta l 
muscle prote in  catabol ism [73] and has been extensively reviewed [86] . This 
pathway is activated in  catabol ic states result ing in  m uscle atrophy. Thus, it more 
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l ikely accounts for t h e  advanced proteolysis seen In  wasting conditions such as 
fasting , sepsis, metabol ic acidos is ,  acute d iabetes, weightlessness and cancer 
cachexia [87] .  
In vitro stud ies of atrophying muscles have demonstrated no involvement of the 
lysosomal  proteases or ca lcium-activated proteases systems.  Yet, inh ibit ing ATP 
production decreased the rate of p roteolysis to that of control m uscles i ndicating that 
the ATP-dependent ubiquit in proteasome pathway is primari ly  responsible for 
skeleta l muscle degradation [88, 89] .  
In m ice beari ng the cachexia- inducing MAC 1 6  tumor, both proteasome proteolytic 
act iv ity and TPP I I  act ivity i ncrease in  paral lel with weight loss reaching a maxim um 
at 1 6% weight loss, after which there was a progressive decrease in activity for both 
proteases with increasing weight loss [90] . In other an ima l  models of cancer 
cachexia and in cancer patients, the ubiquit in proteasome pathway found to play the 
predominant ro le i n  the degradat ion of myofibri l lar  prote ins especia l ly in  patients 
with > 1 0% weight loss [9 1 ] . In yoshida ascites hepatoma (YAH)-bearing rats, 
removal of calcium or blocking the calcium-dependent proteolytic system did not 
inh ibit m uscle protein degradat ion , wh i le  inh ibit ion of the lysosomal function reduced 
proteolysis by 1 2% in  muscles [92]. Nevertheless, when A TP production was 
inh ibited, proteolysis in muscles was s im i lar  to that of controls [92]. The same study 
showed a s ign ificant increase in  ubiqu i t in  m RNA (590-880%),  the level of ubiqu i t in­
conjugated prote ins ,  and of mRNA for mu lt ip le proteosome subunits ( 1 00-2 1 5%) 
[92]. These f indings ind icate that the ubiquit in pathway is  the predominant 
degradation system i n  an imal  models of cachexia. 
Normally, the majori ty of cel lu lar  prote ins are degraded by the proteasome pathway.  
However, for  patients with a low weight loss ( i .e .  2 .9%) ,  muscle biopsies showed no 
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change in  components of  the ubiquit in proteasome pathway,  but rather an increase 
In the expression of cathepsin B mRNA [93]. Another study a lso showed an increase 
In  lysosomal activity, as measured by cathepsin 0 and acid phosphatase, in  skeleta l 
m uscle of cancer patients which i n  part of the subjects a ppears to corre late with 
weight loss [94]. Myoflbnl lar prote in  constitutes half of the tota l muscle protein  and is 
lost at a faster rate than other proteins duri ng atrophy. In a murine model of 
cachexia, myos in heavy chain was select ively ta rgeted by the ubiquit in proteasome 
pathway in  the cachect ic state, whi le other core myofibri l lar  proteins inc luding 
troponln T, tropomyosin (a- and [3-forms), and a-sarcomeric act in remain unchanged 
[95]. 
With increasing evidence of the involvement of the ubiquit in proteasome pathway in 
regulat ing the skeleta l m uscle degradation in cancer cachexia , it is important to 
u nderstand its triggers and how it gets activated .  
1 .4.4 Tumor and H ost Facto rs Infl u encing M u scle Mass in Cachexia 
1 .4.4. 1 Tumor Necrosis Factor-a 
Animal  stud ies provide a considerable evidence for the importance of tumor 
necrosis factor-a (TN F-a) in  tr iggeri ng muscle wast ing in cancer cachexia.  
Transplantation of Ch inese hamster ovary cel ls  that is transfected with the human 
TNF-a gene in  m ice resulted i n  a syndrome resembl ing cachexia ,  with progressive 
wasting ,  anorexia ,  and early death [96]. Also, genetica l ly eng ineered mice deficient 
in  the TNF-a receptor protein type I which are transplanted with Lewis lung 
carcinoma showed reduced wast ing of ske leta l muscle compared with wi ld-type 
m ice, despite the equa l  levels of serum TN F-a in  both g roups [97]. I n  addit ion, acute 
treatment of rats with recombinant TNF-a enhanced protein degradation and 
decreased prote in synthesis in  soleus m uscle [98]. The mechan ism of which TN F-a-
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I nduced muscle wasting has a lso been studied . TNF-a has been shown to induce 
oxidative stress and n itr ic oxide synthase in  murine skeletal m uscle causing 
decrease in  body weight, muscle wast ing , and skeletal muscle molecular 
abnorma lit ies, a l l  of wh ich are prevented by treatment with ant ioxidants or nitr ic 
oxide synthase inh ibitors (99). 
In humans,  recombinant h uman TN F-a admin istered to patients as part of an 
ant ineoplastic reg imen,  caused a dose-re lated metabol ic effects of enhanced energy 
expenditure with e levated CO2 product ion,  i ncreased protein  catabol ism, peripheral 
efflux of am ino acids, decreased tota l arteria l  amino acid leve ls ,  an increase in 
plasma cortisol leve l ,  e levated seru m  triglycerides, as well as i ncreased g lycerol and 
free fatty acid turnover ( 1 00). These metabol ic effects (both ;  muscle and fat) 
resemble those seen in refractory cancer cachexia, a lthough its ro le in the human 
condit ion is questionable .  
1 .4 .4. 2 I nte r leuk i n-6 
I L-6 decreased the ha lf- l i fe of long-l ived proteins in  in vitro studies in  murine 
myotubes by increasing the activity of the proteasome , together with cathepsins B 
and L [ 1 0 1 ] .  However, most research on I L-6 in  cancer cachexia is in  in vivo models 
with variable resu lts. I n h ibit ion of I L-6 secretion and binding to its cel lu lar receptor by 
suramin ,  reduces the catabol ism seen in  colon-26 (C26) adenocarcinoma-bearing 
mice ( 1 02). Also, muscle atrophy is seen in I L-6 transgenic m ice that overexpress I L-
6 ,  which is complete ly reversed by I L-6 receptor ant ibody and is associated with 
increased mRNA leve ls for cathepsins (B and L)  and ubiquit ins [ 1 03].  On the other 
hand ,  wasting was not induced by admin istration of recombinant I L-6 in  m ice, even 
with repeated admin istrat ion [ 1 04) .  I n  contrast , us ing a n  ApcM1n/+ mouse, an  
establ ished model o f  co lorectal cancer and cachexia ,  to  determine the  ro le of 
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circu lat ing I L-6 on the development of cachexia .  M ice with the h ighest circu lating I L-
6 levels had the most severe cachectic symptoms [ 1 05]. Simi larly, admin istration of 
I L-6 to rats acutely activated both total and myofibri l lar  protein  degradation i n  muscle 
[ 1 06]. Un l i ke TN F-a, however, I L-6 produced no change in the express ion of 
ubiqu lt l n  when admin istered intravenously to rats [ 1 07] . Thus, furt her research is 
needed to verify the role of I L-6 in cancer cachexia .  
1 .4.4. 3 I nte rl e u k i n -1 B 
The data for the role of interleuk in-1  � ( I L- 1 �) i n  cancer cachexia is controvers ia l .  
Al ike T NF-a , I L- 1  can i nduce body weight loss and anorexia in  m ice [ 1 08] .  Also, 
chronic treatment of rats with recombinant I L- 1  � resulted in redistr ibution in body 
protein and a s ign ificant decrease in muscle protein content associated with a 
coord inated decrease in  m uscle m RNA levels of myofibri l lar  proteins [ 1 09]. 
1 .4.4.4 I nterfe ron-y 
I n  m ice bearing Lewis lung tumors, admin istration of ant i- interferon-y ( I FN-y) 
monoclonal  ant ibodies markedly decreased cachexia [ 1 1 0] .  Also , nude mice 
inocu lated with CHO- I FN-y cel ls exhibited severe cachexia that was prevented in  
m ice g iven ant i- IN F-y monoclonal ant ibodies prior to injection of  tumor cel ls [ 1 1 0] .  
Expression of  ubiquit in gene in  rat skeletal muscle was also up-regu lated by IFN-y in 
a s imi lar  manner  to TN F-a and I L- 1  � [ 1 07]. 
Studies have investigated ind iv idual  key players in  triggering the main degradation 
pathway in  cancer cachexia ( i . e .  u biquit in proteasome pathway) , but also it looked at 
the effect of combin ing these e lements together. For example, myotubes and mouse 
muscles treated with TN F-a together with I FN-y resulted in  a s ign ificant reduction in 
myosin expression through an RNA-dependent mechanism which ind icates that 
these two cytokines are complementary in  the progression of muscle degradation 
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[95] Nevertheless, murine co lon-26 adenocarcinoma treated with antibodies t o  I L-6 , 
but not TN F-a or I FN-y, attenuated the development of weight loss and other key 
parameters of cachexia [ 1 1 1 ] However, serum levels of cytokines, i ncluding I FN-y, 
TNF-a, I L- 1  r.., and I L-6 are poorly correlated , so far, with weight loss and cachexia in  
cancer patients [ 1 1 2] .  
1 . 5 Gene E xp ression P rofi l i n g  as a mea n  of U n d e rsta n d i n g  Pathology 
The transcriptome is the tota l set of RNA molecules ( i .e .  transcripts) and their 
quantity in  a g iven cel l ,  t issue, organ ,  or  a whole organism [ 1 1 3] .  U n l ike genome, 
which is relat ively static, t ra nscriptome varies from place to place and t ime to t ime in 
response to developmental ,  environmental ,  or  pathological stimu l i  [ 1 1 4] .  
Understand ing the transcriptome is essential for interpreti ng the funct ional elements 
of the genome and reveal ing the molecu lar constituents of cel ls and t issues, and 
also for understanding deve lopment and d isease [ 1 1 3 , 1 1 4] .  One way for the 
characterization of a physiologic andlor pathological condit ion in  a g iven t issue can 
be determ ined by i ts d ifferent ia l ly active genes [ 1 1 4] .  "Gene expression profi l ing" is 
a molecular  biology techn ique that measures and reflects on the activity of many to 
all of the expressed genes between two (pairwise comparison) or more sample 
types ( i .e .  casels vs. contro l/s) at a g iven t ime. 
After pass ing the era of "Human Genome Project", it was necessary to bridge the 
gap between gene sequence a nd funct ion.  A novel technology cal led "DNA 
Microarray" was i ntroduced which enabled s imultaneous measurement or  a whole 
transcriptome ana lysis of the activity of v irtua l ly a l l  genes in the genome. Whole 
transcriptome analysis can be done in  two ma in  methods; the hybridizat ion- or the 
sequence-based approaches. The hybridization-based approach ut i l izes 
different ia l ly  f luorescently labeled cDNA molecules from the desired sample versus 
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I ts control. The m ixed equal quantit ies of cDNA are then incubated on a microarray 
plats that conta i n  spots with probes targeting the desired genes. Gene activity based 
on microarray technology rel ies on spots brightness captured through these probes 
that hybridIze to the d ifferent ia l ly fluorescently labeled g roups of samples. The 
intensity of brightness varies from gene to gene and corre lates to the transcriptional 
activity of the examined genes. This technology was an  enabler in  many aspects of 
cancer biology; we can differe nt iate between tumor and non-tumor, d ifferent tumor 
g rades, r isk of tumor metastasis,  etc. It  even enabled c l in ic ians make decisions 
about the opt imal  treatment of cancer patients. However, the technology d id not stop 
there ! Thus, understanding the transcriptome plays a p ivotal role in interpreting the 
funct ional e lements of the genome and reveal ing the molecular constituents of cel ls 
and t issues, and a lso for understand ing development a nd d isease . 
The sequence-based approaches uses h igh-through put next generation sequencing 
techn iq ues that were developed based on DNA microarray technology. The use of 
next-generation sequencing technology to study the transcriptome at the n ucleotide 
level is known as RNA Sequencing (RNA-Seq) .  R NA-Seq, also cal led Whole 
Transcriptome Shotgun  Sequencing [ 1 1 5] ,  is a technology that uses next-generation 
sequencing capabi l i t ies to revea l  an  overv iew of RNA expression and quantity from 
a genome at a g iven moment i n  t ime [ 1 1 6] .  
Despite being a yet evolving technology that is yet under act ive development, RNA­
Seq is expected to revolut ionize our  u nderstanding of science [ 1 1 3] .  It is a 
technology that outweighs a l l  i ts counterparts in  its advantages. Yet, a major 
exclusive setback is the bioinformatics chal lenges in  assuring the righteous and i n  
managing these tremendous representat ions of data [ 1 1 3] .  
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Chapter 2 :  Research Aim ,  Hypothesis, and Specific Objectives 
Given the fact that cancer cachexia has been known for such a long t ime, our 
u nderstanding of the mechanisms of cancer cachexia lag way beh ind our knowledge 
of other aspects of tumor bio logy. This is despite the increase of the prevalence and 
significance of the syndrome. Exploratory cl i n ical research into the basic 
etiopatholog ical causes of cancer cachexia is lacking and we don't cu rrently have 
any approved effective treatment for the i nvoluntary weight loss in cancer patients. 
The main aim of this thesis was to explore early  d ifferential changes in gene 
expression in cancer patients with or  without cachexia us ing state-of-the-art whole 
expression profi l i ng technology (RNA-Seq) in order to identify the mechanist ic 
pathway/s responsible for early deve lopment of cancer-associated cachexia .  This 
can bring re l iab le ,  representable, and consistent data from the c l in ic and back to the 
bench with more focused ins ights to be investigated and verified . 
It is our hypothesis that ident ification of early changes i n  gene express ion using 
whole transcriptome ana lysis in  cachexia wi l l  lead to a n  improved understanding of 
the tr iggering mechanism in cancer patients. Also, understanding cancer cachexia 
can be best ach ieved through studying representative cl in ical muscle and fat 
samples. 
Our research specific object ives were to: 
1 .  Col lect representative m uscle and fat biopsies from cancer patients with 
cachexia and match them with non-cachectic weight-stable cancer controls .  
2 .  Conduct g lobal gene expression assays from high q ua l ity representative muscle 
and fat biopsies from cancer patients with early cachexia and compare them to 
non-cachectic weight-stable cancer contro ls .  
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3 I dent ify d ifferentia l up and downregulated pathways involved i n  each of the two 
tissues. 
4 Identify and analyze the h igh ly s ign ificantly u p  and downregu lated altered genes 
in each of the two t issues. 
5 Verify expression data from cl in ica l  and precl in ical models of cancer  cachexia 
against the g loba l  gene expression resu lts. 
6 .  Identify and ana lyze the overlapping d ifferent ia l ly expressed genes between 
cachectic skeletal m uscles and cachectic adipose t issues. 
7 Confirm Increased or d ecreased expression of a se lected genes us ing real-t ime 
RT-PCR.  
Chapter 3 :  Materials and Methods 
3 . 1  Eth ica l  App rova l 
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The eth ica l approval request was submitted t o  "AI Ain Medical District Human 
Research Ethics Committee (AAMDHREC)" at the Col lege of Medicine and Health 
SCiences (CM HS) in the U nited Arab Emirates U niversity (UAEU) .  AAM DHREC is 
accredited by the Federa l Wide Assurance ( FWA) under the number 00007 1 09.  
Research ethical proposal and protocol obtained under a pproval number 
AAMDHREC 1 1 /49. Written informed consents were obtained from each subject and 
each subject was also g iven "Patient I nformation Sheet" i n  the language of 
preference ( i .e .  Arabic or Engl ish)  as per the committee recommendat ion.  
3 . 2  S u bj ects 
A tota l  of 24 biopsies were obtained; 1 2  skeletal m uscles and 1 2  v iscera l  ad ipose 
t issue. Each set of the two tissues conta ins 6 biopsies from cachectic cancer cases 
and 6 weight-stable controls .  All subjects (cachectic and weight-stable) were with 
d iagnosed mal ignancies. All samples were obtained through e lective surgeries. 
I nclusion and exclusion criteria were as fo l lowing :  
I nclusion Criteria :  Cancer patients of  any race, sex, and age equal  or a bove 21  year­
o ld with h istolog ica l ly  proven mal ignancy and under active treatment .  Al l  cases 
shou ld have documented or se lf-reported weight-loss (cachexia) that is measured 
by 5- 1 0% invo luntary weight loss of the tota l  body mass in the past 3-6 months who 
are undergoing elective abdominal  surgery who agreed to sign an i nformed consent. 
Exclusion criter ia: Subjects who are u nder 2 1  year-Old.  Any subject with any 
autoimmune and/or m uscular  d isease, uncontro l led d iabetes or thyroid disorder, 
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history of  treatment with any anabol ic/catabol ic agents for the past 6 months, or  
h istory of  physical impai rment that affects mobi l ity was excluded. 
Control subjects were matched for age and d iagnosis (as poss ible) and with no 
documented or self-reported weight loss or gain in the past 3-6 months prior to 
surgery (see F igure 1 for study f low d iagram) .  
Surg ical cancer patients from cliniC visits and OR lists 
I 
Excluded: 
• Age below 2 1  
• Autoimmune and/or muscular 
disease 
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Record screening for el ig ibi l ity . . . . . . . . . .  � 
• Diabetes or thyroid disorder 
• Recent history of treatment 
with any anabol ic/catabolic 
agents for the past 6 months 
Cachectic patients with 5-1 0% weight loss; 
and weight stable controls In thepast 6 months 
Rectus abdominismuscle and 
visceral fat biopsies obtained 
Extracted RNA and Protein •• 
�--------��=--===�--� • 
R NA-Sequencing 
Figure 1 :  Study Flow Diagram.  
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Excluded: 
• Weight loss <5% or > 1 0% 
• Controls with fluctuating weight 
•• •• •• ••• • • • 
. ::.\ 
Excluded: 
• Poor quality RNA samples 
3 . 3  C l i n ical  Paramete rs 
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Body weights were measured with participants in l ight cloth ing using a beam scale 
(Seca) .  Heights were measured using a standard wal l  mounted measure and body 
mass ind ices (BMI )  were ca lcu lated . Al l  current ava i lab le nutrit ional and 
Inflammatory c l in ical  parameters were recorded. H istory of weight changes from 
patients' records and/or se lf-reported weights were also recorded. 
3.4 C o l l ect ion of M uscle and A d i pose Tissue Biopsies 
Al l  biopsies were taken at the start of either open or  laparoscopic abdomina l  
surgeries. S pecimens of approximately 0 .5- 1 . 0  cm3 from the rectus abdominis 
and/or visceral fat were removed . The biopsies were washed with normal sal ine 
solut ion ,  blotted , and immediately p laced in RNALater (AM702 1 ;  Applied 
B iosystems,  Carlsbad ,  CA, USA) and kept overn ight at 4DC to a l low thorough 
penetration of the t issue.  Tissue samples were then frozen at -80DC unt i l  further 
processing . 
3.5  Sample Label i n g  a n d  S u bject C o nfidential ity 
Col lected samples were g iven identification label ing composing of two letters to 
denote orig in (Le .  "M" for m uscle, and "F" for fat) and g roup (Le .  "S" for cachexia 
cases, and "C" for weight-stable controls) .  Each sample i s  then fol lowed by a un ique 
identification number. To ensure confident ia l ity, a l l  other subject identifications were 
removed and never communicated in downstream sample processing. For future 
possible reference to subject data, the l ink of these label ing and actual med ical 
record numbers is  kept under the a ccess of the leading experimenter and the 
principle investigator only .  
3.6  Sam p les P repa ration for RNA a n d  P rote i n  E xtract ion 
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Samples of  muscle (45-59 mg)  adipose t issue (95- 1 73 mg) were homogenized in ice 
in 1 2 ml  of trizol Reagent ( 1 5596-026, TRlzo l® Reagent, Life Technologies, Thermo 
Fisher Scientific, U SA) using the polytron homogen izer (POLYTRON® PT 2 1 00 
Homogenizers, Klnematica, Switzer land) .  Sample homogenizations were done at 
i ntermittent intervals with samples kept in ice in between to avoid RNA and protein 
degradation I ntermittent homogenization was the best method to ensure complete 
retneval of RNA and prote in from samples that a re d ifficult to homogenize (e .g .  
m uscle) or those who have low RNA and protein y ie ld  ( i . e .  fat) [ 1 1 7- 1 1 9] .  
Homogenization was done in batches o f  6 samples o r  less a t  1 500-2000 rpm. 
Completion of each batch took 3 hours (fat) and 4-5 hours (muscle) t i l l  no c lear 
v is ib le homogenate part icles were observed . Polytron generator was cleaned in 
between samples in the fol lowing sequence; D Nase/RNase free dist i l led water, 70% 
ethanol in  DNase/RN ase free dist i l led water,  fol lowed by D Nase/RNase free d isti l led 
water .  To ensure pro per  removal of t issue sticking on the generator, a solut ion of 
1 % of sodium dodecyl su lfate in DNase/RNase free d ist i l led water was used every 
1 -2 hours and as needed to clean the probe . 
3 . 6 . 1  R N A  E xtraction 
Once a complete t issue homogen ization had been achieved, R NA extraction was 
carried out using a combinat ion of the l iqu id- l iqu id extract ion technique; the acid 
g uanid in iumth iocyanate-phenol-chloroform extract ion (AGPC) [ 1 20, 1 2 1 ] ,  and the 
column-based system .  The AGPC method was used to separate the aqueous phase 
(RNA conta in ing phase) .  This step was preceded with an addit ional centrifugation 
for fat samples only in  o rder to remove the floating fat layer before the addit ion of 
the ch loroform . The tota l R NA was then precipitated using ethanol  and processing of 
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RNA isolation was completed using the SV Total  RNA Isolat ion System® (Promega,  
Madison, USA) accord ing to manufacturer's instruct ions. The concentration and 
pUrity of the RNA samples were determi ned by measuring the absorbance at 260 
nm and the ratio  of the absorbance at 260/230 and 260/2S0 nm using 
spectrophotometer (ND-1 000 NanoDrop, Thermo Scientific, Wi lmington, DE,  USA). 
Only ratios � 1 .S were accepted or else, extract ions were repeated t i l l  the requ i red 
purity was achieved. RNA samples were kept on ice during processing and qua l ity 
check and then stored at -SOD C pending further processing .  
3.6. 1 . 1  R N A  Concentrati o n  
Sample yields below 20 ng/lJl were concentrated us ing a cold vacuum centrifuge. 
This was fol lowed by another check for RNA concentration and purity us ing 
spectrophotometer ( N D-1 DOO N anoDrop, Thermo Scientific, Wi lm ington, DE ,  USA). 
3.7 Reverse Transcri ption 
Total RNA was converted into cDNA uSing a High Capacity cDNA Reverse 
Transcription Kit® (H igh Capacity cDNA Reverse Transcription Kit; 4374966; 
Appl ied B iosystems,  Carlsbad, CA, U SA) accord ing to the manufacturer's 
i nstruct ions. Total RNA (420ng) was converted into cDNA in a 301-.11 reaction volume 
using the fol lowing react ion (Table 1 )  and was repeated whenever needed: 
Table 1 :  Reverse Transcription React ion.  
Reverse Transcription M aste r Mix  Com ponents Volume ( 1 x) 
1 0  x RT Buffer 3 .0 IJ I  
2 5  x d NTP Mix 1 .2 IJ I  
10  x RT Random Primers 3.0 IJ I  
Multiscribe™ Reverse Transcri ptase 1 .0 IJ I  
R NASE I n h ibitor 1 .0 IJ I  
R Nase Free H2O = (30 - 9 .2  - vol of 420ng 
tem plate) IJI 
Total Volume Reaction 30.0 1-1 1  
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The a bove reaction g ives a fina l  cDNA concentration of = 420ng/30IJI = 1 4ng/1J 1 .  
Each cDNA sample were then d i luted to  4ng/1J1 and  stored in -200 C .  The reverse 
transcription reaction was carried out in a Veriti thermal cycler (L ife Technologies, 
Applied Biosystems, USA) using the fo l lowing parameter values (Table 2): 
Table 2 :  Parameters of the Thermal  Cycler for Reverse Transcript ion. 
Step 1 Step 2 Step 3 Step 4 
Temp °C 25 °C 37 °C 85 °C 4 °C 
Time 10 minutes 1 20 minutes 5 minutes 00 
3.8 Rea l-T ime Reve rse T ra n s c ri ption Polymerase C ha i n  Reaction 
The expression levels of m R NA were analyzed using target specific TaqMan® gene 
expression assays using real-t ime reverse transcript ion polymerase chain reaction 
(RT -PCR) and performed in a 7900HT Fast ABI  Prism 7900HT Sequence Detection 
System (Applied B iosystems, U SA). The fol lowing TaqMan® pri mers and probes 
kits were purchased from Appl ied Biosystems (Table 3) :  
Table 3: L ist of the TaqMan® Primers for Rea l-Time RT-PCR .  
Assay 1 0  Gene Sym bol 
Assay 10:  Hs01 098873_m 1 Gene Symbol: COL4A2, hCG33042 
Assay 1 0 :  Hs00373339_m 1 Gene Symbol: N RXN2,  hCG 1 8 1 0991 
Assay 1 0 .  Hs00394748_m 1 Gene Symbol :  AGR N  
Assay 1 0 :  Hs01 062 0 1 4_m 1 Gene Symbol :  NOTC H 1 , hCG 1 8 1 8285 
Assay 10. Hs00373 1 36_m 1 Gene Symbol:  PTPRR,  hCG254 1 0  
Assay 10 :  Hs001 92297 _m 1 Gene Sym bol: N O U FS 1 ,  hCG1 7250 
Assay 10 Hs001 74877 _m 1 Gene Symbol :  LEP,  hCG33000 
Assay 1 0 .  Hs00223332_m 1 Gene Symbol :  TNMO,  hCG20 1 9 1  
Assay 1 0 :  Hs00896336_m 1 Gene Sym bol: L HCGR, hCG 1 6776 
Assay 10 Hs04 1 87682_g 1 Gene Symbol: CXC L 1 1 ,  hCG2384 1 
Assay 1 0 :  Hs02800695_m 1 , #432632 1 E  Gene Symbol: HPRT1 
Endogenous 
Assay 1 0 '  Hs0275899 1 _g 1 , #43263 1 7 E  Gene Symbol: GAPOH 
Controls 
Assay 1 0 :  Hs01 060665_g 1 , #43263 1 5E Gene Symbol: ACTS 
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The reaction mix of  1 O�I conta in ing a total  cDNA of  4ng/react ion was prepared using 
TaqMan® H Fast Un iversal PCR Master Mix ,  No AmpErase H UNG (L ife 
Technologies #4352042, Appl ied Biosystems, USA) as fol low (Table 4) :  
Table 4: Real-Time RT-PCR Reaction. 
Real Time PCR Master Mix Reaction Volume ( 1 x) 
DNase/RNase free H2O 3.5 � I  
cDNA (stock concentration 4ng/l-l l )  1 � I  
2 X TaqMan H Fast Un iversa l PCR M aster M ix 5 � I  
20 X Gene of I nterest (GO I )  o 5 � I  
Quant itative real-t ime PCR assay for the  gene of  interest was performed in 
dupl icates and i n  a s ing leplex PCR react ion. The PCR thermal  cycl ing parameters 
were run in fast mode as fol low (Table 5) :  
Table 5: Parameters of the Thermal  Cycler  for Real-Time RT-PCR .  
Step 1 Step 2 Step 3 Step 4 
Temp °C 500 C 95 0 C 40 cycles of 60 0 C 
95 0 C 
Time 2 minutes 20 seconds 1 second 20 seconds 
Results were in it ia l l y  analyzed with the ABI Prism 7900HT SDS program v2, 4, a l l  
remain ing calcu lations and statist ical analys is were performed by the SDS RQ 
Manager 1 . 1 ,4 software using the 2-1'1 Ct method with a re lative quantification 
RQmin/RQmax confidence set at 95%. Three d ifferent endogenous controls were 
tested; human g lycera ldehyde-3-phosphate dehydrogenase (GAPDH) ,  human 
Hypoxanth ine phosphoribosyltransferase (Hprt 1 )  rRNA, and human l3-act in .  Hprt1 
was found to be the best and used to normal ize expression resu lts . Other 
expression related gu idel ines were followed from the M I Q E  g uidel ines [ 1 22] .  
33 
a l  Analysis 
stlcal analysis of the next generation sequencing was carried out by 
in Qatar. Confirmation of changes in  gene expression by real-t ime 
jone using Student's t-test and ana lysis was done us ing the 
1 Software (vers ion 5). 
matics Tools 
a i lable databases and software were used check gene functions, 
ern, protein  interact ion,  and funct ional  pathways. These databases 
e: 
N at ional  L ibra ry of Medicine Nat ional  I nst itutes of Health : 
lcbi . n lm .  n ih  .gov/pubmed 
ome Bioinformatics: http ://genome. ucsc.edu/ 
ttp:/ /www . ensembl .org/index. htm I 
base: http://www . genome.jp/kegg/kegg 1 . html  
//str ing-db.org/ 
;enera l  Repository for I n teraction Datasets : http : //thebiogrid .org/ 
o informat ics Resource Porta l :  
expasy. org/proteom ics/prote in-proteinjnteract ion 
eq uenc i n g  
I t  RNA samples (600ng) were sent i n  d ry ice to  our col laborators in 
led ica l  Col lege i n  Qatar for RNA Sequencing (RNA-Seq) .  RNA-Seq is 
y transcriptomic technique that uses deep-sequencing technologies. 
! ut i l izes a populat ion of RNA that is reversed transcribed i nto a l ibrary 
lents. 
3.9 Statistica l Ana lysis 
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Prel im inary statist ica l ana lysis of the next generation sequencing was carried out by 
our col laborator i n  Qatar Confi rmation of changes in gene expression by real-t ime 
RT-PCR was done using Student's t-test and ana lysis was done using the 
GraphPad Prism Software (version 5). 
3.1 0 Bioinformatics Tools 
Much freely avai lable databases and software were used check gene functions, 
expression pattern, prote in interaction ,  and funct ional  pathways. These databases 
and software are :  
• The US National L ibra ry of  Medicine Nat ional Institutes of  Health : 
http ://www . ncbi . n lm .n ih .gov/pubmed 
• UCSC Genome Bioinformatics: http://genome. ucsc.edu/ 
• Ensembl :  http ://www . ensembl . org/index. html 
• KEGG database: http ://www . genome. jp/kegg/kegg 1 . html 
• String : http://str ing-db .org/ 
• Biological General Repository for I nteraction Datasets: http://thebiogrid .org/ 
• ExPASy Bio informatics Resource Porta l :  
http://www . expasy.org/proteomics/prote in-prote injnteract ion 
3 . 1 1 RNA Seq u e n c i n g  
Muscle and fat RNA samples (600ng) were sent in d ry ice to  our col laborators in 
Wei l l  Cornel Medica l  Col lege in Qatar for RNA Sequencing (RNA-Seq) .  RNA-Seq is 
a revolut ionary transcriptomic technique that uses deep-sequencing technolog ies. 
The technique ut i l izes a population of RNA that is reversed transcribed into a l ibrary 
of cDNA fragments. 
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All  samples underwent qua l ity check prior  to sequencing by measuring the RNA 
I ntegnty Number and ensuring that a l l  samples are with a RNA I ntegrity Number 
value of at least 7 .  Samples were then reversed transcribed into cDNA. R NA-Seq 
was then performed on the I l l umina H iSeq 2500 System.  
Chapter 4 :  Results and Discussions - Muscle 
4 . 1  Demogra p h ic a n d  B iochem ica l  C h a racteristics of S u bj ects 
4 . 1 . 1 Resu lts 
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Demographic and biochemical deta i ls  of patients for muscle cachexia cases (MS) 
and m uscle weight-sta ble controls (MC) a re shown in bellow tables.  The table 
shows the data after excluding two samples (one of each group) s ince they were 
out l iers from the R NA-Seq data. The cause of these two samples as outl iers was 
investigated . Data on the excluded cachexia sample was obtained through patients 
self-report of weight changes in the past six months with the complete absence of 
basel ine data in patient's record . The patient was a referra l to the hospital from a 
d ifferent city j ust to be operated . On the other hand,  fu rther investigation of the 
excluded control sam ple in patient's extended e lectronic records in d ifferent health 
inst itut ions found to have obvious fluctuat ion of patients weight i n  between the two 
t ime points that our  study has in it ia l ly selected patients on .  Al l  samples were then 
ana lyzed based on weight ,  B M I ,  some nutrit ional  parameters, inflammatory markers, 
and other re lated demograph ics. 
Table 6 shows subjects' oncological d iagnoses for muscle b iopsies. Al l  patients 
were with h istolog ical ly confi rmed mal ignancies .  Age and gender d istribution were 
not s ignificantly d ifferent between cachexia m uscle cases (MS) and weight-stable 
m uscle contro ls (MC) (Table 7) .  Al l  biochemical nutrit ional  parameters ( i .e .  
hemog lobin ,  tota l prote in ,  a lbumin ,  urea ,  and creat in ine) and inflammatory markers 
( i .e .  WBC and CRP) were not s ignificantly d i fferent between both g roups (Table 7) .  
Basel ine weights and B M l s  i n  the cachexia group did not d iffer sig n ificantly from the 
contro l .  The time range between current (at t ime of biopsy) and basel ine weights 
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(preceding date of biopsy) was 3-6 months. Mean weight loss from basel ine in the 
cachexia g roup was 4 .6  kg which is 6 .5% of base l ine body weight ( i .e .  3-6 months 
before the date of sample col lect ion) .  Amount and percentage of weight loss was 
sign ificant ly d ifferent from controls that had stable weights; P-va lue of 0.00 1 4  and 
a 0003, respective ly. 
Table 6: Subjects' D iagnoses for Skeletal Muscle Biopsies. 
Cachectic M uscle Cases (MS)  Weig ht-stable Musc le  Controls (MC)  
MS 1 ·  Mal ignant Neoplasm of  Rectum MC1 : Mal ignant Neoplasm of Rectum 
MS2· Mal ignant Neoplasm of Stomach MC2: Mal ignant Neoplasm of Rectum 
MS3· Mal ig nant Neoplasm of Rectum MC3: Mal ignant Neoplasm of Colon 
MS4 Mal ignant Neoplasm of Duodenum MC5: Mal ignant Neoplasm of Connective 
and Soft Tissue 
MS6 Mal ignant Neoplasm of Pancreas MC8: Mal ig nant Neoplasm of Colon 
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Table 7 :  Demographic Data for Cachectic Muscle Cases and Weight-Stable Muscle 
Controls. 
Gender ( M/F) M S :  M e a n  S E M  Median Range P-Va lue 
M S :  4/1 ; MC:  3/2 N=5 
Cha racteristics M C :  
N=5 
Age Cach 61 40 7 .461 67 00 44-83 0 .4406 
Cant 53 .40 6.447 59.00 36-66 
Hemoglobin Cacho 1 1 4 .0  4 .669 1 1 1 . 0 1 03- 1 25 0.9525 
Cant. 1 1 4 .6  8.583 1 22 . 0  90-1 35 
Creatin ine Cacho 65 .75  1 0.23 69.00 4 1 -84 0 .6837 
Cant. 6 1 .60 3. 385 63.00 52-72 
U rea Cacho 6.650 1 . 735 6.300 2 .9-1 1 . 1  0 .0863 
Cant. 3 480 0. 3980 3.900 1 .9-4 .0 
Total protein  Cach o 52 75 4 .535 49.50 46-66 0 .8441 
Cant. 5 1 .60 3.5 1 6  49.00 42-63 
Albumin  Cach o 27 .50 4 .349 25 .00 20-40 0.6047 
Cant. 30.00 2 .280 29.00 23-37 
WBC Cach o 8 .900 1 . 307 9.000 6.0- 1 3. 3  0 .9034 
Cant. 8 .640 1 .6 1 3  9.600 4 .4-1 2. 1 
CRP Cacho 1 2 .50  7 .331  7 . 500 1 -34 0 .8 1 72 
Cant. 1 4 .67 2 .333 1 4 .00 1 1 - 1 9  
Basel ine B M I  Cacho 23 58  2 .378 23.02 1 5 .57 -29.24 ; 0 .0667 
Cant. 29 .86 1 . 765 30.46 25 .26-35 . 38 
Current B M I  Cacho 2 1 .95 2 .030 2 1 .98 1 4 . 8 1 -26.44; *0.0205 
Cant. 29 .79 1 .8 1 1 30.46 24 . 9 1 -35. 38 
Basel ine weig hts Cacho 67 .92 5 . 738 73.00 45.00-74.60; 0 .0689 
Cant. 8 1 .20 2 .653 84 .00 73. 00-87.00 
Current weig hts Cacho 63.38 5.2 1 3  67.90 42.80-7 1 .20; *0.0 1 77 
Cant. 8 1 .00 2 . 8 1 1 84 . 00 72.00-87.00 
Amount of weight Cacho 4 .540 0 88 1 8  4 .000 2 .200-7.000 **0. 00 1 4  
loss Cant. 0.2000 0.2000 0 .0000 0.0000-1 .000 
% of weight  loss Cacho 6 . 552 0.9994 5 .479 4 .558-9.589 ***0.0003 
Cant. 0 .2740 0.2740 0. 0000 0.0000-1 . 370 
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Table 8 compares weight and BMI changes between current and basel ine with in 
each group (paired t-test). The cachect ic muscle cases (MS) had a s ign ificant 
d ifference between current and basel ine data whi le weight-stable controls (MC) had 
no s ignificant change. 
Table 8: Paired t-Tests for Weight and BMI Changes for Muscle B iopsies. 
C h a ra cteristics N-MS/MC; Mean SEM Med i a n  Range P-Va lue 
5/5 
Weight MS Basel ine 67 .92 5 .738 73.00 45 .00-74 .60; * *  0.0068 
(cachectiC) Cu rrent 63.38 5 .2 1 3  67 .90 42.80-7 1 .20 
BMI MS Baseline 23 .58 2 . 378 23 02 1 5. 57-29.24; * 0.0 1 40 
( cachectic) Current 2 1 .95  2 .030 2 1 .98 1 4 . 8 1 -26.44 
Weight MC Baseline 8 1 .20 2 .653 84.00 73.00-87.00 0 .3739 
(weight-stable) Cu rrent 8 1 .00 2 .8 1 1 84 .00 72.00-87 .00 
BMI MC Basel ine 29.86 1 .765 30.46 25.26-35 38 0 . 3739 
(weig ht-stable) Current 29 .79 1 .8 1 1 30.46 24 .91 -35. 38 
4. 1 . 2 D i scussion 
I n  the above demographic analysis ,  patients inc luded in the study were chosen 
meticulously to be at the early stages of cachexia ( i . e .  5 - < 1 0% weight loss). 
Consensus defin it ion had identified early cachexia as weight loss >5% or BMI  
<20kg/m2 and weight loss >2% or  sarcopenia and weight loss >2% with often 
reduced food intake or systemic  i nflammation [7] .  Our subjects had a mean 
percentage of weight loss of 6 .5% (range 4 .6-9.6 %) .  S ince systemic inflammation 
measured via serum CRP may or may not be present in patients with cachexia [7], 
our subjects were inc luded rega rdless of their CRP values (range 1 -34 , Table 6). 
However, the CRP values between cachectic cases (MS) and weight-stable controls 
(FC) were ensured to be not statistica l ly s ign ificant; P= 0 .325 in muscle .  
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Nutritional  and nutrition-re lated biochemical markers were a l l  ensured to be 
comparable i n  both g roups to objectively exclude the possibi l ity of malnutrit ion as 
the primary cause of weight loss. 
4.2  Heat  M a p  of RNA Seq u e n c i n g  Data 
4 . 2 . 1  Resu lts 
Figure2shows the heat map of d ifferent ia l ly reg ulated genes between cachectic 
muscle cases (MS) and weight-stable controls (Me) .  The figure shows a com plete 
and clear cut separation between both g roups. The heat map shows a tota l of 238 
sign ificantly u pregulated genes and 235 downregulated genes (P-value < 0 .05 ;  and 
FDR < 0 .5) .  
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Figure 2 :  Heat Map Representation of the Different ia l ly Expressed Genes in Skeletal 
Muscle Tissue. 
Gene expression is shown for the cachectic muscle cases (MS; purple bars ;  upper 
panel) and weight-sta ble controls (MC;  g reen bar; lower panel ) .  Colors represent 
scaled and centered expression values; red represents h igher expression,  b lue 
represents lower expression.  
4.2.2 D iscussion 
The heat-map provides a g raphical v isual ization of the matrix dataset by 
representing individual  values with d ifferent colors. This necessity stems from the 
increasing data vo lumes generated by scientific studies. Effective data v isual ization 
enables understanding data at both broad and deta i led leve ls .  Recent progress in 
h igh-throughput techniques, such as RNA-Seq, has increased the demand for the 
v isual ization of multi-d imensional in  addition to the numeric data [ 1 23] .  This s imple 
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h ierarchical cluster analysis revealed a clear visual distinction of gene expression 
signature between cachexia muscle cases (MS) from those with weight-stable 
controls (MC).  
4.3 Ana lysis of Diffe rentia l ly E x p ressed KEGG Pathways 
4.3. 1 I ntrod uctio n  to Pathways Ana lysis 
Even for the s implest biological funct ion ,  s ing le-gene expression analysis has its 
own l im itations for understanding the biological mechanism of a d isease/syndrome. 
Compl icated bio logical  and patholog ical processes are a funct ion of hundreds of 
d ifferentia l ly  expressed genes. These genes never work independently. Whole 
genome expression ana lysis draws attention for d iscovering the hidden l i nks 
d isregarded by the sing le-gene analysis .  
The introduction of high throughput technology, l ike m icroarray,  enabled 
simultaneous quantification of thousands of genes to the fu l l  genome express ion .  
H owever, "next generation sequencing" is  m uch more powerful than m icroarray i n  
identifying a more quantitative expression of  genes of  the  whole transcriptome from 
cel ls or t issues. 
4.3. 1 . 1  Why Pathways Ana lysis? 
Pathways analysis has emerged as one of the most important methods to ga in  
ins ight  into the underly ing biology of  d ifferentia l ly  expressed genes.  It is a logical 
next step in any h igh-throughput experimentation . Basing the massive quantity of 
data generated through fu l l  genome expression assays on pathways ana lysis 
reduces the complexity of s ing le gene analysis .  Also, h igh-through put experiments 
do not produce biological find ings. Since gene products do not work a lone,  but in an 
intricate network of interact ions,  pathways analysis helps interpret the data in the 
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context of biological processes; pathways and networks. Thus, it g ives a g lobal 
perspective on the data and the problem in hand.  
Pathways ana lysis a lso provides in-depth and contextual ized findings to help 
understand the mechanisms of disease/condit ions in  q uestion. I t  helps in 
identification of genes and prote ins associated with the etiology of a specific 
disease. Also, it helps to understand how to intervene therapeutica l ly  in d isease 
processes by prediction of d rug targets. It aids in data integrat ion from diverse 
biological information and hence the d iscovery of the function of unknown genes. 
Many pathways analysis approaches and result ing software/tools are ava i lable .  
These tools have evolved i n ,  so far, three generations of  a lgorithms of increasing 
complexity and hence, comprehensiveness [ 1 24]. "KEGG pathway analysis" is one 
of the th i rd generation tools that is  widely used [ 1 24] .  Tools in the fi rst and the 
second generations consider only the number of genes in a pathway or gene 
coexpression to identify s ign ificantly altered pathways. Thus, they a lways produce 
the same results no matter  how they are analyzed [ 1 24] .  H owever, the th ird 
generation pathways analysis uti l izes addit iona l  informat ion ava i lable from these 
knowledge bases [ 1 24]. I t  is  i mportant to u nderstand this concept during data 
analysis s ince vari at ions in statistica l s ign ificance is h igh ly  l ike ly [ 1 25] .  For example ,  
statistical s ign ificance of  cytokine-cytokine receptor interact ion pathway calcu lated 
by three d ifferent methods resulted in P-values of 8 .08x 1 0-6 , 0 .72 ,  and 6 . 1 9 x 1 0-2 
[ 1 25] .  Th is huge difference should be a lways considered during data analysis. 
However, the real value of pathway ana lysis is to generate hypothesis, inferences, 
and explore the overa l l  picture of a com plex unknown 
diseases/condit ions/syndromes. 
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4.3 . 1 . 2  KEGG Pathways 
The Kyoto Encyclopedia of Genes and Genomes (KEGG) database is a project that 
was in it Iated back in 1 995 under the then ongoing Japanese Human Genome 
Program [ 1 26]. It is a col lection of databases (seventeen main databases) that are 
broadly categorized into 4 broad categories that deals with genomes, biological 
pathways, dIseases, drugs, and chemical substances. In our study, our col laborator 
in Qatar has in it ia l ly ut i l ized it to generate a computer representation from our 
molecular-leve l i nformation ( R NA Sequencing results) to explore differential ly 
involved pathways in cachexia pathogenesis [ 1 26,  1 27]. The outcome of this 
analysis is the "KEGG pathway mapping", whereby the gene content in the genome 
is compared with the "KEGG PATHWAY" database to examine wh ich pathways and 
associated functions are l ikely to be d ifferent ia l ly  encoded in the genome. 
Several pathways were found to be different ia l ly expressed ; up- or downregu lated, 
when expression data was analyzed using KEGG pathways analysis .  Each of these 
pathways has severa l genes that are s ign ificantly a ltered and wi l l  be d iscussed 
below. 
4 . 3 . 2 U preg u lated K E GG Pathways i n  Cac hectic Skeleta l M uscle  
4 . 3 . 2 . 1  Resu lts 
Four KEGG pathways are d ifferentia l ly  upregulated in cachectic m uscles cases vs. 
weight-stable control muscles; notch s ignal ing pathway, cel l  adhesion molecules 
(CAMs) ,  acute myeloid leukemia ,  extrace l lu lar  matrix (ECM)-receptor i nteract ion. 
These pathways have 4 ,  6 ,  4 ,  and 4 significantly upregu lated genes respective ly 
(Table 9 ) .F ig ure 2shows the indiv idual genes in each pathway and the overa l l  
statistica l s ign ificance for each of these pathways.  Table 1 0  shows a summary of 
the fu l l  gene name,  fo ld change, and P-value for indiv idual genes in each pathway. 
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Table 9 :  Different ia l ly Upregu lated KEGG pathways in Cachectic Skeleta l Muscle. 
KEGG Gene Gene Gene Gene Gene Gene P- FOR 
Pathway value 
Notch NOTC H 1  NOTCH4 MFNG DTX2 0 .02 1 0 87 
signa l ing 
pathway 
Cell F 1 1 R  CLDN 1 1 ESAM H LA-A H LA-C NRXN 0.025 0 .70 
Adhesion 2 
molecules 
Acute RARA STAT5A TCF7L2 RELA 0.036 0 .70 
myeloid 
leukemia 
ECM- AGRN COL4A2 HSPG2 VWF 0.088 0.90 
receptor 
interaction 
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Table 1 0  Data of I nd iv idual  Genes in the Upregu lated KEGG Pathways in  Cachectic 
Skeletal Muscle . 
Gene Gene F u l l  Name Fold P-
Symbol Change Value 
M uscle-Up I Notch S igna l ing Pathway 
MFNG MFNG O-fucosylpeptide 3-beta-N- 2 .99 0.0022 
acety lg lucosamlnyltransferase 
NOTC H 1  Notch homolog 1 ,  translocation-associated (Drosophi la )  5 .69 0.0 1 43 
NOTCH4 Notch homolog 4 (Drosophi la) 3 .69 0 .0040 
DTX2 deltex homolog 2 (Drosophi la) 3 .70 0 .01 55 
M uscle-Up I Cell  adhesion molecu les ( C AMs) 
F 1 1 R F 1 1 receptor 2 59 0 . 0 1 60 
CLDN 1 1  claudin 1 1  6 .76 0 .01 58 
ESAM endothel ia l  cell adhesion molecu le 3 .39 0. 0004 
H LA-A major h istocompatibi l ity complex, class I, A 2 .92 0.0 1 62 
H LA-C major histocompatibil ity complex, class I, C; major 3 .56 0.0 1 73 
h istocompatibi l ity complex, class I ,  B 
NRXN2 neurexin 2 1 1 .83 0.0 1 48 
M uscle-Up I Ac ute myeloid leukemia 
RARA retlnoic aCid receptor, a lpha 3 .06 0 .0 1 34 
STAT5A signal transducer and activator of transcription 5A 3 .33 0 .0 1 50 
TCF7L2 transcription factor 7-l ike 2 (T-cel l  specific, H MG-box) 2 .36 0.0 1 69 
RE LA v-relretlcu loendotheliosis v ira l  oncogene homolog A 2 .29 0.0069 
(avian) 
M uscle-Up I E C M-receptor i nteraction 
AGR N  Agrin 2 .75  0. 0 1 6 1  
COL4A2 col lagen ,  type IV, alpha 2 8 . 54 0. 0 1 84 
HSPG2 heparan sulfate proteog lycan 2 7 .79 0 .0 1 89 
VWF von Wil lebrand factor 3.22 0 .0 1 67 
4. 3 . 2 . 2  Discussion 
Notch S i g n a l i n g  Pathway 
Notch signal i ng is an evolut ionar i ly conserved interce l lu lar  pathway that regu lates 
i nteract ions between physica l ly  adjacent ce l ls and is a wel l-documented pathway in 
skeleta l muscle development and regeneration [ 1 28] .  Normal ly ,  Notch pathway in  
skeletal muscles regu lates prol iferation and commitment of  activated satell ite cel ls to  
myogen ic l ineage. Also, activation of Notch s ignal ing is a prerequ isite for the 
expansion of  postnata l sate l l ite cel ls and to prevent the premature differentiat ion of 
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myogenic progenitor ce l ls precursors in inju red myofibers into mature muscle [ 1 29, 
1 30]. These two processes ensure m uscu lar  homeostasis. Muscle Injury ,  which is 
the early cachexia in  our case, is known to activate Notch pathway. Two known 
notch receptors NOTC H 1  and NOTCH4 were u pregu lated . I n  addit ion, two known 
act ivators of the pathway [ 1 3 1 , 1 32] were upregulated; MFNG,  which encodes for 
manic fringe (a prote in  fami ly  that a lso i ncludes the rad ica l and l unatic fringe) which 
fucosylates and thereby modu lates notch ,  and DTX2, which encodes for deltex-1 an 
E3  u biqui t in l igase which is positive regu lator of downstream,  were upregu lated 
[ 1 33 , 1 34]. 
C e l l  a d hesion molecu les and EC M-rece pto r i nteraction pathways 
It is  wel l -know that further activation of Notch pathway requ i re more cel l -cel l  
contacts [ 1 35] .  Thus,  no wonder that two other support ive pathways; ce l l  adhesion 
molecules (CAM),  and extracel lu lar  matrix-receptor interaction,  were also 
u pregulated with m u lt ip le genes i nvolved at d ifferent levels .  
On a d ifferent note, e lements in the extrace l lu lar  matrix-receptor interaction pathway 
were a lso correlated to documented l iterature in muscle wasti ng .  For example, agr in 
(AGRN)  fragments a re u nder investigation as a possible b iomarker for sarcopenia 
[ 1 36] and was also found to be upregu lated in  cachectic muscles. Also, expression 
of col lagen type 4 a lpha 1 (COL4A 1 ,  from orig ina l  data) and collagen type 4 alpha 2 
(COL4A2) genes; which are com ponents of the myocyte basal lamina [ 1 37] ,  are 
s ign ificantly u pregu lated. The matrix meta l loproteinase genes (MMP2 and MM P9) 
code for abundant ge lat inases in  m uscle that hydrolyze fibri l lar  col lagens [ 1 38] .  The 
two genes which are normal ly  expressed in q u iescent satell ite cel ls  [ 1 39]. M M P2 is 
act ivated by M M P 1 4  at the sarcolemma [ 1 38] .  MMP2,  its activator; M M P 1 4  and 
M M P9 are massively u pregu lated (but not statist ica l ly s ign ificant) i n  the cachect ic 
4 7  
muscles Th is  signature molecu lar changes in our cachectic muscles reflects the 
qU iescent state of the satel l ite ce l ls  wh ich a re ,  possibly, at its borderl ine activation 
once the degrading forces for the type IV col lagens ( i .e .  COL4A 1 and 2) exceeds 
cel lu lar  degradation res istance threshold. 
Ac ute myelo id  leukemia pathway 
Another upregulated pathway in cachectic muscles is the acute myeloid leukemia .  
One gene is of a particu lar  a nd a just ified importance in  the cachexia context; the 
transcription factor 7 - l ike 2 (TCF7L2) gene. This gene was found in a genome-wide 
association scans to be the most important locus predisposing and consistently 
involved in type 2 d iabetes [ 1 40] .  I nsu l in resistance is an important common feature 
between cancer cachexia and type 2 d iabetes and patients with cancer  cachexia 
have profound insu l i n  resistance [ 1 4 1 , 1 42] .  
A certa in  polymorph ism that increases TCF7L2 gene expression is associated to 
type 2 d iabetes [ 1 40] and it cou ld  be that the same gene involved in  muscles 
contribut ing to insu l in  resistance in cachectic patients. Not only TCF7L2,  but a lso 
another gene in the same pathway; the s ignal  transducer and activator of 
transcription SA (STATSA) gene, plays an important role i n  insu l in  resistance. 
STAT SA is a physiological substrate of the insu l in  receptor that is independent of 
JAK [ 1 43] .  I nsu l in  act ivates STATSA (a long other stats) [ 1 43] . Prolonged insu l in 
exposure in skeleta l muscle cel ls increases STA TS expression which may play an 
important role in  the man ifestation a nd/or progression of  insu l in  resistance i n  
muscles [ 1 44). R E LA ,  which is a member of the N Fkappa8 fam i ly ,  forms a 
heterodimer with p6S-c-Rel to from a transcri ptional  activator. Expression of R E LA 
gene, on the other hand,  was i ncreased in human and mouse model of Huntington's 
disease [ 1 4S] .  
4 . 3 . 3  Downreg u lated K E G G  Pathways i n  Cachectic Skeleta l M uscle 
4 .3 .3 .1  Resu lts 
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Eleven KEGG pathways are different ia l ly downregu lated in cachect ic muscles cases 
vs weight-stable muscles .  Several of these pathways share many of the same 
genes (Table 1 1 ) . We decided to col lective ly  ca l l  these pathways ( i . e .  hypertrophic 
cardiomyopathy, d i lated cardiomyopathy, arrhythmogenic right ventricular 
card iomyopathy, and cardiac muscle contraction) ;  the card iac m uscle contraction 
and cardiac myopathy pathway.  Also, v ia studying the nature of the genes involved 
in the insu l in  signal ing pathway,  we decided to call it g lycogen metabol ism pathway. 
Table 1 1  shows the ind iv idua l  genes in each pathway and the overa l l  statistical 
sign ificance for each of these pathways. Table 12 shows a summary of the fu l l  gene 
name, fold change, and P-value for individua l  genes in each pathway. 
Table 11: Different ia l ly Downregulated KEGG Pathways in  Cachectic Skeletal 
Muscle. 
KEGG Gene Gene Gene Gene Gene Gene Gene Gene P-Pathway value 
Hypertrophic 
IGardlo- jATP2A2 CACNA2D1 CACNA2D3 ITGB6 SGCD TIN TPM2 0 0001 imyopathy 
Dilated cardlo- jATP2A2 CACNA2D1 CACNA2D3 ITGB6 SGCD TIN TPM2 0.001 Imyopathy 
jArrhythmo-�enlc right 
Iventricular jATP2A2 CACNA2D1 CACNA2D3 ITGB6 SGCD CTNNA3 0 003 
ardlo-�yopathy 
�ardlac muscle jATP2A2 CACNA2 D 1  CACNA2D3 TPM2 ATP 1 B4 0 02 ontractlon 
I nsul in signaling PHKA1 PHKB PPP1 R3A PPP1 R3B PPP1 R3C 0 002 pathway 
ivallne leucine land IsoleUCine AUH ACADM ACADSB DLD 0 02 �egradation 
Parkinson s NDUFB5 NDUFS 1 ATP5B PINK1 PARK2 UBE2G1 0.028 �Isease 
!calcium 
is lgnaling jATP2A2 �G PHKA1 PHKB LCB1 I �PP3CB PHKG1 0 029 
pathway 
Long-term .tAMK2J2 IPP� 0 062 potentiation 
MAPK signaling 
[pathway EGF CACNA2D 1 CACNA2D3 PTPRR �C8 MEF2C 0 064 
jA lzhelmer s � Isease ATP2A2 NDUFB5 NDUFS1 ATP5B LC81 �P3CB 0.066 
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FOR 
0 01 
2 
0 06 
3 
0.06 
4 
0 07 
8 
0 33 
0 29 
0 33 
0.31  
0.51 
0 48 
0 46 
so 
Table 1 2 : Data of I ndiv idual Genes In  the Downregu lated KEGG Pathways in 
Cachectic Skeletal Muscle. 
Gene Gene F u l l Name Fold p-
Symbol Change Value 
M uscle-Down 1 Hypertrophic c a rd iomyopathy (H C M) 
ATP2A2 ATPase, Ca++ transporting,  cardiac m uscle, slow -2 .36 0. 0096 
twitch 2 
CAC NA2 D 1  calc ium channel ,  voltage-dependent, a lpha 21delta -3 37 0 .00 1 8  
subunit 1 
CACNA2D3 calciu m channel,  voltage-dependent, a lpha 2/delta -3 65 0 .0052 
subunit 3 
I TG B6 Inteqrin ,  beta 6 -5 09 0.0002 
P R KAB2 protein kinase, AMP-activated , beta 2 non-cata lytic -2 64 0.0001 
subunit 
SGCD sarcog lyca n, delta (35kDa dystrophin-associated -2 .53 0 .01 37 
glycoprotein) 
TIN Titln -2 .09 0.0 1 35 
TPM2 tropomyosin 2 (beta) -2 44 0 .00 1 9  
M uscle-Down I D i lated c a rd iomyopathy 
ATP2A2 ATPase, Ca++ transporting ,  cardiac muscle, slow -2 36 0.0096 
twitch 2 
CACNA2 D 1  calcium channel ,  voltage-dependent, alpha 2/delta -3.37 0 .00 1 8  
subunit 1 
CAC NA2 D3 calc ium channel ,  voltage-dependent, alpha 2/delta -3.65 0.0052 
subunit 3 
ITG B6 inteqnn,  beta 6 -5.09 0.0002 
SGC D sarcog lycan ,  delta (35kDa dystrophin-associated -2 .53 0 .01 37 
_glYcoprotein) 
TIN Titin -2.09 0 .01 35 
TPM2 tropomyosin 2 (beta) -2 .44 0 .00 1 9  
M uscle-Down I I ns u l i n  s igna l ing  pathway 
P H KA1 phosphorylase kinase, a lpha 1 pseudogene 1 ;  -2 . 2 1  0.0 1 85 
phosphorylase kinase, alpha 1 (muscle) 
P H K B  phosphorylase kinase, beta -2 .46 0 .00 1 6  
P H KG 1  phosphorylase kinase, gamma 1 (muscle) -2. 1 4  0 .0 1 42 
P R KA B2 protein kinase, AM P-activated, beta 2 non-catalytic -2.64 0 .0001 
subunit  
P P P 1 R3A protein phosphatase 1 ,  reg u latory ( inh ibitor) subunit -2 . 52 0.0099 
3A 
P P P 1 R3B protein phosphatase 1 ,  reg u latory ( inh ibitor) subunit  -2 . 97 0. 0040 
3 B  
P P P 1 R3C protein phosphatase 1 ,  regu latory ( inh ibitor) subunit  -2 53 0.0081 
3C 
SOS2 son of seven less homolog 2 (Drosoph i la) -2 .39 0 . 0005 
M uscle-Down I Arrhythmogenic rig h t  ventricu lar  c a rd iomyopath\ (ARVC) 
ATP2A2 ATPase, Ca++ transporting ,  cardiac m uscle, slow -2 .36 0.0096 
twitch 2 
CACNA2 D 1  calc ium channel ,  voltage-dependent, a lpha 2/de lta -3.37 0 .00 1 8  
subunit 1 
CACNA2 D3 calcium channel ,  voltage-dependent, alpha 2/delta -3.65 0. 0052 
subun it 3 
CTN NA3 catenin (cad herin-associated protein), a lpha 3 -4.38 0 .0007 
ITGB6 integrin,  beta 6 -5.09 0. 0002 
SGCD sarcoglycan,  delta (35kDa dystrophin-associated -2 . 53 0.0 1 37 
5 1  
glycoprotein ) 
M uscle-Down / Card iac m uscle contraction 
ATP 1 B4 ATPase, (Na+ )/K + transporting, beta 4 polypeptide -2 87 0.01 26 
ATP2A2 ATPase, Ca++ transporting ,  cardiac muscle, s low -2 36 0.0096 
twitch 2 
CACNA2 D 1  calciu m  channel ,  voltage-dependent, alpha 2/delta -3 37 0 .00 1 8  
subunit 1 
CAC NA2 D3 ca lc ium channel ,  voltage-dependent, alpha 2/delta -3.65 0.0052 
subu n it 3 
TPM2 tro�omyosln 2 (beta) -2 44 0.00 1 9  
M uscle-Down / Va l i ne,  leucine and isoleuc ine  degradation 
AUH AU RNA binding protein/enoyl-Coenzyme A -2 . 1 6  0.0007 
hydratase 
ACADM acyl-Coenzyme A dehyd rogenase, C-4 to C-1 2 -3.64 0.0004 
straight chain 
ACADSB acyl-Coenzyme A dehydrogenase, short/branched -2.20 0 .0055 
chain 
OLD d ihydrol ipoamide dehydrogenase -2 .09 0.0026 
Muscle-Down / P a rk inson 's d isease 
ATP5B ATP synthase, H +  transporting ,  mitochondrial  F 1  -2. 1 0  0.00 1 2  
complex, beta polypeptide 
Ndufb5 NADH dehydrogenase ( u biqu i none) 1 beta -2 .04 0. 0009 
subcomplex, 5 ,  1 6kDa 
NDUFS1  NADH dehydrogenase (ub iqu inone) Fe-S prote i n  1 ,  -2 . 34 0.0005 
75kDa (NADH-coenzyme Q reductase) 
P lnk1  PTEN induced putative kinase 1 -2. 1 6  0 .01 53 
park2 Parkinson d isease (autosomal recessive, juven i le )  2 ,  -3.26 0 .00 1 2  
parkin 
u be2g 1 ub iqu itin-conjugating enzyme E2G 1 ( U BC7 -2 . 0 1  0.0063 
homolog, yeast) 
Muscle-Down / Ca lc ium s igna l ing pathway 
ATP2A2 ATPase, Ca++ transporting ,  card iac m uscle, slow -2 . 36 0.0096 
twitch 2 
CAM K2G calciu m/calmodul in-dependent protein kinase I I  -2.09 0.0068 
gamma 
PLC B 1  phosphol ipase C,  beta 1 (phosphoinositide-specific) -2 .06 0. 0057 
P H KA1 phosphory lase kinase, a lpha 1 pseudogene 1 ;  -2 . 2 1  0 .0 1 85 
phosphorylase kinase, a lpha 1 (muscle) 
P H K B  phosphorylase kinase, beta -2 .46 0 .00 1 6  
P H KG 1  phosphorY_lase kinase, gamma 1 (muscle) -2 . 1 4  0 .0 1 42 
P P P3CB protei n  phosphatase 3 (formerly 2 B) ,  catalytic -2 .06 0 .01 39 
subu n it ,  beta isoform 
M uscle-Down I Long-term potentiat ion 
CAM K2G calciu m/calmodul in-dependent protein k inase I I  -2 .09 0. 0068 
gamma 
PLC B 1  phosphol ipase C, beta 1 (phosphoinositide-specific) -2 06 0 .0057 
P PP3CB protei n  phosphatase 3 (formerly 2 B) ,  cata lytic -2 . 06 0.0 1 39 
subunit ,  beta isoform 
RPS6 KA3 ribosomal protein S6 k inase,  90kDa,  polypeptide 3 -2 . 02 0.0001 
M uscle-Down I MAPK signal ing pathway 
CACNA2 D 1  calcium channel ,  voltage-dependent, alpha 2/delta -3.37 0 .00 1 8  
subunit 1 
CACNA2D3 ca lci u m  channel ,  voltage-dependent, alpha 21delta -3.65 0.0052 
subunit 3 
EGF epidermal�!owth factor (beta-urogastrone) -2 . 4 1  0 .0008 
S2 
M E F2C myocyte enhancer factor 2C -2 1 2  0 01 63 
P PP3CB protein phosphatase 3 (formerly 2 B), catalytic -2 06 0 .01 39 
subun it, beta isoform 
PTPRR protein  tyrosine phosphatase, receptor type, R -7 .61 0 0 1 77 
R PS6KA3 nbosomal protein S6 kinase, 90kDa, polypeptide 3 -2 .02 0.000 1 
SOS2 son of seven less homoloQ 2 ( Drosophi la) -2 .39 0.0005 
Musc le-Down I Alzheime r's d isease 
ATP5B ATP synthase, H+  tra nsport ing,  mltochondnal F 1  -2. 1 0  0.00 1 2  
complex, beta polypeptide 
ATP2A2 ATPase, Ca++ transport ing ,  cardiac muscle, slow -2 .36 0.0096 
twitch 2 
Ndufb5 NADH dehydrogenase (ubiquinone) 1 beta -2 04 0 .0009 
subcomplex, 5 ,  1 6kDa 
N DUFS1  NADH dehydrogenase (u biquinone) Fe-S protein 1 ,  -2 34 0.0005 
75kDa (NADH-coenzvme Q reductase) 
PLC B 1  phosphol ipase C, beta 1 (phosphoinositide-specific) -2.06 0 .0057 
P PP3CB protein  phosphatase 3 (formerly 2 B), catalytic -2 06 0 .01 39 
subun it, beta Isoform 
4 . 3 . 3 . 2  Discussion 
C a rd iac M u scle Contract ion a n d  C a rd i a c  Myo pathy Pathway 
Expression of two L-type voltage-gated calcium channel  (VGCC) subunits genes are 
downregulated in the "card iac muscle contraction and cardiac myopathy" pathway;  
CACNA2D 1  and CACNA2D3. VGCCs are mu lti-subunit membrane prote ins that 
regulate calcium influx i nto excitable cel ls  ( i . e .  card iac, smooth ,  and skeletal muscle 
cells) [ 1 46]. Specific subunits are expressed d ifferential ly in d ifferent t issue types. 
CACNA2D 1  and CACNA2D3 are a2iS genes that form two l inked subunits; a2 and is 
(which are both the product of the same gene)  that interacts the most with the a 1  
subunit .  Co-expression of t h e  a2iS enhances the level of expression of the a 1  
subunit and causes a n  increase i n  current ampl i tude, faster act ivation and 
inactivation kinetics and a hyperpolariz ing sh ift in the voltage dependence of 
i nactivat ion. 
Other downregulated genes in the same pathway are the A TP2A2 and TPM2. These 
two genes previously reported as a short-term response gene in muscle in response 
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to atrophy Induction [ 1 47] .  ATP2A2 encodes one of the SERCA Ca2+-ATPases, 
wh ich are Intracel lu lar  pumps located in the sarcoplasmic reticu lum of muscle ce l ls 
which function is coupled with the calc ium transient from the cytosol to the 
sarcoplasmic reticu lum lumen, and is involved in calcium sequestration associated 
with m uscular excitat ion and contract ion. TPM2 is a skeletal muscle contract i le gene 
that IS reported to cause muscle weakness when mutated [ 1 48 ,  1 49] . PRKAB2, on 
the other hand , is the regu latory non-cata lyt ic beta subunit  gene for the AMP­
activated protein kinase (AMPK) .  PRKAB2 is a posit ive regu lator of the AMPK that is 
h ig h ly expressed in skeletal muscle [ 1 50]. AMPK is an important energy-sensing 
enzyme that monitors cel lu lar  energy status in response to ce l lu lar  metabolic 
stresses. PRKAB2 is also reported to be downregulated in a mouse model of 
severe cachexia [ 1 5 1 ] . These two genes (TPM2 and PRKAB2) m ight contribute to 
the muscular fat igabi l i ty and decreased mobi l ity that are evident signs of cachexia . 
The SGCD gene is one of four known components of the sarcoglycan complex, 
which is a fami ly  of transmembrane prote ins and a subcom plex of the dystrophin­
g lycoprote in com plex (DGC).  DGC is responsible for connecting the muscle fi bre 
cytoskeleton to the extrace l lu lar  matrix, preventing muscu lar  damage. Mutations in 
th is gene have been associated with autosomal  recessive l imb-g i rd le  muscular 
dystrophy which is characterized by prog ressive muscle wast ing [ 1 52] .  
Tit in (TIN) is the th ird most abundant sarcomeric protein in muscle; an adult human,  
80 kg weight, have a pproximately 0 .5  kg of tit in [ 1 53] .  Mutation in TIN gene is 
known to cause t ib ia l  m uscu lar  dystrophy which is characterized by weakness and 
atrophy that is  usual ly  confined to the tibialis anterior m uscle [ 1 54] .  One of the ma in  
funct ions of  t it in is  to support the contracti le e lements and mainta in muscular 
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elasticity [ 1 54] . Tit in also plays a key ro le in m ult iple s ignal ing pathways, being a 
b inding s ite for mu lt ip le l igands for a large number of other muscle proteins [ 1 54]. 
The integnn beta 6 ( ITGB6) gene is h igh ly expressed in skeletal muscle [ 1 55]. I t  is 
downregu lated in mouse models of cachexia [ 1 56] I ntegrins are a group of 
transmemebrane receptors that have two d ifferent chains, the a lpha and beta 
subunits that form obl igate heterodimers. I n  mammals ,  there are eighteen a and 
e ight � subunits [ 1 57]. This downregulation of ITGB6 is of un ique interest in the 
context of cachexia because our data shows u pregulation in a lmost every single 
subu nit i n  a l l  integrins (though not statistica l ly  s ign ificant in  any) except for the 
ITGB6. 
CTNNA3 is  one of three a lpha-catenin genes [ 1 58] .  Alpha-T-caten in  belongs to the 
fami ly of ce l l-cel l  adhesion molecules and is bel ieved to act as a l ink between 
cadhenns and act in-containing f i laments of the cytoskeleton result ing in strong cel l­
cel l  adhesion [ 1 58]. I t  is  expressed in card iomyocytes, skeletal muscle, testis and 
bra in [ 1 58] .  I n  s i l ico ana lysis revealed that the a lpha-T-catenin promoter conta ins 
several b inding sites for card iac and m uscle-specific transcription factors [ 1 58] . The 
two known promoters for CTN NA3 are either unexpressed (GATA4) or  s ignificantly 
downregulated (MEF2C) in our cachectic muscle samples (data from orig ina l  fi le) 
[ 1 58] .  
G lycogen Metabol i s m  Pathway 
Another downregu lated pathway is the insu l in  S igna l ing pathway which we rather 
cal l  "Glycogen metabol ism Pathway" due to the function of the genes involved. 
Three phosphory lase k inase genes (PHKA 1 , PHKB ,  and PHKG 1 )  and three protein 
phosphatase 1 (PP 1 ) genes (PPP1 R3A, PPP1 R3B,  and PPP1 R3C) are 
downregu lated . Phosphorylase kinases are a serine/threonine-specific protein 
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k inase wh ich activates g lycogen phosphorylase to release g lucose-1 -phosphate 
from g lycogen [ 1 59J. Protein phosphatases 1 ,  on the other hand, are a class of 
protein serine/threonine phosphatases that inactivate the act ive (phosphory lated) 
form of phosphorylase and a lso act ivate the inactive form of g lycogen synthase 
[ 1 60J. These two groups of prote ins play a crucial  ro le in the regulation of g lycogen 
metabol ism.  In muscle ce l ls ,  to power activity instantly when energy is in demand, 
glycogenolysis is needed to hydrolyze the stores of g lycogen to g lucose by the 
sequent ia l  removal of g lucose monomers .  This provided a prompt energy supply for 
immed iate activity in muscle cel ls  [ 1 59] .  Phosphorylase kinase stimulates g lycogen 
hydrolysis into free g lucose by phosphorylati ng g lycogen phosphorylase and 
stabi l iz ing its active conformation[ 1 59]. This is the rate- l imit ing step in 
g lycogenolysis [ 1 59] .  Phosphory lase "a" in i ts active R state has PP1 bound tightly 
preventing any phosphatase activity of PP1  and mainta ins the active phosphory lated 
configuration resu lt ing in a cascade of events that generate the requ i red energy.  
These changes in gene expression are l i kely to be involved in the known reduction 
in g lycogen turnover in pat ients with cancer cachexia ,  wh ich in turn leads to muscle 
weakness and rapid fat igue [ 1 6 1  J. PRKAB2is a 5'-AMP-act ivated protein k inase 
subunit beta-2 that encodes for the regu latory subun it of the AMP-activated prote in 
k inase (AM PK) .  AMPK is an important energy-sensing enzyme that monitors ce l lu lar  
energy  status.  This subu nit may be a positive reg ulator of AMPK activity that is 
h igh ly  expressed in skeletal muscle [ 1 62] .  PRKAB2 knockout m ice had reduced 
maximal  and endurance exercise capacity during treadmi l l  running which was a lso 
associated with a lso reduced levels of muscle a nd l iver g lycogen [ 1 62] . 
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C a l c i u m  S i g n a l i n g  Pathway and Long Term Pote ntiation 
CAMK2G encodes for calci um/ca lmodu l in-dependent protein kinase type I I  gamma, 
which is invo lved i n  sarcoplsamic  reticu lum Ca2+ transport in skeletal muscle [ 1 63] .  
In slow-twitch m uscles, is involved in reg ulation of sarcoplasmic reticu lum Ca2+ 
transport and I n  fast-twitch muscle part ic ipates in the control of Ca2+ release from the 
sarcoplasmic reticu lum through phosphorylation of the ryanodine receptor-coupl ing 
factor triad in .  I n  neurons, may participate in the promotion of dendrit ic spine and 
synapse formation and maintenance of synaptic p lasticity wh ich enables long-term 
potentiation ( L  TP) .  
PLCB1  encodes for phosphol ipase C ,  beta 1 which cata lyzes the formation of 
inositol 1 , 4 , 5-trisphosphate and d iacylg lycerol from phosphatidyl inositol  4 ,5-
bisphosphatephosphatidyl inositol 4 ,5-bisphosphate. This is an important part of  the 
calcium signa l ing second messenger system that is crucial for m uscle cel l  g rowth 
and different iat ion [ 1 64] . 
Parkinson's  D isease and Alzheimer's Disease 
Three genes a re downregulated in Parkinson's and Alzhe imer's d iseases; NDUFS1 , 
NDU FB5, and ATP5B.  Both N D U F S 1  and NDUFB5 encode subunits of proteins in 
the Complex I. Complex I or NADH :  ub iquinone oxidoreductase, is the fi rst enzyme 
of the mitochondria l  e lectron transport chain that in it iate cel lu lar  respi ration or 
oxidative phosphorylation in the mitochondria in the inner m itochondrial  
membrane.ATP5B is a subun i t  of the ATP synthase. I t  cata lyzes ATP synthesis 
through using the proton motive force created by the e lectron transport chain across 
the inner membrane as a source of energy in the process of oxidative 
phosphory lat ion .  
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I t  is  clear that common genes in  the Parkinson's and Alzheimer's d iseases might 
sound at the face value to be i rrelevant in the context of cancer cachexia .  However, 
these are genes at the core requ i rements for cel l u lar respirat ion ,  and hence energy 
generation in m uscle cel ls and can clearly contribute to the poor mobi l ity and 
fat igabi l ity in  cachectic patients. 
4.4 Ana lysis of H i g h ly S i g n i fi c a ntly A l te re d  Genes in Cac hectic M uscles 
From our experience, data generated via high throughput gene expression 
technology is more l i kely to be reproduced via other confi rmatory gene expression 
methods such as quantitative RT-PCR only when it has the h ighest statist ical 
s ignificance leve ls .  Thus, we decided to data-mine our expression data and iso late 
selected genes with more than two-fold change, h ighest P-va lue ,  and lowest 
possible FOR.  I n  muscle, 30 genes showed h igh ly sign ificant change in expression 
(5 u pregulated and 25 downregu lated: P<0.0005 - P<0.00001 ,  FOR 0.2) .  
4.4. 1 H ig h ly S i g n if ica ntly U preg u lated Genes 
4.4. 1 . 1  Res u l ts 
Table 1 3  shows the 5 h igh ly sign ificantly u pregu lated genes i n  cachectic muscle. 
(P<0.0005 - P<0.0000 1 , FOR 0 .2 ) .  They include 2 involved with calci um signal ing 
and 2 with cel l matrix interact ions, and one transcript ional  regu lator. Table 13 
categorizes ind ividua l  gene funct ion into respective funct ional  domain .  I t  a lso shows 
the fu l l  gene name,  fo ld change, and the P-value.  
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Table 1 3 : H igh ly Significantly Upregulated Genes in Cachectic Skeletal Muscle. 
Gene Gene Fu l l  Name Fold P-Va lue  
Sym bol change 
Sig nal ing 
PLCXD1  phosphatidyl inosltol-speclfic phosphol ipase C,  X domain 4.60 <0. 0000 1 
conta in ing 1 
P ITPNM2 phosphatldyl lnosltol transfer prote in ,  membrane- 3.82 0. 00005 
associated 2 
Cel l  Matrix i nteraction 
ESAM endothel ia l  ce l l  ad heSion molecule 3 .39 0.0004 
PXN Paxi l l in  2 . 1 6  <0. 00001 
Transcription 
MLLT1 myeloid/lymphoid or mixed-l ineage leukemia (trithorax 2 .36 < 0 .0003 
homolog , Drosophi la) ;  translocated to, 1 
4.4. 1 . 2  Disc ussion 
C a l c i u m  S i g n a l i n g  G enes 
Two genes which a re suggested to be involved in s ignal ing are significantly 
upregulated in cachect ic muscles; P LCX0 1 and P ITPNM2.  PLCX01 codes for 
phosphatidyl inositol-specific phosphol ipase C ,  X domain conta in ing 1 .  
Phosphol ipase C (PLC )  is a g roup of enzymes with d ifferences i n  domain structure ,  
that cleave the phosphol ipid phosphatidyl i nositol 4 , 5-bisphosphate (P I P2) into d iacy l  
g lycerol (OAG) a nd inositol 1 ,4 , 5-trisphosphate ( I P3). DAG remains bound to the 
membrane, and I P3 is re leased as a soluble structure into the cytosol to b ind to I P3 
receptors, particu larly  calc ium channels in the smooth endoplasmic reticu lum.  Th is 
causes the cytosol ic concentration of ca lc ium to increase, causing a cascade of 
intracel lu lar  changes and activity [ 1 65,  1 66] .  I n  turn, calcium and OAG together work 
to activate protein k inase C, wh ich goes on to phosphorylate other molecules, 
leading to a ltered cel lu la r  activity [ 1 65] .  Phosphol ipases are u biquitously expressed 
and have diverse biological funct ions [ 1 66] .  In tumor cel ls ,  PLCX 0 1  suppress 
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g rowth when transfected In melanoma cel l  l ine [ 1 67] . There are no further functional 
studies characterizing th is gene, however, l ike other phosphol ipases ,  it undoubtedly 
plays an important role in cel lu lar  s ignal ing specifical ly through calcium release, 
wh ich is important in modu lat ing many muscle-related funct ions. 
The second upregu lated gene is P ITPNM2 which codes for phosphatldyl inositol 
t ransfer  prote in (P ITP) membrane-associated 2 prote in .  PITP prote ins are 
u biqu itous cytosol ic domain involved in transport of phosphol ip ids from their site of 
synthesis in the endoplasmic reticu lum and Golgi  to other cel l  membranes. 
P ITPNM2 is not functional ly  characterized yet. H owever, P ITPa, a member of the 
PITP fami ly that was also upregulated in our study, was ident ified as an essent ia l  
component in ensuring substrate supply to phosphol ipase C by d ictat ing the rate of 
inositol tr isphosphate production by promoting the synthesis of P I P2 [ 1 68] .  
Thus,  these two genes could be funct ioning through I P:JDAG pathway. Thus, 
P ITPNM2 might be promoting P I P2 synthesis and making it readi ly  avai lable for PLC 
( in  our  case is PLCXD 1 )  which in turn cleaves the P I P2 into P I P3 and DAG. Both of 
which work as key second messengers, which via mu lt iple cascades of events, 
causes Ca2+ transient i nto the cytosol .  Calcium ,  in turn, part ic ipates in the cascade 
by activating proteins.  
Cel l  M atr ix  I nteract ion 
Two cel l  matric interaction genes were markedly upregu lated in cachectic muscles; 
ESAM and PXN. ESAM encodes ffi an endothel ia l  ce l l -selective adhesion molecu le .  
Though ESAM has never been studied, per 5e, in  skeleta l muscle, it has been 
studied in the context of coronary vascu lar  disease (CVD) and kidney d isease [ 1 69] . 
Skeletal muscle vasculatu re is of considerable importance. Around 20% of card iac 
output is  d i rected towa rd skeletal muscle vasculature during rest and more than 
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80% of card iac output can be d i rected to contracting muscles. I ncreased expression 
of ESAM may Ind icate early endothel ia l  dysfunction that precedes kidney function 
decl ine among ind ividuals with establ ished CVD [ 1 69] .  Also, induced endothel ia l  
dysfunction in skeletal muscle arterioles compromise g lucose uti l ization and 
facI l i tates the development of hypertension in d iabetes [ 1 70] . Muscular vasculature 
is of a g reat Importance to m uscle development, ma intenance,  and funct ion. The 
dysfunct ional vascular endothe l ium associated with h igher ESAM in CVD and 
kidney d isease may ind icate the importance of ESAM in healthy muscular 
vasculatu re .  Thus, h igher  ESAM in the muscle of cachectic patients may have a 
deleterious effect in vasculature com promis ing blood flow and/or g lucose ut i l izat ion. 
Paxi l l in  (encoded by PXN)  is a s ignal  transduct ion,  adaptor, cytoskeleta l ,  
extrace l lu lar  matrix (focal adhesion) protein involved in  act in-membrane attachment 
[ 1 7 1 ] . The C-termina l  reg ion of paxi l l in  conta ins fou r  LIM domains that target paxi l l in  
to focal adhesions. I t  is presumed through a d i rect association with the cytoplasmic 
ta i l  of beta-integrin [ 1 7 1 ] . The N-term inal  reg ion of paxi l l in  is r ich in p rotein-prote in  
interact ion s ites [ 1 7 1 ] . 
One might wonder why two cel l  matrix i nteract ion proteins are upregu lated in 
m uscles of patients with ear ly cachexia . However, muscle hypertrophy (not 
hyperplasia) in both cardiac and skeletal m uscle is an adaptation to reg ular, 
increasing workloads that exceed the preexisting capacity of the muscle fibers. Thus 
hypert rophy a l lows card iac m uscle to pump b lood more effectively, whi le skeleta l 
m uscle becomes more efficient at transmitt ing forces through its tendonous 
attachments to bones [ 1 72] . Pax i l l in  has been associated with the reg ulation of 
cytoskeletal organization ,  focal adhesion format ion ,  cel l  migration and cel l  moti l i ty 
[ 1 73] .  Paxi l l i n  is also local ized to the myotendinous and neuromuscular j unctions of 
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skeleta l muscle [ 1 74] . Whi le expression of  non-phosphorylatable paxi l l in  mutants in  
canine tracheal smooth muscle inh ibits tension development [ 1 73]. 
Wasted patients are usual ly weaker. That said,  normal/regular activit ies can be 
envisioned as progressive overload causing intermittent levels of stress to skeletal 
m uscle .  Thus, as an adaptation to wasting , paxi l l i n  may be attempting but fa i l ing to 
promote hypert rophy in this situat ion. Muscular hypertrophy means its abi l ity to 
adapt by increasing the s ize and amount of contract i le proteins (ce l l  matrix 
interact ion prote ins) ,  which comprise the myofibri ls with in each muscle fiber, leading 
to an i ncrease in the size of the ind iv idual  muscle fibers and their consequent force 
production [ 1 72]. That is s im i lar  to previously reported evidence of the increased in  
paxi l l in  expression a long other proteins u pon the i ncreased mechanical load per  unit 
of cross-sect ional area dur ing short period of an increasing load [ 1 75] .  
T ra n s c r i pt ional  Reg u lation 
Transcript ional  regulat ion is a compl icated series of mechanisms used by cel ls  to 
increase or decrease the expression of specific gene products. These soph isticated 
programs of gene expression serve several purposes of wh ich developmental and 
adaptive responses are j ust a few. Transcript ional regu lation is a versat i le and 
adaptable mechanism a l lowing the cel l  to express prote ins when needed. For these 
reasons, upregulat ion of genes involved in transcript ional regulat ion is expected in 
the context of wasti ng m uscle. Whether cachectic muscles d ie via a poptosis or 
necrosis ,  attem pt to regenerate or differentiate, or just change in its morphogenic 
features, regu lation of transcription is defin itely needed. 
MLL T1 gene, or myelo id/lymphoid or mixed-l ineage leukemia trans located to 1 ,  
codes for a transcript ional  reg ulator that is h igh ly significantly upregu lated in 
cachect ic muscle . MLL T 1  has never been studied i n  the context of cachexia nor 
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muscular  transcriptional regu lat ion. However, evidence suggests an important 
developmental role of th is gene.  MLL T1  has nuclear loca l ization s igna l ,  and 
expressed widely in variant t issues suggesting its role as a coactivator act ivating 
indiv idual l i neage developmental programs [ 1 76]. MLLT1 has been shown to be 
requ i red for early  embryonic development in the mouse, as knock-out embryos are 
non-viable [ 1 76]. Also, an enhanced MLL T1 expression plays a ro le in test icular 
germ cel l  tumors [ 1 77]. Thus,  M LL T1 gene could be an activator for gene 
expression of m ult iple genes that can either expla in  the pathology of wast ing and/or 
i l lustrate an early compensatory role to resist wasting .  Identifying which of these 
roles MLL T1 p lays would requ ire further investigation .  
4.4. 2 H i g h ly S i g n if icantly Downre g u lated Genes 
4.4. 2 . 1  Resu lts 
Table 1 4  shows the 5 h igh ly s ign ificant ly downregu lated genes in cachectic m uscle. 
(P<O 0005 - P<0.0000 1 , FOR 0 .2 ) .  Analysis of the 25 downregu lated genes involved 
include 7 that are involved with metabol ism (5 of which a re m itochondria l ) ;  4 with 
s ignal ing;  4 with ubiq u it ination ; and 3 with intrace l lu lar  trafficking.  There was marked 
downregu lat ion of mu lt iple genes involved in g lycogen metabol ism which corre lates 
with the lack of g lycogen,  muscle weakness, and fatigue;  characteristic of cachexia. 
Table 1 4 , a lso categorizes i nd iv idual  gene function into respect ive functional 
domain .  I t  also shows the fu l l  gene name,  fold change, and the P-value.  
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Table 1 4 .  Highly S ign ificantly Downreg ulated Genes in Cachect ic Skeletal Muscle. 
Gene Gene F u l l  Name Fold P-Va l u e  
Symbol C hange 
M itochondria l Meta bol ism 
SUCLA2 succlnate-CoA l igase, ADP-form lng,  beta subunit -2.33 <0. 0003 
ALDH5A 1  aldehyde dehydrogenase 5 fami ly ,  member A 1 -4 . 1 6  <0 .00001 
ACADM acyl-CoA dehydrogenase, C-4 to C-1 2 stra ight chain -3.64 <0. 0004 
NARS2 asparag lnyl-tR NAsynthetase 2 ,  mitochondrial -2.05 0 0003 
(putative) 
N N T  nicotinamide nucleotide transhydrogenase -2.62 0. 00003 
Metabol ism 
PRKAB2 protein kinase, AMP-activated, beta 2 non-cata lytic -2.64 0 .0001  
subunit 
AGL amylo-a lpha- 1 ,  6-g lucosidase, 4-alpha- -3. 5 1  0 .0002 
g lucanotransferase 
Sig nal ing 
PLCL 1 phosphol ipase C-l ike 1 -3.64 <0. 00008 
NXPE3 neurexophl l in  and PC-esterase domain fami ly, -2.90 <0. 00005 
member 3 
ZFYVE9 zinc fi nger, FYVE domain conta in ing 9 -2.07 0 .0002 
RPS6KA3 ribosomal protein  S6 kinase, 90kDa, polypeptide 3 -2 .02 <0. 00008 
Z N F4 1  Z inC finger protein  4 1  -2. 1 2  0 .0003 
M uscle Contraction 
PPP 1 R 1 2B protein  phosphatase 1 ,  reg u latory subunit 1 2B -2. 1 0  0. 00005 
Cel l  Matrix I nteraction 
ITGB6 integr in ,  beta 6 -5.09 0.0002 
Ubiq u it ination 
WWP1 WW domain conta in ing E3 ubiq uit in protein l igase 1 -3.37 0.0000 1 
ZYG 1 1 B zyg- 1 1 fam ily member B, cell cycle regu lator -3.0 1  0 . 00007 
F BXL 1 7  F-box and leucine-rich repeat protein 1 7  -2 . 38 0 .00005 
DCAF6 D D B 1  and CUL4 associated factor 6 -2 .59 0 . 0004 
I ntace l lu lar  Trafficking 
RAB9B RAB9B, member RAS oncogene fami ly -3. 1 0  <0. 00009 
RAB 1 0  RAB 1 0, member RAS oncogene fami ly -2 . 1 8  0.00006 
C LASP2 cytoplasmic l inker associated protein 2 -2. 30 0. 0004 
Apol i poproteins 
VLDLR very low density l ipoprotein  receptor -2 .9  <0.00005 
APOOL apol ipoprotein O-l ike -2 .06 <0. 0003 
Uncharachterized 
C 1 0rf 1 92 chromosome 1 open read ing frame 1 92 -3.87 <0. 0004 
4.4. 2 . 2  Discussion 
M itoc hondr ia l  Meta bo l ism 
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S UCLA2 (succinyl-CoA l igase [ADP-form ing] m itochondria l )  encodes for ADP­
forming succinyl-CoA synthetase, a mitochondrial matrix enzyme which cata lyzes 
the revers ible synthesis of succinyl-CoA from succinate and CoA [ 1 78] .  It plays a 
key role as one of the catalysts involved in  the citric acid cycle,  a central pathway in 
ce l lu lar  metabol ism [ 1 65] .  Decreased SUCLA2 activity due to mutation was found i n  
m uscle mitochondria of patients with encephalomyopathy and  mtDNA depletion 
[ 1 79] .Myopathy is a d isease of dysfunct ional  muscle fibers result ing in  muscular 
weakness. 
ALDH5A 1 codes for succinate-semia ldehyde dehydrogenase, m itochondria l ,  an 
enzyme that belongs to the aldehyde dehydrogenase fami ly  of proteins [ 1 80] . 
ALDH5A 1 deficiency results in muscle hypotonia and developmental delay [ 1 8 1 , 
1 82] .  Hypotonia is a state of low m uscle tone (the amount of tension or resistance to 
stretch in a muscle) ,  often involving reduced muscle strength .  M ice with a 
homozygous knockout of ALDH5A 1 exh ibit  symptoms including reduced body 
weight [ 1 83] .  
ACADM encodes for an acyl-coenzyme a dehydrogenase that is important for 
hydrolyzing medium-chain fatty acids to produce energy,  especial ly during periods 
of fast ing [ 1 84] . Fatty acid oxidation spares g lucose during fasting and is a lso 
requ i red for amino acid metabo l ism,  which is  essentia l  for the maintenance of 
adequate g lucose production [ 1 85] .  With a deficiency of this enzyme, med ium-chain 
fatty aC ids cannot be hydro lysed then these fatty ac ids are not converted into 
energy,  leading to weakness, lethargy,  and low blood sugar [ 1 86]. Tra in ing 
i ncreases fatty ac id oxidation and skeletal muscle oxidative capacity by increasing 
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expression of ACADM wh ich results in increased use fatty acids to enhance skeletal 
muscle oXidative capacity [ 1 87] .  
NARS2 codes for asparag inyl-tRNA synthetase 2 [ 1 88] . This class- I I  synthetase is 
specific for a lan ine,  asparagine,  aspart ic acid, g lycine, hist id ine , lysine,  
phenyla lan ine,  prol ine,  serine ,  and threonine [ 1 89] . NARS2 m utations cause severe 
myopathy characterized by prox imal  m uscle weakness, severe amyotrophy 
(progressive wasting of m uscle t issues), excessive fat igabi l ity, dysarthr ia ,  paresis of 
facial  muscles, and ptosis [ 1 90] . Skeleta l m uscle biopsies show atrophic fibers, 
ragged-red fibers, and enlarged mitochondria [ 1 90] . Other NARS2 mutations cause 
Leigh Syndrome, which results in hypotonia ( low muscle tone and strength), 
dystonia ( involuntary ,  sustained muscle contract ion) ,  and ataxia ( lack of contro l  over 
movement). Mutations in m itochondrial seryl-tRNAsynthetase , another member of 
the class I I  amino-acyl tRNA fami ly, cause severe cachexia [ 1 9 1 ] . 
NNT codes for n icot inamide nucleotide transhydrogenase, an integral prote in of the 
inner m itochondrial membrane. Under physiologica l  condit ions, th is enzyme uses 
energy from the m itochondria l  proton gradient to produce high concentrat ions of 
NADPH.  The result ing NADPH is used for biosynthesis and in free radical 
detoxification [ 1 92] . 
M eta bol ism 
As mentioned above PRKAB2 is the regu latory non-catalyt ic beta subun it gene for 
the AMP-activated prote in k inase (AMPK) .  PRKAB2 is a positive reg ulator of the 
AMPK that is h igh ly expressed in skeleta l muscle [ 1 50]. AMPK is an important 
energy-sensing enzyme that monitors cel lu lar  energy status .  PRKAB2 is a lso 
reported to be downregu lated in a mouse model  of severe cachexia [ 1 5 1 ] . PRKAB2 
knockout mice had reduced maximal and endurance exercise capacity during 
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treadmi l l  running which was a lso associated with a lso reduced levels of muscle and 
l iver g lycogen [ 1 62]. Thus, PRKAB2 might contribute to the muscular fat igabi l ity and 
the decreased mobi l ity that are evident signs of cachexia . 
AGL codes for the g lycogen debranching enzyme which faci l itates the hydrolysis of 
g lycogen i n  through g lucosyltransferase and g lucosidase activity [ 1 93] .  Mutation in  
AGL causes one of  the g lycogen storage diseases (type I I I )  and results in periphera l 
m uscular  impairment which can vary from min ima l  to severe [ 1 94] as wel l  as muscle 
weakness [ 1 95]. 
S igna l ing 
PLCL 1 codes for phosphol ipase C-Like 1 ,  one of severa l phosphoinositide 
phosphol i pase C enzymes that play an important role in signal transduction [ 1 96] . 
These enzymes participate in phosphatidyl inositol 4 ,5-bisphosphate (P IP2) 
metabol ism in a calc ium-dependent manner. Al l  members in  th is fam i ly are capable 
of catalyzing the hydrolysis of P I P2 into two i mportant second messenger molecules 
( DAG and I P3) , which go on to a lter mult iple cel lu lar  responses such as prol iferation, 
d ifferentiat ion , apoptosis, cytoskeleton remodel ing ,  vesicular trafficking, ion channel 
conductance, endocrine funct ion and neurotransmission.  
However, it is  not the on ly mem ber in the PLC fam i ly that is downregulated . PLC B 1  
is  a lso downregulated in  m ult ip le muscle downregu lated KEGG pathways (Table 
1 2) .  This is  important s ince calc ium s ignal ing is  important for muscle contract ion and 
thus,  it affects muscle contract ion and eventual ly causes weakness. NXPE3 codes 
for neurexoph i l in  and PC-esterase domain fam i ly ,  member 3 which is another 
u ncharacterized gene [ 1 97] .  
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ZFYVE9 encodes a zinc finger FYVE domain-conta in ing protein 9 or SARA (SMAD 
anchor for receptor activation) [ 1 98] .  SARA conta ins a double z inc fi nger (FYVE 
domain) .  SARA is an anchoring protein involved in transform ing growth factor beta 
(TGF-!3) s ignal ing . It binds to the R-SMADs S MAD2 and SMAD3 [ 1 99] . l t faci l i tates 
the phosphorylat ion of the R-SMAD, which subsequently d issociates form SARA 
and the receptor and binds a co-SMAD where they enter the nucleus as 
transcription factors. All S MADs are downstream to myostatin (and TGF-!3 and a l l  of 
its re lated proteins) ,  which is bel ieved to be activated in wast ing muscle.  However, 
our data shows significantly downregu latedmyostat in  i n  cachectic muscles (as wi l l  
be explained in deta i ls  later). Thus ,  a downregu lated ZFYVE9 may be further 
evidence of an adapt ive response to myostatin signa l ing in cachexia .  
RPS6KA3 codes for the ribosomal  prote in S6 kinase which is a member of the RSK 
(ribosomal S6 kinase) fam i ly of serine/threonine kinases.  This kinase 
phosphorylates various substrates ,  including members of the m itogen-act ivated 
kinase ( MAPK) s ignal ing pathway (wh ich one of the downregulated KEGG pathways 
in cachectic m uscles as a bove) [200] .  The activity of th is enzyme has been 
impl icated in control l ing cel l  g rowth and d ifferentiat ion .  In muscle ce l ls ,  it mediates 
cel lu lar  d ifferentiat ion through regulat ion of N FAT3 [20 1 ] . Mutations in th is gene are 
associated with Coffin-Lowry syndrome [202] ,  which is characterized by g rowth and 
psychomotor retardation, hypoton ia ,  and progressive skeleta l changes [203]. Also, 
RPS6KA3 knockout mice have a ltered extrace l lu lar  s ignal-regu lated kinase 
signal ing and g lycogen metabol ism in skeleta l muscle , 1 0% reduction i n  weight, and 
are 1 4% shorter than wi ld-type l ittermates [204]. A study of patients with Coffin­
Lowry syndrome showed episodes of sudden, non-epi leptic col lapse with atonia, 
described as a form of cataplexy (Cataplexy comprises an abrupt, complete, or 
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partial loss of voluntary muscle tone and IS  usual ly seen in response to strong 
emotion) [205] . 
ZNF4 1  encodes for zinc finger protein 4 1 ,  a member of zinc finger fam i ly of 
transcript ion factors [206] . So far, l itt le is known about ZN F4 1 . However, having one 
of the h ighest expressions of ZNF41  in skeletal muscle [207] is an indicator of its 
transcriptional  Importance. 
M uscle Contraction 
PPP1 R3A codes for the regu latory subunit  and myosin b inding sUbunits of myosin 
l ight chain phosphatase (MLCP), wh ich is abundantly expressed in  skeletal and 
cardiac m uscle [208] . This gene plays an important regulatory ro le in muscle 
contract ion. 
U b i q u it inat ion 
Ubiqu it inat ion (a lso known as u biqu itylat ion) is a n  enzymatic, post-translat ional 
modification ( PTM) process in which ubiquit in protein is  attached to a substrate 
prote in ,  target ing the protein  for degradation . This resu lts in the addit ion of one 
(monoubiqu it inat ion) or mu lt ip le (polyubiquit inat ion) u biqu it in  molecules to the 
substrate prote in  [209]. The ubiqui t ination system funct ions in  a wide variety of 
cel lu lar  processes. 
WNP1 codes for a N EDD4- l ike E3 ubiqu it in-prote in l igase,  which belongs to a fami ly 
of E3 ub iqu it in- l igases that regu late key trafficking decis ions, including targeting of 
proteins to proteosomes or Iysosomes.  I nterest ingly ,  studies a imed at understanding 
chicken m uscular dystrophy showed m utations in  WWP1 in  dystrophic ch icken 
[2 1 0] .  Another study on ch ickens treated with dexamethasone (which causes 
wasting) found that WNP 1 expression was dependent on the duration of 
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dexamethasone treatment, short-term resulted in decreased \NWP 1  expression, 
wh i le long-term increased \NWP1 expression [21 1 } . Detection of highly sign ificant 
downregulat ion of \NWP 1 in cachect ic muscles in our patients suggests an adaptive 
response to the early cachexia. 
ZYG 1 1 B codes for zyg- 1 1 fami ly  member B ,  a cel l  cycle regulator protein .  It 
probably acts as target recru itment subunit in the E3  ubiquit in l igase com plex 
ZYG 1 1  B-CUL2-Elongin BC [2 1 2} .  One study showed that erythropoietin (EPO) 
functional knock-out mice have lower ZYG 1 1 B expression in skeleta l m uscle 
compared to contro ls [2 1 3} .  The E PO receptor is h igh ly expressed in muscle and 
may suggest impo rtant ro le of EPO in stimulating skeleta l muscle regeneration 
[21 3] .  
F BXL 1 7  codes for the F-box and leucine-rich repeat protein 1 7 , a member of the F­
box prote in fami ly .  Complexes, formed by the presence of F-box proteins act as 
protein-ubiqu it in l igases [2 1 4] .  There is no further information regard ing th is gene.  
I ntacel l u l a r  Traffi c k i n g  
RAB9B codes for a member of  sub-fami ly  of the  RAS sma l l  guanosine triphosphate 
(GTP)-binding prote ins that reg u late membrane trafficking. The encoded prote in 
may be involved in  endosome-to-Golg i  transport [2 1 5] .  Diseases associated with 
RAB9B include pel izaeus-merzbacher disease which has early onset hypotonia .  
With progressive d isease, even more severe muscu lar  involvement is evident. 
RAB 1 0  codes for another member i n  the RAS oncogene fami ly [2 1 6). RAB 1 0  has 
the highest expression in  heart and skeletal muscle [2 1 7] .  It is involved in the insu l in 
s ignal ing cascade that causes i ntrace l lu lar  vesicles conta in ing g lucose transporter-4 
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(GLUT4) to translocate to and fuse with the plasma membrane and enhance 
g lucose uptake [2 1 8 , 2 1 9] .  
C LASP2 codes for cytoplasmic l inker  associated prote in 2 ,  a microtubule plus-end 
tracking protein that promotes the stab i l ization of dynamic m icrotubules. It is also 
requ i red for the polarization of the cytoplasmic microtubule arrays in migrati ng cel ls 
towards the leading edge of the cel l .  L ike RAB 1 0, C LASP2 has a role in insu l in  
signal ing and g lucose u ptake in myocytes and adipocytes [220] . CLASP2 
coloca l lzes with the g lucose transporter GLUT 4 at the plasma membrane within 
areas of insul in-med iated cort ica l act in remodel ing [220]. CLASP2 knockdown 
inhibits insul in-st imu lated GLUT 4 translocation and g lucose transport [220]. 
This downreg ulat ion of this pathway undoubtedly contr ibutes to the insu l in 
resistance and m uscle fat igue in cachectic patients. 
On the other hand ,  a ha l lmark of the neuromuscular j unct ion (NMJ) is the h igh 
density of  acetylchol ine receptors (AChRs) in  the postsynapt ic muscle membrane 
[22 1 , 222] .  C LASP2 mediates microtubule captur ing at the synaptic membrane for 
the maintenance of a normal neuromuscular phenotype [222, 223] .  The absence of 
C LASP2 Impairs the maintenance of the neuromuscular j unction with a decreased 
subsynapt ic membrane in m uscles, and a decrease of synapt ic AChRs [224] .  The 
sign ificant downregu lat ion of C LASP2 in  cachectic m uscles wi l l  a lter the vital ity of 
the NMJ and it tu rn cause impairment of muscle excitabi l ity [224]. Even more 
interest ingly,  the reg ulat ion of CLASP2 strictly control led by agr in (AGRN)  [223],  
which is itself downregu lated in the KEGG pathways as d iscussed above . 
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A p o l i poprote i n s  
VLDLR IS  a very-low-density-I ipoprote in receptor; a transmembrane l ipoprote in 
receptor of the low-density- l ipoprotein (LDL) receptor fami ly .  VLDLR is widely and 
h igh ly expressed in heart ,  m uscle ,  and adipose t issues, which are active in fatty acid 
metabol ism [225) . so the receptor targets l ipoproteins to these tissues [226] . 
Although the mechanism of VLDLR function in  muscle is not fu l l y  understood , the 
defective clearance of tr iglyceride-rich l ipoprote ins leads to impaired energy 
metabol ism , reduced exercise capacity, cachexia , and malnutrit ion syndrome In 
patients with advanced chronic kidney disease [227]. Also, reduced levels of 
l ipoprotein l ipase and VLDLR contri bute to cachexia and reduced exercise capacity 
[227]. Mutations of this gene causes type I l issencephaly ;  a condit ion of which one 
of the symptoms is h ypotonia [228]. 
APOOL encodes an apol ipoprotein O-l ike prote in .  The apo l iprotein O- l ike domain is 
found i n  the protein  component of circu lat ing l ipoprote in complexes. Apolipoprotein 
o is  a card io l ip in-binding component of the Mitofi l i n/M I NOS prote in  complex 
determin ing cristae morphology in  m itochondria (the fo lds in the inner membrane of 
a m itochondrion) [229]. Downregu lat ion of APOOL impairs m itochondrial  respiration 
and causes major a lterations in cristae morphology; wh ich are only a ltered under 
pathological condit ions [229]. The important para log ; APOO [229].  APOO transgenic 
mouse fed a h igh-fat d iet exhibited depressed ventricu lar  function with reduced 
fract ional shortening a nd ejection fract ion , and the myocard ia l  sections revealed 
m itochondrial degenerative changes [230]. Hence ,  APOO represents a l ink between 
impaired mitochondria l  function and card iomyopathy onset causing impaired 
contract i l ity [230] . Furthermore, APOO enhances m itochondria l  uncoupl ing and 
respirat ion, both of which were reduced by targeted knockdown of APOO [230] . I f  
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that is the case in card iac muscle, then APOOL downregu lat ion in  our  cachectic 
muscle could be an early s ign of impai rment in skeletal muscle contract i l ity as a 
result of damaged mitochondria.  
4.5 Antic i pated Res u l ts from P rev ious Stud ies 
Precl in ica l  studies have a few produced fi nd ings i n  mu lt ip le sett ings that attempt to 
expla in  the pathogenesis of cancer cachexia . Without except ion,  these findings so 
far have fa i led to expla in cachexia in the cl i n ical sett ing .  This sect ion a ims to look at 
some of the prominent findings from cl in ical and precl in ical models of cancer 
cachexia in order to see its reproducibi l ity in our sequencing data . 
4.5. 1 P rec l i n ic a l  F i n d i ngs 
4 .5. 1 . 1  Atro p hy-S pecific U bi q uit in  Ligases 
I t  is long bel ieved that cachexia is a resu lt of a negative nitrogen balance caused by 
decreased protein synthesis combined with increased protein degradation. The 
u biqu it in  proteasome pathway is the main prote in  degradation pathway involved . 
Two genes were repeatedly found to be downregu lated in precl in ical models of 
cachexia ;  F BX032 (atrog in- 1 /MAFbx) and T R I M63 (MU R F 1 ) .  
FBX032 codes for F-box only protein  32 [23 1 ] , wh i le  TRI M63 codes for E3 ubiquit in­
prote in l igase also known as M U RF 1 .  These a re two atrophy-specific ubiqu it in  
l igases that  are two of the several key regu lators of  the ubiquit in proteasome 
degradation pathway. Both of the genes mediate sarcomeric breakdown and inh ib it 
protein synthesis [232]. F BX032 expression was s ign ificantly u pregu lated in 
atrophying muscles in cachectic rats and m ice secondary to fast ing , d iabetes , renal 
fa i lu re or  experimental cancer [23 1 ] . This upregu lat ion was a lso confi rmed in vitro in 
a m urine skeletal muscle cel l  l ine [233]. Both M u R F 1  and MAFbx were substantia l ly  
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upregulated I n  rat skeleta l  muscle after immobi l ization , denervation ,  h ind l imb 
suspension or treatment with interleukin- 1 or dexamethasone; condit ions that  are a l l  
associated with a s ignificant loss of muscle mass [234J .  
I n  our data of cachectic muscle, nether of the two genes were found to be 
upregu lated . I ndeed, in contrast, F BX032 was even found to be sign ificantly 
downregulated. S imi larly, the two major microarray experiments documenting gene 
expression changes in human m uscle biopsies of cachectic patients a lso found no 
change in the expression leve l of e ither of these two genes, which were long 
bel ieved to be key players in the pathogenesis of cachexia [235, 236]. The 
downregulat ion of F BX032 was not a surprise s ince the downregu lat ion of the 
ubiqult in pathway was a lso evident with 4 other h igh ly  s ign ificantly downregulated 
genes (as d iscussed earl ier) .  Oownregulat ion of th is  protein degradation pathway 
may be a compensatory mechanism to defend against wasting in the cachectic 
subjects. 
Myostatin (MSTN) and its associated receptor activin (ACVR2B) have recently 
stolen the l imel ight as a possible cause of cachexia .  MSTN or g rowth and 
d ifferentiation factor 8 (GOF8) is  a TGF-13 fami ly  member. Mutations in the MSTN 
gene causes muscular hypertrophy in  an imals [237] as wel l  as humans [238]. On 
the other hand,  overexpression of MSTN caused pronounced m uscular atrophy 
[239]. 
MSTN which is main ly synthesized in skeletal m uscle cel ls works by activating 
ACVR2B receptor that in turn,  recruits an Alk fam i l y  k inase result ing in  activation of 
a SMA02 and SMA03 transcription factor com plex and lead ing to activation of 
muscle loss signals that are as yet not fu l ly  understood [240J. For that, many 
attem pts have been tried to block th is s ignals i n  atrophying muscle .  For example,  
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blocking the ACVR2 B  receptor in  m ice can reverse cachexia and muscle wasting 
[24 1 ]  
Neither the present study nor the previous c l in ical expression studies have shown 
any upregu lation in MSTN , its receptor, or any downstream e lements. In contrast, 
our  data shows s ign ificant downregu lat ion in both , MSTN and ACVR2B, which again 
may reflect the bodies' com pl icated response to try to prevent wasting. Based on the 
previous animal studies, severa l c l in ica l  tria ls are currently i nvest igat ing the outcome 
of block ing MSTN with monoclonal antibodies or  inh ibit ing elements of its 
downstream s ignal ing .  We bel ieve that because the receptor and downstream 
elements are downregu lated that these tr ia ls are desined to fa i lu re .  However, i t  
m ig ht give some reversal to the syndrome in unique sett ings.  I t  should be noted that 
some cancers a ppear themselves to produce MSTN [242]. If th is is found to be a 
general phenomenon then downregu lat ion of muscle MSTN and its receptor may be 
considered adapt ive responses to protect the m uscle from tumor-derived MSTN.  
A very interesti ng find ing from our  data is the sign ificant overexpression of  GOF 1 5. 
GOF 1 5  is a g rowth and development factor 1 5  (NAG- 1 ;  M I C- 1 ) .  It belongs to the 
transforming g rowth factor beta superfami ly  [243] that has a role in regu lating 
inflammatory and a poptot ic pathways i n  inju red t issues and during d isease 
processes [244] .  In advanced cancer, high serum levels of GOF 1 5 can lead to 
cachexia via central regu lat ion of appetite [245] .  In m ice, cachexia induced by 
GOF 1 5  overexpression can be reversed by ant i-GOF 1 5  monoclonal ant ibodies 
[245] . Our data shows a very i nteresting sign ificantly upregu lated GOF 1 5  in 
cachectic m uscle ( 1 2 .9  fold change ; P-value 0 .028) .  This leve l of change is  reported 
for the fi rst t ime with in the m uscle ,  ind icating its probable role in cachexia 
pathogenesis that warrants further i nvestigat ion. 
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4.5. 2 P rev ious C l i n ic a l  F i n d i n g s  
4.5. 2. 1 I nflam mato ry C ytoki nes a n d  T u m o r  S pecific Factors 
The proteolysis- inducing factor (P IF )  was isolated from urine using monoclona l  
ant ibody in munne cachexia model  [246] as wel l  as human subjects with pancreatic 
cancer [247] .  P I F  is  bel ieved to possess an abi l ity to degrade skeletal m uscle. 
Although P I F  has been l inked with weight loss in patients, other g roups have fa i led 
in reproducing the above find ing ;  hence P I F  was not redetected [248] . Despite our 
knowledge that P IF was orig ina l ly  captured in subjects' ur ine,  we were st i l l  
interested i n  checking its expression with in  the cachectic muscles. P IF (OeD;  
dermicidin) was not detected in our  sequencing data .  I t  should be noted that  i f  the 
tumor itself is the source of P I F ,  we would not have expected to detect i t  in the 
m uscle t issue; so we cannot d iscount i ts  existence at th is t ime.  
Many i nflammatory cytokines have long been impl icated in m uscle wast ing .  Those 
inc lude tumor necrosis factor-a lpha (TN F) ,  interleukin-6 ( I L6), and interferon-gamma 
( I FNG) .  Precl in ical  studies showed s ign ificant contribut ion of  each of  these cytokines 
in the development of cachexia [96, 1 1 0 ,  1 1 1 ] . U n l ike TN F and I FNG which were 
not found to corre late to weight loss in h uman [ 1 1 2] .  c irculat ing levels of I L-6 have 
been shown to correlate with weight l oss in cancer patients [249] . In the present 
study,  the expression levels of these three cytokines in cachectic muscle were not 
statistical ly  s ign ificant (Table 1 5) .  However, for I L6 and I FNG expression was 
h igher, but not s ign ificant. I t  is  possible that expression of these cytokines is 
increased in some but not all cachect ic pat ients. 
Table 1 5 . I nflammatory Cytokines and Tumor S pecific Factors .  
Gene Fu l l  Name Gene Fold C h a nge P-Va lue  
Tumor necrosIs factors-a lpha TNF 1 . 1 2  0 8997 
I nterleukln-6 I L6 6 96 0 224 1 
I nterferon-gamma I F NG 5 .47  0. 1 8 1 9  
Dermcid in/proteolysis-inducing factor DCD/PI F  Not expressed 
4.5.3  Resu lts from P rev ious Genome Wide E x p ress ion Ana lysis 
76 
Stephens et al .  (20 1 0) were the first g roup to look at genome wide express ion 
profi l ing in muscle biopsies obtained from weight losing cancer patients compared to 
weight stable non-cancer  controls [235]. Usi ng muscle b iopsies from the rectus 
abdomin is ,  e ight genes were found to be d ifferentia l ly expressed by the microarray 
that were also confi rmed by RT-PCR .  Changes in expression of these eight genes 
were then rechecked in two different g roups of muscles (d iaphragm and vastus 
latera/is) from a d ifferent center. Only two genes were reproducible from the 8 
genes; TI E 1  and CAM K2B .  Both genes are "endurance exerc ise"-activated genes. 
Overexpression of such two genes may s igna l  muscles attempt to ma inta in  its 
v iabi l ity through activat ion of pathways usua l ly  active during moderate endurance 
activity [235]. We looked at the expression level of a l l  the genes that was found to 
be sign ificant in the previous microarray study 1 (Table 1 6) .  Only T I E 1  was found to 
be s ignificantly upregu lated in the present study, in- l ine with what was previously 
reported. How HTI E 1  functions is sti l l  unknown , however it is  an exercise activated 
gene,  usual ly upregu lated in response to pro longed tra in ing [250]. 
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Table 1 6  Resu lts of Sign ificantly Altered Genes in Previous Microarray Study 1 .  
Gene F u l l  Name Gene Fold Change P-Va lue 
AdenomatosIs polYPosIs coli down-regulated 1 APCDD1  3 .50 0. 1 063 
Calcium/ca lmod ul in-dependent protein k inase 
CAM K2 8  1 .00 0.9963 I I  beta 
Eukaryotlc translation in itiation factor 3, subunit 
E IF3 1  - 1 . 1 1  0 .5461 I 
Hepatocyte growth factor-regulated tyrosine 
HGS 2.67 0.0936 kinase substrate 
NudC nuclear d istribution protein N U DC - 1  1 6  0 .51 05 
Polymerase (R NA) m itochondrial  (DNA 
POLRMT 1 .25  0.754 1  d irected) 
Tyrosine kinase with Immunog lobu l in- l ike and 
TIE1  4.50 0.02 1 8  EGF-l ike domains 1 
Tuberous sclerosis 2 TSC2 1 .8 1  0 .031 
Serum/glucocort icoid reg ulated kinase 1 SGK1 4 . 52 0 .3278 
In 20 1 2 , the same group of investigators of the a bove study reattempted another 
m icroarray-based, genome-wide expression ana lysis of quadriceps m uscle biopsies 
in s ing le biopsies from healthy controls and in paired biopsies (pre-resect ion 
basel ine and 8 month post-resection fol low-up) from cachect ic cancer patients [236] . 
They detected 1 0  genes where expression was s ign ificantly changed (Table 1 7) .  
Tab le  1 7 : Resu lts of  S ign ificantly Altered Genes in Previous Microarray Study 2 .  
Gene F u l l  Name Gene Fold C h a nge P-Value 
Carti lage ol igomeric matrix protein COMP Not expressed 
Adlponectin ,  C1 Q and col lagen domain 
ADI POQ 6.98 0.3605 conta in ing 
Matrix meta l lopeptidase 3 MMP3 Not  expressed 
Phosphoenolpyruvatecarboxykinase 1 
PCK 1  1 5 .29 0 .2891 
(soluble) 
Ang iopoietin- l ike 7 ANG PTL7 1 . 75 0. 3664 
Heat shock protein 90kDa a lpha (cytosolic), 
HSP90A8 1 - 1 .29 0.2028 
class 8 member 1 
Solute carrier fam ily 25  ( mitochondrial iron 
SLC25A37 -1 .24 0.229 
transporter), member 37 
Prospero homeobox 1 PROX1 - 1 . 4  0 .4232 
Regu lator of calcineurin 1 RCAN 1 2 . 4 1  0 . 3536 
H istid ine triad nucleotide b inding protein  3 H INT3 -2.45 0.0061 
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Of the genes studied, the only s ignificantly changed gene that is common with the 
present study IS  the H I NT3. H I NT3 is a h istid ine triad nucleotide binding protein 3 
[25 1 ] . It IS an uncharacterized gene. However, it has been recently found to be 
expressed in skeletal muscle i n  the chimpanzee [252]. 
4.6 Verified Resu lts Us i n g  Rea l -Time Reverse Transcri ption pe R 
Despite of the h igh reliance of the quantitative capabi l ity of the RNA sequencing 
resu lts,  i t  is important to verify part of the expression results using a d ifferent 
method. A cherry-picked selection of genes that are of a h igh s ign ificance and high 
fold-change were picked. Confi rm ing the d ifference of h igh fold-change expression 
data can a l low us to check and verify them later-on at protein level .  Four 
upregulated genes; COL4A2 , N RXN2,  NOTC H 1 ,  and AGR N ,  and two 
downregu lated genes; N D U FS 1 , and PTPRR were chosen .  
4.6 .1  Resu lts 
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Figure 3 :  Upregulat ion of Expression of Selected Genes Confirmed by Real-Time 
RT -PCR in Cachectic Skeletal Muscle. 
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Figure 4 :  Downregulation of Expression of Selected Genes Confirmed by Real-Time 
RT-PCR in  Cachectic Skeletal Muscle. 
Al l  chosen genes that were previously shown to be upregu lated/downregulated were 
reproducible via real-t ime RT-PCR (F igure 3 and 4) .  
4.6 .2  Discussion 
Expressions of  four  upregu lated genes that  are statistica l ly  s ign ificant were 
confi rmed via real-t ime RT -PCR .  
AGRN (Agrin) and  COL4A2 (col lagen type 4 a lpha 2) (section 4 .3 .2 .2)  are e lements 
in the extracel lu lar  matrix-receptor interact ion.  AGRN fragments a re under 
investigation as a possible b iomarker for sarcopenia [ 1 36] and was also found to be 
upregu lated in cachect ic muscles. Also, COL4A2 is a com ponent of the myocyte 
basal lamina [ 1 37] . 
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However. the other two genes; NOTC H 1  receptor (section 4 .3 .2 .2 ) ,  an activators of 
the notch pathway [ 1 3 1 , 1 32] ,  and N RXN2 (a cel l  adhesion molecules) are two 
poorly charactenzed genes in skeletal muscle and their confirmed upregulation 
warrant further research 
The confi rmed downregulated genes were the NDUFS1  and the PTPRR.  The 
NDUFS1  is  upregulated in the Parkinson's and Alzheimer's d iseases (sect ion 
4 .3 3.2) .  NDUFS1  encodes subunit of prote ins in the Complex I .  Complex I or 
NADH. ubiqu inone oxidoreductase, is the first enzyme of the mitochond ria l  electron 
transport cha in  that in i t iate cel lu lar  respiration or oxidative phosphorylat ion in the 
mitochondria in  the inner mitochondria l  membrane.A TP5B is a subunit of the ATP 
synthase. I t  catalyzes A TP synthesis through using the proton motive force created 
by the electron transport chain across the inner membrane as a source of energy in 
the process of oxidative phosphorylat ion. 
PTPRR IS a prote in tyrosine phosphatase, receptor type, R. PTPRR gene is  a 
MAPK signal ing pathwaygenethat is uncharacterized in the skeletal muscle and is  
corre lated for the fi rst t ime to cachexia.  
Chapter 5 :  Results and Discussions - Adipose Tissue 
5.1  Demog ra p h i c  a n d  B iochem i ca l  C h a racte ristics of  S u bjects 
5. 1 . 1 Resu lts 
82 
Demographic and biochemical deta i ls of patients for fat cachexia samples (FS) and 
fat weight-stable contro ls (FC) are shown in bel low tables The tables show data for 
6 samples in  each group.  Samples were analyzed based on weight ,  BM I , some 
nutrit ional parameters, inflammatory markers and other re lated demographics. 
Table 1 8  shows subjects oncological diag noses for viscera l  adipose tissue biopsies. 
Al l  patients were with h istolog ical ly confirmed mal ignancies. Age and gender 
d istribution were not s ign ificantly d ifferent between cachexia fat cases (FS) and 
weight-stable controls (FC) (Table 1 9) .  Al l  biochemical nutrit ional parameters ( i .e .  
hemog lobin,  tota l prote in ,  a lbumin ,  u rea,  and creat in ine) and inflammatory markers 
(I e .  WBC and CRP) were not sign ificantly different between both g roups (Table 1 9) .  
Basel ine we ights and BMls  in  the cachexia g roup d id not differ sign ificantly from the 
contro l .  The t ime range between current (at t ime of biopsy) and basel ine weights 
(preceding date of biopsy) was 3-6 months. Mean weight loss from basel ine in the 
cachexia g roup was 4.6 kg wh ich is 6 .5% of basel ine body weight ( i .e .  3-6 months 
before the date of sample col lect ion) .  Amount and percentage of weight loss was 
sign ificant ly d ifferent from controls that had re latively stable weights; P-va lue of 
0 .0001 and < 0.000 1 , respective ly .  
Table 1 8: Subjects' Diagnoses for Ad ipose Tissue Biopsies. 
Cachexia Fat Cases (FS)  Weig ht-sta ble Fat  Controls (FC)  
FS1 Mal ignant Neoplasm of  Rectum FC3' Mal ignant Neoplasm of Colon 
FS2 Mal ignant Neoplasm of Stomach FC5 Mal ignant Neoplasm of Colon 
FS3 Mal ignant Neoplasm of Rectum FC6' Mal ignant Neoplasm of Connective 
and Soft Tissue 
FS4 Mal ignant Neoplasm of Duodenum FC7: Mal ignant N eoplasm of Rectum 
FS5. Mal ignant Neoplasm of Colon FC9: Mal ignant Neoplasm of Rectum 
FS6 Mal ignant Neoplasm of Pancreas FC1 0:  Mal ignant Neoplasm of Colon 
Table 1 9 ' Demographic Data for Ad ipose Cachectic Cases and Weight-Stable 
Ad ipose Contro ls .  
Gender ( M/F) FS:  Mean SEM Median Range P-Va lue 
FS: 4/2 ;  F C :  4/2 N=6 
Characteristics FC:  
N=6 
Age Cach o 58.67 6.677 56.00 44-83 0.7002 
Cant. 55 .50 4 .387 58.00 4 1 -66 
Hemog lob in Cach 1 1 5 5  4 . 0978. 1 1 7 .0  1 03-1 25 0. 7803 
Cant. 1 1 8 . 2  356 1 2 1 . 0 90- 1 4 3  
Creat in ine Cach 64.40 8.035 59.00 4 1 -84 0.8 1 42 
Cant 66. 83 6 . 300 64 .50 49-94 
U rea Cach o 5 .940 1 . 520 5.300 2 .9-1 1 . 1  0 .2451  
Cant. 4 . 1 00 0 .501 3 3 . 800 3 .0-6 .5  
Tota l prote in Cach 52.20 3 .555 50.00 46-66 0.2 1 63 
Cant. 6 1 . 50 5 .620 64 .00 42-79 
Albumin Cach o 27 80 3. 382 26.00 20-40 0. 1 248 
Cant 35.33 2 .929 37.00 23-44 
WBC Cach o 9 .633 1 .295 9.350 6.0- 1 3 .3  0. 1 797 
Cant.  7 . 1 00 1 . 1 86 5 .900 4 .4- 1 2 . 1 
CRP Cach o 1 1 . 00 5 .874 7 .000 1 -34 0.3966 
Cant. 1 8 .40 5 .8 1 0  1 9.00 1 -34 
Basel ine BMI  Cach o 24 .79 2 .290 25 .27 1 5. 57-30 . 86;  0 . 1 692 
Cant. 2 8 . 4 1  0 .8553 28.66 25.26-3 1 .23 
Current BMI  Cach 23 . 1 2  2 .027 23.6 1 1 4 .8 1 -28 .96;  * 0 .0397 
Cont. 2 8. 37 0 .9097 28 .58 24.9 1 -3 1 .23 
Basel ine Cach o 70. 1 0  5 . 1 68 73.50 45.00-8 1 . 00; 0. 2066 
weig hts Cant. 78.07 2 . 843 75.50 7 1 .40-89.00 
Current weig hts Cach o 65 .48 4 .748 68 .45  42. 80-76. 00;  *0 .0489 
Cant. 77 .93 2 . 883 75 .30 72.00-89.00 
Amount of WT Cacho 4 .6 1 7  0 .724 1 4 . 500 2 .200-7.000 *** 0 .0001 
loss Cant. 0 . 1 33 0 .2 1 7 1  0 .0000 (-0.6000)-1 .000 
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% of WT Loss Cach o 6 .489 0 .8 1 85 5 .826 4 . 558-9.589 ***< 0 .0001 
Cant. 0 . 1 78 0 .2991 0 .0000 (-0. 8403)- 1 . 370 
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Table 20 compares weight and BMI  changes between current and basel ine with in 
each group (paired t-test) . The cachect ic fat cases (FS) had a sign ificant d ifference 
between current and basel ine data whi le weight-stable fat controls (FC) had no 
s ign ificant change. 
Table 20: Paired t-Tests for Weight and 8MI Change for Adipose Biopsies. 
Characteristics FS/F C :  N=6/6 Mean SEM Med ian Range P-Value 
Weight FS Basel ine 70. 1 0  5 . 1 68 73.50 45. 00-8 1 .00 **0.00 1 4  
(cachectiC) Current 65 .48 4 748 68 .45 42. 80-76. 00 
BMI  FS Basel ine 24.79 2 .290 25 .27 1 5. 57-30 . 86 **0.0035 
(cachectiC) Current 23. 1 2  2 .027  23.6 1 1 4 . 8 1 -28. 96 
Weight FC Basel ine 78.07 2 843 75.50 7 1 .40-89 .00 0 .5659 
(weig ht-stable) Cu rrent 77 .93 2 . 883 75.30 72 . 00-89 .00 
BMI  FC Basel ine 2 8 . 4 1  0 . 8553 28.66 25.26-3 1 .23 0.6247 
(weig ht-stable) Current 28 .37 0 .9097 28.58 24 .9 1 -31 .23 
5. 1 . 2 Discussion 
Sim i lar to the d iscussion in  sect ion 4 . 1 . 2 ,  in  the a bove demographic analysis ,  
patients included in  the study were chosen meticulously to be at the early stages of 
cachexia ( i .e .  5 - < 1 0% we ight loss). Our subjects had a mean percentage of weight 
loss of 6 .5% (range 4 .6-9 .6 %). S ince systemic inflammation measured via serum 
CRP may or may not be present in  patients with cachexia [7] , our subjects were 
included regardless of their  CRP values (range 1 -34 , Table 1 9) .  However, the CRP 
values between cachectic cases (FS) and weight-stable controls (FC)  were ensured 
to be not statist ical ly s ign ificant; P= 0.325 in  muscle. 
Nutritional and nutrit ion-related biochemical markers were al l  ensured to be 
comparable in  both g roups to objectively exclude the possibi l ity of malnutrit ion as 
the primary cause of weight loss. 
5 . 2  Heat M a p  o f  R N A  S e q u e n c i n g  Data 
5 . 2 . 1  Resu lts 
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Figure 5shows the heat map of d ifferent ia l ly reg ulated genes between cachectic fat 
cases (FS) and weight-stable fat controls (FC) .  The figure shows separation 
between both groups but not as clear cut as that seen in  skeletal muscle. The heat 
map shows a tota l of 365 s ign ificantly upreg u lated genes and 93 downregulated 
genes (P-va lue < 0 .05; and FDR < 0 .5) .  
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Figure 5: Heat Map Representation of the Differentia l ly  Expressed Genes in Ad ipose 
Tissue. 
Gene expression is shown for the cachectic fat cases (FS; purple bars; lower panel) 
and weight-stable fat controls (FC; g reen bar; upper panel ) .  Colors represent scaled 
and centered expression values: red represents h igher expression,  blue represents 
lower expression. 
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5 . 2 . 2  Discussion 
This s imple h ierarchical c luster ana lysis revea led a c lear v isua l  d istinction of gene 
expression signature between cachexia fat cases (FS) from those with weight-stable 
fat controls (FC) .  
5.3 A n a lysis of Differenti a l ly E x p ressed KEGG pathways 
5 .3 . 1 U p re g u lated KEGG Pathways i n  Cachectic Adi pose Tissue 
5 .3 .1 . 1  Resu lts 
Five KEGG pathways are d ifferentia l ly upregulated in cachectic fats cases vs. 
weight-stable control fats; Prion diseases, steroid biosynthesis, cytokine-cytokine 
receptor interact ion,  systemic lupus erythematosus (SLE) ,  and N-Glycan 
biosynthesis. These pathways have 5,  3, 11 , 6, and 4 s ignificantly upregu lated 
genes respect ive ly (Table 2 1 ) .  Table 21 shows the ind iv idual  genes in each pathway 
and the overa l l  statist ica l sign ificance for each of these pathways. The level of 
statistical sign ificance for the prion d isease pathway is an order of magnitude 
greater than that for the other pathways. Thus, it was the only d iscussed pathway as 
below. However, Table 22 shows a summary of the full gene name, fold change, 
and P-value for individual  genes in each pathway. 
Table 2 1 :  Differentia l ly  Upregu lated KEGG Pathways in  Cachectic Ad ipose Tissue. 
KEGG Pathway Gene Gene Gene Gene 
ALG 1 DPM2 MAN 1 B 1 R P N 1  
Gene Gene p. FOR 
0.062 0 .87 
0.077 0 . 8 7  
8 7  
Table 22: Data of  I nd ividual  Genes i n  the U pregu lated KEGG Pathways in Cachectic 
Adipose Tissue. 
Gene Gene Full  N a me Fold p-
Symbol Change Value 
Fat-Up I P rion d iseases 
BAX BCL2-associated X protein 2 .30 0.0272 
C 1 QC complement component 1 ,  q subcomponent, C 3.24 0.0239 
chain 
C6 complement component 6 2 .26 0 .0473 
LOC407835 m itogen-activated protei n  k inase kinase 2 3.65 0 .0246 
pseudogene 
NCAM2 neural cell ad hesion molecule 2 2 .27 0.0406 
Fat-Up I Steroid biosynthesis 
E B P  emopami l  b ind ing protein (sterol isomerase) 2 .34 0.0266 
SQLE squaleneepoxidase 2 .45 0 .01 6 1  
SOAT 1 sterol O-acyltransferase 1 2 .22 0.0222 
Fat-Up I Cytokine-cytokine receptor interaction 
CCR1 chemokine (C-C motif) receptor 1 2 .48 0.0234 
CCR5 chemokine (C-C motif) receptor 5 2 . 1 0  0 .0293 
CXCL 1 0  chemokine (C-X-C motif) l igand 1 0  4 . 3 1  0 . 0364 
CXCL 1 1  chemokine (C-X-C motif) l igand 1 1  5 .84 0.0076 
I L  1 R 1  interleu kin 1 receptor, type I 2 .04 0 .0339 
I L20RA interleuk in  20 receptor, alpha 5 . 7 1  0 .0094 
I L23A i nterleuk in 23, a lpha subun i t  p1 9 2 . 98 0.0389 
M ET met proto-oncogene (hepatocyte g rowth factor 2 .08 0.0307 
receptor) 
TG FB1  transforming growth factor, beta 1 2 .40 0 .0235 
TNFRSF 1 1 A  tumor necrosis factor receptor superfamily ,  member 3 .35 0.0087 
1 1  a ,  N FKB activator 
T N F RSF8 tu mor necrosis factor receptor superfamily ,  member 2 . 96 0. 0302 
8 
Fat-Up I Systemic lupus erythematosus (SLE)  
FCGR 1 A  Fc fragment of IgG,  h igh affi n i ty Ic ,  receptor (C 064) ;  4 .26 0 .01 1 8  
Fc fragment of IgG, h igh affin i ty la ,  receptor (C064) 
C 1 QC complement component 1 ,  q subcomponent, C 3 .24 0.0239 
chain 
C6 complement component 6 2 .26 0.0473 
H I ST 1 H31  h istone c luster 1 ,  H3j ;  h istone cluster 1 ,  H 3i ;  h istone 4 . 1 4  0 .0345 
cluster 1 ,  H3h; histone c luster 1 ,  H 3g ;  histone 
cluster 1 ,  H 3f; h istone cluster 1 ,  H3e; h istone c luster 
1 ,  H 3d;  h istone cluster 1 ,  H 3c; h istone cluster 1 ,  
H 3b; h istone cluster 1 ,  H 3a;  h istone cluster 1 ,  H2ad; 
h istone cluster 2 ,  H3a; h istone cl uster 2 ,  H 3c; 
h istone cluster 2, H3d 
H LA-OMA major histocompatibi l ity complex, c lass I I ,  OM alpha 2 .03 0 . 0036 
S N R P B  smal l  n uclear ribonucleoprote in  polypeptides B and 2 . 0 1  0 . 0205 
B 1  
Fat-Up I N-Glyc a n  biosynthesis 
ALG 1 asparag ine- l i nked glycosylation 1 ,  beta- 1 ,4- 2 .24 0 .01 07 
man nosyltransferase homolog (S. cerevisiae) 
OPM2 dol ichyl-phosphate mannosyltransferase 2 . 52 0 .02 1 2  
polypeptide 2 ,  regu latory s u bun i t  
MAN 1 B 1 mannosidase, a lpha,  c lass 1 B ,  member 1 2 . 1 4  0 .0460 
R P N 1  ribophorin I 2 .02 0. 0 1 76 
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5.3. 1 . 2 D iscussion 
Pr ion Diseases 
BAX IS a pro-apoptotic member of the BcI-2 gene fami ly .  Apoptosis regu lator BAX 
promotes apoptosis by binding to and antagonizing the Bcl-2 prote in [253]. Activated 
BAX results in the release of cytochrome c and other pro-apoptotic  factors from the 
mitochondria ,  often referred to as m itochondrial outer membrane permeabi l ization ,  
leading to activation of  caspases [254] .  
C6 gene codes for complement com ponent 6 protein that is  involved in the 
complement system. I t  i s  part of the membrane attack complex which can i nsert into 
the cel l  membrane and cause cel l  lysis to clear pathogens from an organ ism via a 
number of smal l  proteins.  The system is stimu lated by one of several triggers 
causing release of proteases that cleave specific prote ins to release cytokines and 
in it iate an ampl ifying cascade of further cleavages. Thus results in massive 
ampl ification of the response and activation of the cel l -k i l l i ng membrane attack 
complex. Activation of BAX and C6 in ad ipose cel ls of cachect ic patients could 
reflect their same funct ional  properties prior  to wasting of ad ipose t issue. NCAM2 
encodes for one of three neura l  cel l  adhesion molecule (NCAM) ,  a lso cal led CD56, 
is expressed on the surface of neurons,  g l i a ,  skeletal  muscle and natural ki l ler cel ls .  
5.3 .2  Dow n reg u l ated KEGG Pathways i n  Cac hectic A d i pose Tissue 
5 .3 .2 . 1  Resu lts 
One KEGG pathway is d ifferent ia l ly downregu latedin cachectic fat cases vs. weight­
stable fat contro ls ;  the neuroactive l igand-receptor interact ion.  Th is pathway has 6 
S ign ificantly downreg ulated genes and overa l l  has a very h igh level of statist ical 
s ign ificance (Table 23) .  Table 23 shows the indiv idual  genes in the pathway. Table 
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24 shows a summary of the fu l l  gene name, fold change, and P-value for individual 
genes in the neuroactive l igand-receptor interact ion pathway. 
Table 23' Different ia l ly Downreg ulated KEGG Pathway in Cachectic Adipose Tissue. 
KEGG Pathway Gene Gene Gene Gene Gene Gene P-value FOR 
Neuroactive receptor GAB R G 1  GRIA4 LEP LHCGR N M U R 1  NPY 1 R 0.002 0.068 
l igand interaction 
Table 24: Data of I ndiv idual  Genes in the Downregu lated KEGG Pathway in 
Cachectic  Ad ipose Tissue. 
Gene Gene Ful l  N a me Fold p-
Symbol C h a nge Value 
Fat-Down I Neuroactive l igand-receptor interaction 
GABRG1 gamma-amlnobutyric acid (GABA) A receptor, gamma 1 -3.26 0.0249 
G RIA4 g lutamate receptor, ionotroph ic, AM PA 4 -3. 1 0  0 .01 72 
LEP Leptin -3.50 0.0032 
LHCGR luteinizing hormone/choriogonadotropin receptor -3.90 0.0028 
N M U R 1  neuromedin U receptor 1 -2.69 0 .01 33 
N PY 1 R neuropeptlde Y receptor Y 1  -3 .47 0.0242 
5.3 .2 .2  Disc ussion 
N e u roactive L i g a n d -Receptor I n teraction Pathway 
LEP encodes for lept in ,  a "satiety hormone" that signals energy sufficiency and 
thereby inh ibits hunger. Leptin discovery was a breakthrough in 1 994 , I t  is secreted 
from adipocytes in proportion to fat stores and acts on receptors in the 
hypotha lamus to regulate appetite [255] . Leptin suppresses feeding and decreases 
adiposity in part by release of aMSH and cocaine and amphetamine re lated 
transcript that d i rectly suppress appetite, in  part by inh ibit ing hypothalamic NPY 
synthesis and release , s ince NPY stimulates a ppetite , and partly by inh ibit ing 
release of agout i-related pept ide that acts by blocking the act ion of aMSH at its 
receptor [256]. The regulat ion of a ppetite is a complex process involving mult iple 
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hormones [257). Hypotha lamus is the main appetite regulator in the body that 
senses externa l  mu lt ip le hormonal stimu l i .  
Leptln decreases food intake by  affecting the balance between orexigenic and 
anorexigenic hypothalamic pathways [258) . Low leptin increases a ppetite and body 
weight .  Crosstalk between lept in and inflammatory signal ing known to be activated 
may be responsible for th is paradox [258). Many studies looked at the serum level of 
leptin in cancer patients. Cachectic esophageal cancer patients had decreased 
circulat ing leptin [259-262) .  
I nterest ingly ,  in vitro and in vivo, i nsu l in  plays a major transcriptional  activation that 
stimulates leptin circu lation level [263). However, patients with cachexia do usual ly 
have h igh insu l in  resistance which does not e levate, at least in our  study,  the 
adipocyte production of lept in .  This downregulat ion of lept in production in adipocyte 
does not seem to increase appetite in cancer patient. This reflects that the 
deregulat ion of appetite and weight in cachect ic pat ient is  a complex process. 
Leptin levels are low, as expected,  s ignal ing that there are NOT sufficient energy 
stores i n  fat . However, th is is not reflected in the expected increase in  a ppetite ! 
Paradoxica l ly ,  N PY expression in the ARC is decreased (you wou ld expect it to be 
increased in the absence of lept in  s ignal ing) and that of POMC (source of aMSH) 
increased (you would expect i t  to be decreased in a bsence of lept in) .  There is 
specu lat ion that th is is  a response to GAD 1 5 in the hypothalamus and GAD 1 5 
expression was s ignificantly increased in cachectic m uscle in the present study 
[258). 
Lept in level are negatively corre lated with the degree of cachexia [259]. Although 
regulat ion of fat stores is deemed to be the pr imary function of lept in ,  obese 
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ind iv iduals have a decreased sensit ivity to lept in occurs, resu lt ing i n  a n  inabi l ity to 
detect satiety despite h igh energy stores [264). 
LHCGR codes for the lute in iz ing hormone/choriogonadotropin receptor protein .  
LHCGR is abundantly expressed in preadipocytes and mature adipocytes [265) . I t  i s  
studied the  most in the  gonads. I n  the  ovary ,  the  LHCGR is required for fol l icu lar 
maturation and ovulation ,  as we l l  as  l utea l  function upon hormonal stim ulation [266) . 
Low levels  of the receptor are repeatedly l i nked to infert i l ity .  
Whi le the funct ion of th is receptor is uncharacterized in adipose t issue, we do 
bel ieve there is a strong corre lat ion between the downregu lation of that receptor and 
the depletion of fat stores.  Female ath letes one of the commonest examples of 
inferti l ity caused by depletion of fat stores which both could be possibly due ,  at least 
in part ,  to the downregulat ion of the receptor in gonads and adipose t issue. 
NPY1 R codes for the Neuropeptide Y receptor type 1 prote in .  NPY, the 
neuropeptide Y,  is a neurotransmitter involved in food intake and body weight 
regulat ion [267) and prevention of l ipolysis [268] v ia Y 1  and Y5 receptors. Y1  
receptors are coded by N PY 1  R which is increased in ad ipose t issue samples of 
obese patients and in tu rn s ignals for inh ibit ion of l ipolysis [269) . Addit i onal ly ,  
N PY 1  R expression in visceral ad ipose t issue is positively  corre lated with body 
weight, 8 M I ,  and insu l in leve ls  [267). Downregu lat ion of the gene in cachectic 
adipose t issue neutra l izes its " l ipolysis inh ibit ion" s igna l  wh ich may contribute to 
adipose wast ing .  
N M U R 1  codes forneuromedin-U (NMU) receptor 1 .  NMU overexpressing tumors in 
m ice resu lted in lowering of body weight and cachexia [270) .  N M U R 1  in h uman is 
h igh ly  expressed in intest ina l  ad ipose t issue [27 1 ] . 
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I ntracerebroventncular admin istration of NMU marked ly suppresses food intake in  
rats [272] . The downregu lation of  N M U R 1  could be a com pensatory mechanism to 
oppose the possible outcome of  receptor st imulation with is documented to lead to  
cachexia in mice 
GABRG 1 encodes for gamma-aminobutyric acid receptor subunit gamma- 1 protein 
which I S  a subun it of the GABAA receptor. GABAA receptors are located 
synaptica l ly  as wel l  as  presynaptical ly and are activated by gamma-aminobutyric 
acid (GABA) [273] .  GABA is a neuro inh ibitory transmitter in the brain [273] . Oral 
GABA g iven activates periphera l  GABA receptors and this improves g lucose 
tolerance , improves insul in sensit ivity, and prevents obesity without a ltering calorie 
intake in m ice [274] . Thus, the downregu lat ion in cachectic ad ipose t issue could play 
a role in insu l in res istance seen in cachect ic cancer patients and could be a 
compensatory measure try ing to stimulate weight gain .  
GRIA4 encodes for g l utamate receptor 4 .  It is  a member of a fami ly  of L-glutamate­
gated ion channels that mediate fast synaptic excitatory neurotransmission. 
G lutamate receptors are protein complexes known to be the main excitatory 
neurotransmitter receptors in the mammal ian bra in  [275] .  The regulat ion of 
g lutamate receptors is infl uenced by lept in levels [276] which is also downregulated 
in cachectic ad i pose t issues. 
Surpris ingly ,  five out of the six above genes are receptors. The sixth gene is lept in ,  
wh ich a lso funct ions to downregu late one of  receptors ( i .e .  G R IA4) is a lso 
downregu lated. Most of these receptors are wel l  studied and characterized in the 
bra in ,  whi le th is  i s  the first t ime they are reported , as far of our  knowledge, to be 
col lectively downregu lated in human ad ipose t issue. 
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5.4 A n a l ysis of H i g h l y S i g n ifica ntly Altered Genes in Cac hectic Ad i pose 
Tissues 
I n  visceral fat, 1 6  genes showed h igh ly s ignificant change in  expression ( 1 0 
upregulated and 6 downregulated : P<0. 00 1 -0.0002 . FOR 0. 5) .  
5.4. 1 H ig h ly S i g n if icantly U p re g u l ated Genes 
5.4. 1 . 1  Resu lts 
Table 25 shows the 1 0  h igh ly s ign ificantly upregu lated genes in cachect ic fat 
(P<0.00 1 -0.0002; OFR 0.5) .  They include 2 involved with transcript ional regu lat ion. 
2 transporters. on i n  each of the development.  angiogenesis inh ib itor. metabol ism. 
and signal ing . and 2 uncharacterized .  
Table 24 categorizes i nd iv idual  gene into respective funct ional  domain .  It a lso 
shows the fu l l  gene name. fold change. and P-va lue.  
Table 25: Highly S ign ificantly U pregu lated Genes i n  Cachectic Adi pose Tissue. 
Gene Gene Ful l  Name Fold p-
Sym bol C h a nge Value 
Transcription reg u lat ion 
RPP40 RibonucieaseP protein subu n it p40 3 .49 0.001 
IGF2 BP2 insul in- l ike g rowth factor 2 m R NA binding protein 2 2 .49 <0 .001 
Transpo rters 
SLC 1 9A1 Solute carrier fam ily 1 9  (folate transporter). member 1 2 . 34 0 .00 1 
STEAP3 Meta l loreductase STEAP3 2 . 57 0.0002 
Development 
I FR D2 interferon-related developmental regu lator 2 2 .25 0 .00 1 
Ang iogenesis I n h i bitor 
BAI2 Bra in-specific angiogenesis inh ibitor 2 4 .43 0. 0008 
Meta bolism 
PUSL 1 pseudouridylate synthase-l ike 1 2 . 37 0 .00 1  
Signal ing 
LYPD 1  Ly6/PLAU R domain-conta in ing protein 1 5 . 54 0 .001 
U n-cha racterized 
CCDC94 Coi led-coi l  domain conta in ing  94 2 . 5 1  0 .0003 
C 1 50rf57 chromosome 1 5  open read ing frame 57 2 .49 0 .001 
5.4. 1 . 2 D iscussion 
Tra n s c ri pt ion Reg u lation 
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RPP40 encodes for r ibonuclease P prote in subun it p40,  which generates mature 
tRNA molecules by cleaving the 5'-end of the leader sequence of precursor tRNA. 
RNase P is a nbozyme; a unique form of RNase that functions as a catalyst in the 
same way that a protein enzymes work [277] and is required for normal and efficient 
transcription of various smal l  noncoding RNAs, such as tRNA, 5S rRNA, SRP RNA 
and U6 snRNA genes [278, 279] .  However the RNase P in human m itochondria is a 
protein with no RNA component. Moreover, the enzyme is composed of a tRNA 
methyltransferase, a short-chain dehydrogenase/reductase-fami ly member, and a 
prote in of hitherto unknown funct ional and evolut ionary orig in ,  possibly representing 
the enzyme's meta l lonuclease moiety [280]. 
I GF2BP2 encodes insu l in- l ike g rowth factor 2 m RNA-binding prote in 2, a member of 
the IGF- I I  mRNA-binding protein fami ly  [28 1 ] .  It funct ions by b inding to the 5' UTR of 
the insu l in- l ike g rowth factor 2 mRNA and reg ulates its translation by modulating the 
rate and location at wh ich it encounters the translat ional apparatus and sh ields it 
from endonuclease attacks or microRNA-med iated degradation [28 1 ] . An important 
paralog of th is gene is IGF2BP3 [28 1 ] .  There is a strong association between 
IGF2BP2 insul in resistance and type 2 d iabetes mel l i tus, however, the exact 
mechanisms has not been determined [282-285] .  
On the other hand, ad ipose t issue plays a role in secreting a variety of factors which 
are involved in the modulat ion of adipose mass [286]. Adipose tissue development 
and metabolism are regu lated by g rowth hormone (GH) and the insu l i n-l ike g rowth 
factor ( IGF) system [286]. GH plays an ant i- insu l in  effect ; however, the mechanism 
by which GH antagon izes insul in st imulat ion of l ipogenesis is  unknown [286] . 
9S 
IGF28P2 downregulates the expression of IGF2;  a g rowth factor that plays a pivotal 
role in control l ing adipogenesis [287]. Therefore , IGF28P2 may contribute to type 2 
d iabetes through a lterations in adipose tissue [287]. Also, a more than two-fold 
increase I n  IGF28P2 expression level was observed in the adipose t issue of d iabetic 
patients com pared to controls [288]. S imi la rly ,  an a ltered expression of IGF28P2 in 
adipocytes of subjects with type 2 d iabetes compared with healthy people was a lso 
detected [289] . Thus, an increase in  the IGF28P2 in  the adipose tissue of cachectic 
subject i n  our study is no surprise since it alters adipogenesis and promotes insul in 
resistance. 
Transporters 
SLC 1 9A 1 encodes for solute carrier  fami ly 1 9  (fo late transporter) ,  mem ber 1 protein .  
I t  facil itates intrace l lu lar  u ptake of  reduced folate to maintain intracel lu lar 
concentrations of folate. Despite of the plethora of studies on SLC 1 9A 1 ,  the majority 
of these investigated it in  terms of polymorphic effects on drug dosing ( i .e .  the 
antimetabol ite; methotrexate). Thus,  studies i nvestig at ing the role of this transporter 
i n  adipose tissues are lacking. However, SLC 1 9A 1 has three protein k inase C (PKC) 
phosphory lat ion s ites [290] .  Effect of PKC is cel l  type specific. In ad ipose tissue, 
PKC transduces the effects of adrenergic agonists (specifical ly agonists of the 133 
receptor). 133-adrenergic agonists stimu late brown adipose t issue thermogenesis 
[29 1 ] . I n  wh ite adipose t issues; however, 133-adrenerg ic  agonists increase energy 
expenditure and l ipolysis, which in turn promote l ipid mobi l ization [29 1 ] . These 
effects causes adipose t issue wasting and decreased fat stores [29 1 ]  which are a l l  
key man ifestations in the cachect ic patients. 133-Adrenerg ic agonists also enhance 
g lucose d isposal to provide energy for the maintenance of metabol ic activity and 
m uscle function under l im ited energy ava i labi l ity [29 1 ] . Other adrenoreceptors have 
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other effects on l ip id and g lucose metabol ism; a 1 -adrenoceptors and 132-
adrenoceptors are l inked to g lycogenolysis and g luconeogenesis in adipose t issue; 
whi le 13 1 -adrenoceptors and 133-adrenoceptorsare l i nked to l ipolysis in adipose 
tissue [292] .  
STEAP3 codes for six-transmembrane epithel ia l  ant igen of prostate STEAP fami ly 
member 3 ,  a metal loreductase that is capable of convert ing i ron from an insoluble 
ferric (Fe3+) to a soluble ferrous (Fe2+) form . This fami ly  comprises STEAP 1 -4 ;  a l l  of 
which share metal loreductases act ivity [293] .  They part ic ipate in a wide range of 
biolog ic processes, such as molecular  trafficking in the endocytic and exocytic 
pathways and control of ce l l  pro l iferation and a poptosis [293]. STEAP3 is a lso 
known as tumor-suppressor activated pathway-6 (TSAP6) or  dud ul in-2 .  Mutations in 
STEAP3 result  in  an autosomal recessive trait characterized by an inefficient supply 
of i ron to e ryth rocytes, leading to anemia and i ron overload [294] . 
STEAP3 is upregu lated in white ad ipose t issue of rats fed h igh fat diet and 
significantly downregu lated in rats treated with capsaic in (a potential ant i-obesity 
d rug) [295] . This ind icate that STEAP3 increases when fat supply is abundant and 
not du ri ng t imes of energy deficit .  I t  is possible that STEAP3 increases as a 
compensatory mechanism to s igna l  resistance to fat loss and/or to stimulate energy 
storage that m imic the state of abundance under the forces or tr iggers of wasting . 
On the other hand,  one anti-obesity strategy is to block adipocyte different iat ion, 
prevent ing fat storage and the secretion of ad ipokines [296]. STEAP3 is upregulated 
in d ifferent iat ing ad ipocytes [296]. This suggests that the adipose t issue in cachexia 
is undergoing an early-onset protective mechanism by inducing ad ipocyte 
d ifferentiat ion in an attempt to prevent further l i polysis and wast ing . 
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Deve lopment 
I FRD2 codes for interferon-related developmental regulator 2 .  Very l ittle is known , 
so far, a bout I the FRD2 gene. H owever another member of th is gene fami ly ,  I FRD1  
i s  expressed in  skeleta l and cardiac muscle. I t  i s  a lso expressed in differentiating 
myoblasts in vitro [297]. I FR D 1  knockout mice have delayed muscular regeneration 
after muscle crush damage [298]. In contrast, u pregu lation of IFRD1  in inju red 
m uscle potentiates m uscle regeneration [299] . 
I FR D 1  was also recently studied i n  white adipose t issue in o bese mice, where its 
expression is increased [300]. I t  is  a lso upregu lated u nder stressfu l stimu l i  such as 
hypoxia [300] ,  where it prevents the inh ibit ion of adipogenesis [300] . This effect is 
abrogated by knockdown of I FR D 1  by shRNA which inh ib its ad ipogenesis. These 
findings suggest that I FR D 1  may play a ro le in adipogenesis under condit ions of 
hypoxia and obesity . 
The uniqueness of importance of I FR D 1  in muscle regeneration and ad ipogenesis, 
suggests a s im i la r mechanism of act ion for I F RD2, which may be more specific for 
ad ipose t issue.  Furthermore, s ince I FR D 1  potentiates the regenerative process, 
I FR D2 m ight be activated in cachect ic adipose t issue as a defense mechanism to 
reduce the loss of ad ipocytes due to wasting.  
M eta b o l i sm 
PUSL 1 encodes for pseudouridylate synthase- l ike 1 ,  an uncharacterized 
metabol ism protein with pseudourid ine synthase activity. Pseudouridylate synthase 
is an enzyme that catalyzes the conversion of uraci l and D-ribose 5-phosphate to 
pseudour id ine 5'-phosphate and H20 .  This enzyme belongs to the fam i ly of Iyases 
that participate in pyrimid ine metabol ism; an ind icator for the rate of DNA turnover 
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[30 1 ] . Despite not knowing exact ly how the PUSL 1 enzyme functions in adipose 
t issue, what we know so far about pyrim idine metabol ism is extremely excit ing . Al l  
PYrim id ine nucleotides are synthes ized de novo, main ly in the l iver. Pseudourid ine is 
an intermediate i n  the pyrimid ine synthesis pathway. Pseudouridy late synthase 
activity a l lows E. co l i  to grow in the presence of pseudouridine, with g rowth 
paral le l ing measured enzymic activity [302]. More exciting ly ,  pseudouridylate 
synthase is a catabol ite repressible enzyme [303] .  Catabol ite repression, usual ly 
observed in bacteria and other m icroorganisms, is  the inh ibit ion of synthesis of 
enzymes involved i n  catabol ism of carbon sources other  than the preferred one 
[304] . 
The above data can be corre lated to cachect ic patients whose ad ipose tissues is 
trying to repress catabol ism and as a compensatory mechanism , rather try ing to 
bui ld up the key bu i ld ing blocks of ad ipogenesis ( i .e .  ri bonucleic acid material or 
pyrim id ines) . With pyrimid ines being mostly synthesized in the l iver; it is not 
surprising that un l ike the atrophying l ivers of patients losing weight due to starvation, 
the l ivers of patients with cachexia become sign ificantly enlarged, probably due to 
overload.  
S i g n a l i n g  
L YPD 1 encodes for Ly6/PLAUR domain-conta in ing prote in 1 .  However, the 
understanding of th is prote in in the context of cachexia is hard since very l i tt le, i f  
any,  is  known a bout it .  L YPD1 part ia l  s i lencing results in a highly s ign ificant 
increase in overa l l  anchorage-independent g rowth in HeLaHF cel ls .  L YPD1  
overexpression reduced cel l  surv iva l  and anchorage-independent growth and 
induced higher levels of apoptosis in soft agar [305] . 
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L YPD1 IS associated with bannayan-ri ley-ruvalcaba syndrome, a rare overgrowth 
syndrome [306] . One of the predominant features of the syndrome is the occurrence 
of mult iple subcutaneous l ipomas [306, 307]. 
A n g iogenesis I n h i b itor 
BAI2  encodes for bra in-specific ang iogenesis i nh ibitor 2, a member of the adhesion­
G-prote in cou pled receptors (adhesion-GPCRs) fami ly of receptors [308].  BAI 2  and 
BAI 3  are simi lar to BAI 1 ,  have s imi lar  t issue specificities and structure and may also 
p lay a role in  angiogenesis [309].  BAI2  is dominantly expressed in  the bra in [31 0] . 
However, i ts funct ions are st i l l  unclear but it is suggested that BAI 2 is a funct ional 
GPCR regulated by proteolytic processing a nd activates the N FAT pathway [3 1 0] .  I t  
is  known that the nuclear factor of act ivated T ce l l  (NFAT) g roup of transcription 
factors contributes to g l ucose and insu l in  homeostasis [31 1 ] . Expression of NFATc2 
and N FATc4 is induced u pon adi pogenesis and in obese mice, whi le ablat ion of 
both N FATc2 and N FATc4 i ncreases insu l in  sensit ivity [3 1 1 ] . 
If BAI 2  u pregu lat ion is confi rmed to activate the NFAT pathway, th is suggests that 
such activation signa ls induced adipogenesis as an  adaptive response to the 
wasting triggers in  cachexia .  Also, upregulat ion of th is pathway cou ld  expla in ,  at 
least in part, by the i ncreased insu l in resistance in these patients. 
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5.4. 2 H ig h ly S i g n ifica ntly Downre g u l ated Genes i n  Cac hectic Adi pose 
Tissues 
5.4. 2 . 1  Res u lts 
Table 26. H igh ly Sign ificantly Downregulated Genes in Cachect ic Ad ipose Tissue . 
Gene Symbol Gene Full  N a me Fold Change P-Value 
Meta bolism 
CES1 L iver carboxylesterase 1 -5.65 0.0006 
NQ01 NAD(P)H dehydrogenase [qu inone) 1 -3.82 <0.0006 
T ra nscr iption Factor 
AFF3 AF4/FMR2 fam i ly member 3 -2.30 0.00003 
Ang iogenesis Inh ib itor 
T N M D  Tenomod ul in  - 1 5 .46 <0 .0007 
Uncharacterized 
LOC 1 00996634 Transmem brane protein FLJ 37396 -1 5 .24 0.0001 
TR IM 1 6L Tripartite motif conta in ing 1 6-l ike -2 .98 <0.0002 
5.4.2.2 Disc ussion 
M etabol ism 
CES 1 codes for the l iver carboxylesterase 1 enzyme. CES 1 is present in  most 
t issues with h igher levels in the liver [31 2] ,  and is h igh ly regu lated in adult adipose 
t issue [3 1 3], with h igher leve ls in  obese subjects and lower leve ls during weight loss 
[3 1 4] .  This enzyme hydrolyzes long-cha in fatty acid esters and th ioesters. CES 1 is 
an inducible seri ne esterase that hyd ro lyses many drugs (to activate or  inactivate 
them) and a nutrients, as wel l  as cholesterol esters, etc. C E S 1  cou ld be an 
i mportant player in metabol ism of triglycerides and cholesterol in adipocytes [31 5] . 
Thus,  C E S 1  is suggested to play a major role in  the trafficking of l ip ids and l ipid 
metabol ism in  hepatocytes and its upregu lat ion mediates adipocyte l ipolysis through 
the hydrolysis of cholesteryl  esters and trig lycerides [3 1 3] .  Studies correlated 
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increased expression to be a measure of adiposity and insul in resistance (wel l  here 
we have decreased adiposity but insul in resistance. 
Expression level of CES 1 in  adipose tissue was posit ively associated with body 
mass index, homeostasis model assessment- insu l in  res istance, and level of fasting 
g lucose, insu l in ,  and trig lycerides [31 5] .  In murine adipocytes,  CES3 was ident ified 
as a gene that increased l ip id storage [31 6] .  All of which are measures and/or 
triggers of adiposity. 
In vitro and in vivo studies suggested that inh ibit ion of CES1  could help treat type 2 
d iabetes [3 1 6] .  I n  murine models of d iabetes, a C ES3 inh ibitor protected an imals 
from weight ga in ,  decreased l iver l ipid accumu lat ion and increased insu l in  sensit ivity 
[3 1 6] .  C E S 1  activity was u pregulated in adipose t issue from patients with type 2 
d iabetes , compared with that i n  lean controls [3 1 6] ,  a nd also upregu lated in  obese 
chi ldren [3 1 3] .  
Hence, the h igh ly sign ificant ly downregu lated C E S 1  in  the ad ipose t issue of our 
cachect ic pat ients reflects the actual  weight losing state of our patients , and expla in 
the com pensatory state of ad ipose tissue to resist l i polysis and the state of insul in 
res istance. 
NQ01 codes for an NAD(P)H dehydrogenase [qu inone] 1 enzyme which is a 
member of fami ly of enzymes that prevents the one electron reduction and 
detoxification of qu inones and their derivatives that results in the production of 
rad ical species [31 7] . NQ0 1 has a h igh expression i n  human adipose tissue, 
part icu la rly in large adipocytes and is reduced by weight loss (sim i lar  to C ES 1 )  and 
also corre lates with ad iposity [3 1 8] .  
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NQ01 regulates the ubiqu it in- independent p53 degradation pathway through 
stabi l ization of p53. NQ01 downregu lation reduces p53 stab i l ity, leading to 
resistance to some drugs including chemotherapeutics. One important and exciting 
correlat ion is the increased hematotoxicity in  benzene-exposed workers in  Ch ina 
with a certa i n  NQP1 genotype isolated from bone marrow that  showed fa i lure to 
express NQ0 1 [3 1 9] NQ01 nu l l  mice exhib ited increased toxicity when 
admin istered menadione [320]. However, these mice exhibit s ign ificantly lower 
levels of abdomina l  adipose t issue, lower blood levels of g lucose, no change i n  
insu l in ,  and h igher levels of triglycerides, b-hydroxy butyrate , pyruvate , lactate, and 
g lucagon and insul in resistant as compared with wild-type mice [31 7] .  Also, the l iver 
g lycogen reserve was found to be decreased [31 7] .  A l l  of which data suggest that 
the loss of NQ0 1 causes a lterat ion in  the intrace l lu lar  redox activit ies leading to 
reduction in  pyrid ine nucleotide synthesis and reduced g lucose and fatty acid 
metabol ism result ing in  a sign ificant red uction in  the amount of abdominal  adipose 
tissue [3 1 7] .  I n  addit ion ,  the loss of NQ01 leads to the a lteration in l ip id deposit ion 
due to the decrease in  g luconeogenesis and fatty acid metabol ism [32 1 ] . 
NQ01 mutations are a lso found to be associated with tard ive dyskinesia (TO) an 
incurable form of dyskinesia; a d isorder result i ng in  involuntary ,  repetit ive, and 
tardive (slow or  belated onset) body movements [322] .  
Tra n s c ri ption Factor 
AFF3 is an AF4/FMR2 fami ly member 3 that encodes a t issue-restricted nuclear 
transcriptiona l  activator [323] that funct ions in lymphoid deve lopment and 
oncogenesis [324, 325] .  AFF3 is associated with kidney d isease in  d ia betics with 
type 1 [326] but not type 2 d iabetics [327]. 
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A n g i ogenesis I n h i b itor 
TNMD codes for tenomodu l in ,  a novel chondromodu l in- I  related gene. 
Chondromodul in- I  is  a cart i lage-specific g lycoprotein  that functions to stimulate 
chondrocyte g rowth and to inh ib it tube formation of endothel ia l  cel ls [328]. The 
TNMD transcript is found In hypovascular t issues such as tendons and l igaments 
and that is bel ieved to be an ang iogenesis inh ibitor [329]. TNMD is a lso expressed 
in both the ad ipocyte and stromal vascu lar fract ion of adipose t issue [330] . 
TNMD expression is decreased in  the adipose t issue of subjects who have lost 
weight and its expression level is  strongly correlated with body mass index [330] . 
Expression remained was also consistently remained downregulated after weight 
loss of subjects on a low-calorie d iet and after weight maintenance [33 1 ] . TNMD is 
associated the risk of developing d iabetes [332] ,  a l though this association is not yet 
wel l-understood . However, genetic variat ion of the TNMD gene is associated with 
serum leve ls of systemic immune mediators wh ich have a wel l -establ ished 
connect ion to obesity, metabolic syndrome, and type 2 d iabetes [333]. 
The potentia l  mechanisms that l i nks TNMD with the pathogenesis of obesity, 
d iabetes, and metabol ic syndromes a re yet to be confi rmed [330]. However, in  the 
context of our weight losing cachectic patients, TNM D downregu lat ion is perhaps 
expected . However, the 1 5-fo ld downregu lation is massive g iven the smal l  degree 
(5- 1 0%) weig ht loss. Thus, we be l ieve this dramatic downregu lat ion is important 
g iven the effect of weight loss, insu l i n  resistance ,  and the metabol ic syndrome of 
cachexia .  
5.5 Ant ic i pated Results from P rev ious Studies 
5 .5 .1  P rec l i n ica l  F i nd i ngs 
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Adipose depletion in cachexia is a funct ion of l ipolysis [334] .  Ad ipose tissue atrophy 
starts with the excessive hydrolysis of trig lycerides to free fatty acids and g lycerol 
that is then mobi l ized and released in the circu lation . The key enzymes cata lyzing 
this reaction are the hormone sensitive l ipase (L l PE) and ad ipose trig lyceride l ipase 
(PNPLA2) [335] Precl in ical stUdies showed that inh ibit ion of l ipolysis through 
genetic ablat ion of L l P E  or PNPLA2 amel iorates certa in features of murine model of 
cancer cachexia [336). Expressions of neither L lPE nor PNPLA2 were significantly 
a ltered in the present study. However, a d ifferent l ipid mobi l iz ing factor; zinc-a 
g lycoprotein 1 (AZG P 1 ) ,  has been prev iously shown to be involved in cachexia as a 
cl in ical finding [337) .  Expression of AZG P 1  was a lso increased in the present study 
but with only border l ine s ign ificance (Fold change 2 . 79 ,  P-va lue 0 .0576). 
Parathyroid hormone-re lated protein (PTHLH)  is a causative factor of hyperca lcemia 
in mal ignancy. A recent suggested hypothesis to cancer cachexia is that there is 
adipose t issue "browning" that resu lts i n  an increased in  energy  expenditure leading 
a nd greater thermogenesis [338) . In m urine model cancer cachexia ,  PTHLH induced 
the expression of genes i nvolved i n  thermogenesis in adipose t issues whi le blocking 
PTH LH blocked ad ipose tissue browning [339). The present study revea led no 
change in expression of either PTH LH or i ts associated receptor, PTH 1  R suggest ing 
that t issue browning theory that mediates thermogenesis and consequently an 
increase in energy  expenditure is not  the one of  the contribut ing factors in h uman 
subjects. 
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5.5.2 C l i n ic a l  F i n d i ngs 
I n  recent years ,  ad ipose t issue is been recognized to have major endocrine 
functions [340]. Several pro-inflammatory cytokines and hormones are be l ieved to 
be produced in  cancer cachexia patients, at least in part by the ad ipose t issue. 
Cytokines (TNF,  IL6, and I FNG) and hormones (such as lept in )  have been 
investigated in the context of cancer cachexia. Leptin is  the "satiety hormone" made 
by ad ipose cel ls that helps in the regulat ion of energy balance by suppressing 
appetite [255]. In obese i nd iv iduals ,  however, the body has a decreased sensit ivity 
to lept in  resu lt ing in an inab i l ity to detect satiety despite of the h igh energy stores 
[264]. C l in ical stud ies found that leptin levels are sign ificantly lower in cachectic 
patients [259, 261 , 34 1 ]  wh i le h igher levels of I L6 were associated with future 
deve lopment of cachexia [34 1 1 . 
The present study shows a sign ificant reduct ion in lept in  expression as expected 
(Fold change -3. 50, P-va lue 0 .0032) .  This suggests that lept in does not play an 
important role in  cancer cachexia development but  rather an  ind icator for deplet ing 
adipose stores in  these patients. On the other hand,  expression of I L6 was elevated 
but not statistica l ly s ign ificant. However, it is possible that I L6 expression is 
increased in  some but not al l  cachect ic cancer patients. 
5.6 Verified Resu lts U s i n g  Rea l -Time Revers e  T ranscri pt ion P C R  
Despite of  the  h igh  rel iance of the  quantitative capabi l ity of  the RNA sequencing 
resu lts ,  it is important to verify part of the expression resu lts using a different 
method. A cherry-picked selection of genes that are of a h igh s ign ificance and h ig h  
fo ld-change were picked .  Confirm ing t h e  d ifference of h i g h  fo ld-change expression 
data can a l low us to check and verify them later-on at protein leve l .  One upreg ulated 
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gene; CXCL 1 1 ,  and three downregu lated genes; TNMD, LEP, and LHCGR were 
confi rmed 
5 . 6 . 1  Resu lts 
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Figure 6 Upregu lat ion of Expression of Selected Genes Confirmed by Real-Time 
RT-PCR in  Cachectic Adipose Tissue. 
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Figure 7 :  Downregu lation of Expression of Selected Genes Confirmed by Real-Time 
RT-PCR in  Cachect ic Adipose Tissue. 
Al l  chosen genes that were previously shown to be upregu lated/downregulated were 
reproducible via real-time RT-PCR (F igure 6 and 7) .  
5.6 .2  D i scussion 
Expressions of one upregu lated gene;  CXCL 1 1  that is statistica l ly s ign ificant was 
confirmed via rea l-t ime RT-PCR .  
CXCL 1 1  codes for chemokine (C-X-C motif) l igand 1 1  prote in  (Table 22) .  I t  i s  a 
smal l  cytokine that belongs to the CXC chemokine fam i ly that is also cal led 
interferon-inducible T-cel l  alpha chemoattractant ( I -TAC) and I nterferon-gamma-
Inducible prote in  9 ( I P-9) [342] . Normal ly ,  expression of CXCL 1 1  in  m ice adipose 
t issue was found to be consistently very low [343] .  Adipose t issue macrophages 
(ATM) , which are t issue resident macrophages, are present in  adipose t issue. I t  was 
found that these ATMs are transiently recru ited to adipose t issue at t imes of acute 
weight loss [344, 345]. ATM was found to have a h igh leve l expression of CXCL 1 1  
[346]. So far, the right j ustificat ion of e levated levels of CXCL 1 1  in  ad ipose tissue is 
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not reached. However, we know that their expression level is  normal ly 
downregu lated. 
The confi rmed downregulated genes were TNMD, LEP ,  and LHCGR .  The TNMD 
(section 5 .4 .2 .2) is  an angiogeneic inh ibitor gene that codes for tenomodul in ;  a novel 
chondromodul in- I  re lated gene.  TNMD is expressed in both the adipocyte and 
stromal vascu lar fraction of ad ipose tissue [330] . TNMD expression is decreased in 
the adipose tissue of subjects who have lost weight and its expression level is 
strongly correlated with body mass index [330]. Expression remained was a lso 
consistent ly remained downregu lated after weight loss of subjects on a low-calorie 
diet and after weight maintenance [33 1 ] . TNMD is associated the risk of developing 
d iabetes [332] , a l though this associat ion is not yet wel l -understood. However, 
genetic variation of the TNMD gene is associated with serum levels of systemic 
immune mediators which have a wel l -establ ished connection to obesity, metabol ic 
syndrome, a nd type 2 d iabetes [333]. 
The potent ia l  mechanisms that l inks TNMD with the pathogenesis of obesity, 
d iabetes , and metabol ic syndromes a re yet to be confi rmed [330] . However, in  the 
context of our weight losing cachect ic patients , TNMD downregu lat ion is  perhaps 
expected . However, the 1 5-fo ld downregu lation is  massive given the small degree 
(5- 1 0%) weight loss. Thus, we bel ieve this dramatic downregulat ion is important 
g iven the effect of weight loss, insu l in  resistance, and the metabolic syndrome of 
cachexia .  
LEP (as d iscussed in  sect ion 5 .3 .2 .2 )  encodes for lept in ,  a "satiety hormone" that 
s ignals energy sufficiency and thereby inh ibits hunger. Leptin d iscovery was a 
breakthrough in 1 994. It is secreted from adipocytes in proportion to fat stores and 
acts on receptors in the hypotha lamus to regulate appetite [255]. Leptin suppresses 
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feed ing and decreases adiposity in  part by re lease of aMSH and cocaine and 
amphetamine related transcript that d i rect ly suppress a ppetite , in  part by inh ibit ing 
hypothalamic N PY synthesis and re lease, s ince NPY st imu lates appetite, and partly 
by inhib i t ing release of agouti-related pept ide that acts by blocking the act ion of 
aMSH at its receptor [256] . The regu lat ion of appetite is a complex process involving 
m ult iple hormones [257]. Hypotha lamus is the main appetite regulator in the body 
that senses external m ulti ple hormonal  stimu l i .  
Lept in decreases food intake by affect ing the balance between orexigenic and 
anorexigenic hypotha lamic pathways [258] . Low leptin increases appetite and body 
weight .  Crossta lk between leptin and inflammatory signa l ing known to be activated 
may be responsible for this paradox [258]. Many studies looked at the serum level of 
leptin in cancer patients. Cachectic esophageal cancer patients had decreased 
circulating lept in [259-262] .  
I nterest ingly ,  in vitro and in vivo, insu l in  p lays a major transcriptional activation that 
st imulates leptin c i rcu lation leve l [263] .  However, patients with cachexia do usua l ly  
have h igh insu l in  resistance wh ich does not elevate, at least in  our study, the 
adipocyte product ion of lept in .  This downregulat ion of leptin production i n  adipocyte 
does not seem to increase appetite in cancer  patient. This reflects that the 
deregulat ion of appetite and weight in  cachectic patient is a complex process. 
Lept in levels are low, as expected , s igna l i ng that there are NOT sufficient energy 
stores in  fat. However, th is is  not reflected in  the expected increase in a ppetite ! 
Paradoxica l ly ,  N PY expression in  the ARC is  decreased (you would expect it to be 
increased in  the absence of leptin signa l ing)  and that of POMC (source of aMSH)  
increased (you wou ld  expect it to  be decreased i n  absence of  lept in) .  There is  
speculation that  th is  is  a response to  GAD 1 5 in  the hypothalamus and GAD 1 5  
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expression was s ign ificantly i ncreased in cachectic muscle in  the present study 
[258]. 
Leptin level are negatively corre lated with the degree of cachexia [259]. Although 
reg ulation of fat stores is deemed to be the primary function of leptin, obese 
ind ividuals have a decreased sensit ivity to leptin occurs, resu lt ing in an inabi l ity to 
detect satiety despite h igh energy stores [264] . 
LHCGR (as d iscussed in section 5 . 3 .2 .2 )  codes for the lute in izing 
hormone/choriog onadotropin receptor protein .  LHCGR is  abundantly expressed in 
preadipocytes and mature adipocytes [265] .  I t  is studied the most in the gonads.  I n  
the  ovary, the  LHCGR is requ i red for fol l icu lar  maturation and  ovulat ion, as  wel l  as  
luteal funct ion u pon hormonal stim ulat ion [266]. Low levels of  the  receptor are 
repeatedly l inked to i nferti l i ty. 
Whi le the funct ion of th is receptor is uncharacterized in ad ipose t issue, we do 
bel ieve there is a strong corre lation between the downregu lat ion of that receptor and 
the depletion of fat stores .  Female ath letes one of the commonest examples of 
infert i l i ty caused by depletion of fat stores which both could be possibly due,  at least 
in part ,  to the downregu lat ion of the receptor in gonads and adipose t issue. 
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Chapter 6 :  Overlappin g  Genes i n  Skeletal Muscle and Adipose Tissue 
This chapter a ims at looking at the significantly altered gene expressions that are 
commonly altered i n  both;  muscle and adipose t issues. 
6 . 1  U p re g u l ated Ge nes 
6 . 1 . 1  Res u lts 
Table 27 :  Upregulated Overlapping Genes. 
Gene Gene Ful l  Name Muscle 
Symbol Fold P-Va lue 
chan�e 
ASS 1  Arg in inosuccinate Synthase 1 3 . 70 0.0064 
CLCN2 Ch loride Channel ,  Voltage- 9A8 0.0 1 63 
Sensitive 2 
PGAP3 Post-GPI Attachment To Proteins 2 .80 0. 0032 
3 
RPS 1 0  Ribosomal Protein S 1 0  4 .58 0. 0045 
SLC36A1 Solute Carrier Fami ly 36 4 .00 0. 0039 
(Proton/Amino Acid Symporter), 
Member 1 
TGM2 Transg lutam inase 2 2.20 0 .01 1 4  
6 . 1 . 2  Discussion 
Fat 
Fold P-
chanQe Value 
2. 1 4  0. 0323 
2 .29 0.0239 
2. 1 2  0.0066 
2 . 1 8  0.0256 
2 .07 0.0323 
2 A2 0.0244 
ASS 1 is an arg in inosuccinate synthase enzyme that catalyzes the penultimate step 
of the arg in ine biosynthetic pathway. Arg in ine is class ified as a semi-essent ia l  or 
cond it ional ly essent ia l  amino acid, depending on the developmental stage and 
health status of the i ndiv idual [347] .  Arg in ine biosynthesis is  on ly  needed in  
unhealthy indiv iduals because there are not  getting enoug h nutrit ional supply. I t  
serves many important roles such as cel l  d iv is ion, wound heal ing ,  ammonia 
metabol ism,  immune funct ion , and the re lease of hormones [347, 348] . The d i rect 
corre lat ion of arg in inosuccinate synthase funct ion in skeletal and ad ipose t issues in 
cachect ic ind iv iduals is  unknown . It can be stipulated that in both t issues (when 
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com bined, they constitute t h e  majority of human body mass),  cachexia i s  a huge 
insu lt requ i ring heal ing and repair (probably) ,  and defin itely replacement .  
On the other hand,  mutat ions in  the ASS 1 gene cause type I citru l l inemia because 
of alteration of an important step of the urea cycle [349] . I ndividuals with type I 
citru l l inemla develop symptoms when a lteration i n  the enzyme causes ammonia 
bui ld u p  in  the body. Hyperammonemia is s ign ificantly h igher  i n  termina l ly i l l  cancer 
pat ients [350] . Symptoms of hyperammonemia in  type I citru l l inemia includes lack of 
energy ( lethargy) ,  poor feeding , vomit ing, and others. Al l  of which are seen in 
cachexia.  Skeletal muscle plays a ro le in  ammonia detoxificat ion .  Ammonia is also 
known to stimu late the hypothalamic satiety centers which suppress appetite and 
lead to cachexia [35 1 ] . General ly ,  L-arg in ine  reduces adiposity, increase muscle 
mass, and improve the metabol ic profi le in animals and humans [352]. All of which 
are important adaptive requ i rement in  cachectic patients. 
CLCN2 codes for ch loride channel  protein 2 that is one of 1 3  members in  the 
ch loride channel superfami ly  of poorly understood ion channels that are impl icated 
in many cel lu lar  processes .  Ch loride channels in skeletal muscle play a role in 
setting and restoring the resting membrane potentia l ,  thus prevent ing muscle 
stiffness or myotonia [353]. M utations in the h uman skeleta l muscle chloride channel 
a re associated with dominant and recessive congenital  myotonia [353]. Wh i le such a 
role is clearly correlated to m uscle regulation ,  the reason of the upregu lation in  
adipose t issue is yet to be understood . 
PGAP3 codes for post-GP I  attachment to proteins 3 that encodes a 
g lycophosphatidyl inositol (GPI )-specific phosphol ipase A2 that is expressed i n  the 
Golg i  apparatus. The enzyme is involved in  fatty acid GPI remodel i ng that is critical 
for proper association between GPI -anchored prote ins and l ipid rafts [354] . I n  
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muscle m utation in PGAP3 causes muscular hypotonia [354] . PGAP3 is 
responsible for the modification of the fatty acid residues on the GPI anchor in a 
maturat ion process that occurs i n  the endoplasmic reticu lum and Golgi [354] .  
RPS 1 0  is another important gene in the cachect ic organs that is l ike ly to be involved 
in the adapt ive responses to the forces of wasting.  RPS 1 0  codes for the 40S 
nbosomal  protein S 1 0  that is one of the two subunits making the ribosomes; the 
organel les that catalyze protein synthesis [355]. Also, RPS 1 0  expressed sequence 
tags were isolated from the skeletal muscle of neonatal healthy and splay leg pig lets 
[356] . It belongs to the S 1 OE fami ly  of ribosomal prote ins.  RPS 1 0  expression was 
reduced in brown adipose t issue of h ibernating arctic ground squ i rrels compared to 
m ice [357] .  H ibernation is  an energy-saving strategy adopted by a wide range of 
mammals to survive h igh ly seasonal  or unpred ictable environments. 
SLC36A 1 codes for a solute carrier fami ly  36 (a  proton-coupled amino acid 
transporter (PAT 1 ) prote in ,  that mediates symport of protons and small neutral 
amino acids. This carrier has a role i n  absorption of amino acids from luminal prote in 
digestion of the brush border membrane driving transport of amino acids into the 
cytosol (presumably in the g ut during absorpt ion) [358] . These amino acids ,  in turn, 
activate mTORC 1 ,  and subsequently st imulate protein synthesis and consequently 
skeletal muscle growth [359]. S LC36A 1 expression was increased fo l lowing 
res istance exercise in  young and older men [359] .  Also, fol lowing a single bout of 
h igh-intensity resistance exercise, SLC36A 1 expression increased amongst many 
other skeletal muscle amino acid transporters in both healthy men and women, 
independent of age [360] .  SLC36A 1 is yet to be characterized in adipose tissue.  
TGM2 codes for t issue transg lutam inase, a calc ium dependent enzyme of the 
protein-glutamine y-g lutamyltransferases fami ly [36 1 ] . I t  cross- l inks prote ins 
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between a lys ine residue and a g lutamine residue, creating an inter- or 
Intramolecu lar bond that is h igh ly resistant to proteolysis [362]. What prote ins get 
cross- l i nked and the consequence of that cross- l ink ing in the context of cachexia is 
yet to be investigated . TGM2 -/- and F 1 3a 1 -/- double nu l l  mice showed no loss of 
bone mass and maintained normal bone minera l density to 1 2  months age. Bone 
marrow adipocity showed large increases in  both fat percent (+70 . 7%) and 
adipocyte numbers (+65%) suggesting that TG2 and FXI I IA might regu late an 
osteoblast-adipocyte switch via fi bronect in matrix stabi l izat ion [363, 364] .  
TGM2 is downregulated in  bone marrow in  response to age as it was found to 
enhance cel l  g rowth and survival through anti-apoptosis s ignal ing which is usual ly 
downregu lated during aging [365] .  TGM2 was one of severa l genes that have higher 
expression in  human brown adipose tissues compared to white adipose t issues 
[366] . 
6 . 2  Dow n regu lated Genes 
6 . 2 . 1  Resu lts 
Table 28: Downregu lated Overlapping Genes. 
Gene Gene Full  Name M uscle 
Symbol Fold p-
change Value 
ACOO7246. 3  Antisense U ncharacterized -2 .98 0.0 1 66 
LOC728730 
GPL01  Glycosylphosphatidyl i nositol -6.27  0.0 1 72 
Specific Phospholipase 0 1  
GSTT1 Glutathione S-Transferase Theta 1 -2.73 0.0 1 08 
LOC283731 U ncharacterized LOC28373 1  - 1 3.65 0.0006 
PPP1 R9A Prote in  Phosphatase 1 ,  Regulatory -2.62 0.0052 
Subuni t  9A 
SYNM Synemin ,  I ntermediate Fi lament -2 .26 0 .01 26 
Protein 
Fat 
Fold p-
change Value 
-2.23 0. 0 1 9  
-2 .22 0.0 1 2  
-3.40 0 .046 
-4 .04 0 .045 
-2. 04 0. 022 
-2 .26 0.035 
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6 .2 .2  Disc ussion 
GPLD1 codes for phosphatidy l inositol-g lycan-specific phospholipase 01 
enzyme[367]. Many proteins at  the extrace l lu lar p lasma membranes are attached 
via a g lycosylphosphatidyl inositol (GP I )  anchor. GPLD1 is a GP I  degrading enzyme 
that hydrolyzes the inositol phosphate l inkage in  proteins a nchored by GPI thereby 
a l lowing release of the attached prote i n  [368]. I n  vitro, GPLD1  overexpression is 
associated with i ncreased expression of de novo l ipogenesis genes [369] . Also, 
insu l in resistance in  h uman subjects was found to be associated with increased 
serum levels of GPLD1  which is a lso involved in l ipid metabol ism (trig lyceride 
metabol ism) [370). It could be,  therefore, a gene that is downregu lated in  cachectic 
muscle and adipose tissue as a compensation for the presence of insu l in resistance. 
Despite this evidence, the ro le of the gene in  muscle has not yet been invest igated . 
GSTI1 codes for g lutath ione S-transferase theta- 1 ,  that is a member of a 
superfamily of e nzymes that cata lyze the conj ugat ion of reduced g lutathione. 
G lutathione exists in  both reduced (GSH) and oxid ized (GSSG) states .  In healthy 
states, the majori ty of g lutathione a re in  the reduced form (GSH) .  The ratio of 
oxid ized-to-reduced (GSSG-to-GSH)  is considered ind icative of oxidative stress 
[37 1 ] . GSTI1 funct ions on the reduced g l utath ione. GSTI1 is expressed in both,  
muscle [372] and ad ipose t issue [373] .  
Fat deposit ion was investigated i n  fat vs.  lean chicken. GSTI 1  was found to be one 
of the d ifferent ia l ly  u pregu lated genes i n  ad ipose t issue of fat ch icken [374] . 
GSTI1 was found to co-vary with N NAT expression in  m u rine fed h igh fat diet wh ite 
adipose t issue [373] .  N NAT is an acute d iet-responsive gene in white adipose t issue 
and hypothalamus;  it may play an  important role in metabol ism, adipogenesis, and 
resolut ion of oxidat ive stress and inflammat ion in  response to d ietary excess [373] . 
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Thus, th is decreased expression of GSTT1 in  the  skeleta l muscle and  adipose 
tissues of cachectic subject could reflect red uced cel lu lar  abi l ity to manage free 
rad icals and consequently altering ce l lu lar  functions. 
PPP1  R9A codes for prote in  phosphatase 1 ,  regulatory subunit 9A. The PPP1 R9A 
protein I S  I nvolved in actin cytoske leton dynamics and in synapt ic formation and 
function [375, 376]. PPP1  R9A is also imprinted main ly in  skeletal muscle [376]. It is 
found to be h igh ly concentrated in  the synapses of developed neurons [377] .  I t  is 
suggested that downregulat ion of PPP1  R9A and other genes is an evidence that 
deficiencies in cytoskeletal dynamics play a role in  H untington's disease 
pathogenesis [378]. PPP1  R9A was one of many expressed genes that were stably 
reta ined in H9-hESCs cel l  l ine throughout d ifferentiation [379]. 
SYN M (synemin or  desmusl in)  codes for an intermediate fi lament ( IF )  protein  [380] . 
I Fs function by integrating mechanical stress and mainta in structural integrity in  
eukaryotic cel ls .  Diseases involving Ifs have defects i n  the organ ization of  the 
contract i le apparatus of  skeletal and cardiac muscle [38 1 ] . SYNM was main ly 
studied i n  the sarcomere of skeleta l myocytes [380] . I t  l ocal izes at the Z-d isk and 
has been shown to act as a mechan ica l  l i nker, transmitt ing force lateral ly throughout 
the t issue, especia l ly  between the contracti le myofibri ls and extracel lu lar  matrix 
[380] Synemin is expressed main ly  in  heart and skeleta l muscle [380] . 
Synemin knockout m ice have a mi ld  skeletal muscle phenotype, characterized by 
decreased fiber size and increased sarcolemmal deform a bi l ity a nd suscept ibi l ity  to 
inju ry [38 1 ] . On the other hand,  a bnormal accumulat ions of synemin  and desmin i n  
m uscle fibres was seen in mu lt ip le myopathies [382]. Other study on synemin 
knockout mice showed a h igher hypertrophic capacity with increased maximal  force 
and fat igue res istance fol lowing mechanical overload, compared with control m ice 
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[383]. Molecularly, th is I ncreased remodel ing capacity was accompanied by the 
decreased express ion of myostatin and atrog in  expression.  and increased fo l l istatin 
expression [383]. 
Knockdown of synemi n  expression with s iRNAs within mammal ian cel ls  resulted in 
sign ificantly compromised cel l  adhesion and cel l  moti l ity. suggesting a possib le role 
of synemin as a focal adhesion molecule that is essentia l  for cell adhesion and 
migration [384] . 
Synemin upregulat ion or  downregu lat ion has marked effects on skeletal muscle .  I n  
cachectic patients. t h e  downregu lation of expression of th is gene m a y  have put the 
muscle under higher suscept ib i l ity for inj u ry whi le decreasing the f iber size and 
contributing to the wast ing phenotype .  However. so far. no data is avai lable about 
the ro le of synemin i n  adipose t issue. 
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Chapter 7 :  Overal l  Discussion 
Cancer cachexia is a mu lt ifactorial syndrome that is responsible for at least one-th ird 
of cancer-related death worldwide and contributes to the death of many others. 
More than 80% of cancer patients are cachectic towards the end of l ife. Despite 
intensive research, the mechanisms of cancer cachexia are sti l i  poorly understood 
and its mult i-faceted etiopathogenesis has never been thoroughly reflected on in a 
s ingle set of experiments. /n vitro and in vivo experimentat ion,  so fa r, has not led to 
any leap in our understanding of cachexia ,  s ince no model is able to recapitu late the 
whole spectrum of the cancer  cachexia syndrome. In addit ion, the few conducted 
cl in ical studies using m icroarray had neither g iven us good insight,  nor were 
reproducib le .  
I t  is our bel ieve that identification of early changes in gene expression in cachexia 
target tissues (muscle and adipose tissue) wi l i  lead to an improved u nderstanding of 
the mechanisms that trigger this important problem in cancer patients. Next 
generat ion sequencing is the state-of-the-art technique to generate h igh throughput, 
high qua l ity results. This technique has proven to be much more powerfu l and 
d iscrim inatory than microarray and is now considered to be the state-of-the-art .  
The decisions to include a l i of  the cachectic and non-cachect ic cancer pat ients was 
made solely based on body weight changes in the past 3-6 months and by 
meticulous exclusion of samples that m ight have reflected any etiogenesis that 
could contribute/aggravate cachexia ( i . e .  ma lnutrit ion ,  muscu lar/endocrine/other 
metabol ic d iseases, etc . ) .  The cachectic and the weight-stable group showed no 
sign ificant differences in any of the measured biochemical parameters. The 
Glasgow prognostic score , which is suggested to be a measure for d iagnosing and a 
gu ide for treatment of cachexia, fa i led to d istingu ish a signature d ifference in the 
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cachectic g roup.  It contrast it revealed more advance scores in  non-cachectic 
controls However, our small sam ple size cannot fu l ly refute the possibi l ity of that 
measure to predict cachexia if a pp l ied on a larger sca le of samples. Yet, we bel ieve 
it may not be the method of choice for looking at early stages of cachexia.  
7 . 1  C ha n ges i n  G e n e  E x p ression i n  S keleta l M uscle 
Genes whose expression changed in cachectic m uscles reflect of a large spectrum 
of genes encod ing skeleta l muscle structura l  prote ins ,  proteins in the muscle 
contract i le machinery, energy metabol ism, and others. 
Several skeletal muscle prote ins in the basement membrane were upregulated, 
namely agrin , perlecan ,  co l lagen,  lamin in ,  and neurexin (F igure 8) .  Agrin is required 
for the organ ization of the cytoskeleton and amel iorat ion of function in d iseased 
muscle [385] ; perlecan is important in mainta in ing muscu lar integrity [386] ; col lagen 
and lamin in  are u pregu lated during endurance tra in ing [387]. On the other hand, 
many genes encoding tra nsmembrane and intrace l lu lar  m uscular structura l  prote ins 
were downreguated , such asintegr ins,  sarcospan,  e lements of sarcog lycan com plex, 
myot i l in ,  desmin ,  t it in ,  and a-catin i n .  Col lectively, the funct ions of the upregu lated 
genes in the basement membrane of myocyte reflect a defensive adapt ive protective 
response to ma intain muscular homeostasis which is possibly triggered by the down 
regulat ion of essential interace l lu lar  proteins.  
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Figure 8 :  Skeletal Muscle Extrace l lu lar  Matrix and Structura l  Muscle Prote ins .  
I tems circled in  red are upregulated ; items circled in  b lue are downregu lated . 
Amended from [388]. 
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I n  add It Ion , Integnns, t it in [389], and tropomysin [390] , which were also 
downregulated, are essentia l  component in  the contract i le machinery (Figure 9) .  
Normal ly ,  an  action potent ia l  causes skeletal muscle to depolarize opening the 
voltage-gated L-type calcium channels (two subun its of which are downreguated) .  
ThIS increases intrace l lu lar  calci um causing it to bind to calmodu l in ,  wh ich in turn 
activates myosIn l ight cha in  k inase (MLCK) (both of which are downregu lated) .  
MLCK then phosphorylates the regu latory l ight cha ins of the myosin heads leading 
to a cascade of events that causes muscle contract ion (F igure 1 0) .  Both ,  the 
s Ignal ing cascade and the structu ral response machinery are a ltered in the muscle 
of our cachectic patients. Another interest ing change in expression was seen in 
genes involved in the cytoskeleton and myofibers . This ind icates that morphological 
changes can be also evident in  cachectic muscles before/during the cachectic 
changes. Expressions of genes impl icated in ce l lu lar  t rafficking were a lso affected .  
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Figure 9 :  Muscu lar  Contract i le Machinery .  
I tems circled in  b lue are downregu lated. Amended from [39 1 ] .  
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Figure 1 0 : Molecular Signal ing in Muscular  contraction .  
I tems circled in b lue are downregulated .  Amended from [392] .  
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Glycogen IS an  immed iate reserve source of energy for skeleta l muscle. Many 
d isorders of g lycogen metabol ism (as mentioned above) result in  muscular 
phenotypes. Many genes encoding prote ins or  prote in subunits that are necessary 
components I n  the machinery needed for g lycogen metabol ism were downregu lated 
in the cachectic muscles (F igure 1 1 ) .  The involved genes are necessary for either 
the in it iation or progression of g lycogenesis (e .g .  PGM 1 ;  encoding phosphomutase, 
protein  hosphatase; PPP1 R3A, PPP1  R3B,  and PPP1 R3C; necessary for act ivation 
of g lycogen synthase, and AGL; encod ing g lycogen branching enzyme),  or 
g lycogenolysis (Phosphorylase kinase; PHKA 1 ,  PHKB,  PHKG 1 ;  necessary for 
activation of g lycogen phosphorylase) (F igure 1 1 ) .  Ath letes experiencing a 
phenomenon cal led "h itt ing the wal l " ,  which is caused by depletion of g lycogen 
stores [393], often experience sudden fat igue and loss of energy [394] ; two 
symptoms repeatedly reported by cachectic patients. Such a lteration i n  the g lycogen 
turnover in  cachect ic patients l im its energy ava i lab i l ity and redirects muscle cel ls to 
energy from other sources,  such as fat and protein catabol ism.  
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Aerobic cel lu lar  respiration is responsible for the most efficient energy production in  
ce l ls[396] I nterest ingly in  our fi nd ings,  the machinery responsible for that process 
was found to be downregu lation at many levels .  Norma l ly. aerobic respiration is 
In it iated by g lycolysis leading to the production of pyruvate . Pyruvate is then 
converted i nto acetyl-CoA via a 3-step sequence of enzymatic activit ies mediated by 
"pyruvate dehydrogenase complex". Dihydrol ipoyl dehydrogenase (E3) enzyme that 
is responsible for the last step of the process was found to be downregulated. 
Acetyl-CoA should then be used in the "citric acid cycle" to generating 
NADH(nlcot inamide adenine d inucleotide) [ 1 59] .  Three enzymes (dihydrol ipoyl 
succinyltransferase, succinyl-CoA synthetase, and succinate dehydrogenase) in  th is 
mu ltistep process were found to be downregu lated. NADH can fina l ly enters the 
oxidative phosphory lat ion via the e lectron transport pathway [ 1 59], which is itse lf 
has several downregulated genes in its 5 d ifferent complexes (Complex I :  NDUFB5 
and NDUFS 1 ;  com plex I I :  SDHC; complex I I I :  CYCS and UQCRC2;  complex IV: 
COX20; and complex V: A TP5B) .  
Our evidence of the d isru pted aerobic cel lu lar  respiration and the c l in ical evidence of 
an  increased lactate product ion in muscle of cachectic patients [397] , is suggestive 
of the possible domination of the anaerobic respirat ion .  This process occurs in 
an i ma l ce l ls under hypoxic (or partia l ly anaerobic) cond it ions in oxygen starved 
muscles I n  cachectic patients, hypoxic condit ions might not be the d irect cause for 
such switch but rather the slowed aerobic respiration process with increasing 
demands of muscles for energy product ion.  I n  many t issues, th is is a cel lu lar  last 
resort for energy that most an ima l  t issue cannot tolerate for an extended period of 
t ime.  I t  is an energy wasting process that requ i res lactate to be recycled back into 
g lucose by the l iver. The production of lactate via g lycolysis as a source of energy 
and the fol lowed recycl ing results in  a net loss of 4 ATP molecules which could be 
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the d i rect cause of cachexia due to an  increasing demand of t issue catabolism to 
meet the requ i red demand of energy (F igure 1 2) .  
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Figure 1 2 : Liver Lactate Recycl ing and Net ATP Production . 
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The pentose-phosphate pathway is a paral le l  pathway to g lycolysis [398] . The 
reaction sequences of central metabol ism,  g lycolysis and the pentose phosphate 
pathway provide essential precursors for nucleic acids, amino acids and l i pids [398] . 
The upregulation of th is pathway (F igure 1 3) is one finding in  th is study that reflects 
adaptation or compensatory muscu lar  changes. We a lso found upregulat ion of 
genes Involved in skeleta l muscle prol iferat ion, differentiat ion ,  and regeneration.  We 
bel ieve that increased expression of these genes reflects a compensatory 
mechanism that is attem pt ing to ma intain muscular homeostas is .  These above 
mechanisms requ i re adequate and strong cel l-cel l  contacts which were ev ident with 
the upregulat ion of many ce l l  adhesion molecules and extracel lu lar matrix pathway 
genes. 
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Figure 1 3: Pentose Phosphate Pathway. 
Items circled in  red are upregulated .  Amended from [399] . 
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Symptoms of cachexia were a lso reflected in changes in gene expression. 
Weakness and easi ly fat igabi l ity may also be expla ined by changes in expression of 
mult iple genes Impl icated in maintenance of muscu lar tone, and contracti le 
machinery .  In addit ion , many of the downregulated genes have a documented 
evidence of genetica l ly inherited muscular a i lments which are known to affect 
muscular  tonicity and contract i le abi l ity. Also, expression of mu lt iple genes that are 
impl icated in Insu l in resistance, a key feature of cachexia, were sign ificantly a ltered . 
The major  degradation machinery (the ubiqu it ination pathway) was surpris ingly 
downreg ulated with reduction in  expression of mult ip le genes and at various 
different levels .  The ubiqu it in system has been repeatedly impl icated in the 
precl in ical models as the major mechanisms leading to wasting in many in vitro and 
in vivo experiments. Al l  c l in ical studies have fa i led to reproduce any upregu lation of 
th is degradation system in human skeletal muscle biopsies. However, amongst 
other ground breaking changes in the signature of the cachexia ,  the present study is 
the fi rst to show that the pathway is actual ly sign ificantly downregu lated , perhaps in 
com pensation for the wasting triggers. This gave us a reassurance and evidence 
that our  samples represent true early cachect ic changes that are subject to bodi ly 
defensive com pensatory mechanisms attem pting to maintain homeostasis. 
None of the i nflammatory or tumor specific factors were s ignificantly a ltered . For 
example, no transcripts for the dermicid in gene, which .conta ins the sequence that 
codes for the backbone peptide of proteolys is- inducing factor, were detected . 
Although of course their expression in the tumors themselves may wel l  be altered . 
Furthermore , the genes encoding inflammatory cytokines and their major  receptors 
were not found to be sign ificantly a ltered . I n  contrast, inflammation is a d i rect cause 
for cachexia in condit ions such as sepsis, severe trauma,  or burns. But cancer 
1 3 1  
cachexia has a slower progression phenotype and may be med iated by 
Inflammatory cytokines, at least in part, in its advanced stages. 
The myostatin pathway is at the top of the research agenda for cachexia 
researchers Many an imal  studies strongly correlated its upregu lation to the 
pathogenesis of wasti ng .  However, expression of myostatin in  our study was 
s ign ificantly decreased as was its receptor, possibly reflect ing end organ adaptation 
to tumor produced myostati n .  
One un ique and  Interest ing gene is T I E 1 .  Expression of  th is gene was s ign ificantly 
Increased in a previous human microarray study and was a lso upregulated in  the 
present study. The T I E 1  gene is not wel l  characterized,  however, its upregu lation in 
two separate genome-wide expression studies certain ly  warrants further attent ion. 
7 . 2  C ha n g es i n  G e n e  Express i o n  i n  A d i pose Tissue 
Since cachexia is predominant ly associated wi th skeleta l muscle changes, changes 
in  adipose tissue have received much less attent ion with regard to the pathogenesis 
of cachexia . Many of the genes impl icated to be involved from the resu lts of the 
present study are either uncharacterized or have not been previously studied in 
adipose t issue. However, several of these encode metabol ic enzymes and 
receptors. 
Expression of leptin was downregu lated as expected from many previous studies. 
This is  ind icative of depleted fat stores and should result  i n  increased feed ing 
(F igure 1 4) .  However, as has been d iscussed the hypothalamus does not respond 
normal ly to decreased leptin in the cachect ic state. S im i lar  to leptin ,  tenomodu l in  
downregu lation is a lso reflective of  fat depletion [330] and fu rther support the 
involvement of fat wast ing In  the cachect ic process. 
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Expression of  z lnc-a-2-g lycoprote in ( l ipid mobi l iz ing factor) was sign ificantly 
upregulated as expected . On the other hand,  the expression of other genes 
previously Impl icated with cachexia ,  such as hormone sensitive l ipase and adipose 
tissue trig lyceride l ipase, were unchanged. 
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Figure 1 4 : Lept in Product ion and its Function in  the Central Nervous System .  
Amended from [400]. 
Expression of genes that are involved in ad ipogenesis and impl icated in insu l in  
resistance were also upregulated .  On the other hand,  expression of genes that 
resist l ipolyt ic forces were also u pregu lated, perhaps in  an attempt to neutra l ize the 
cachect ic state . With the except ion of lept in ,  there were no changes in expression of 
any genes previously impl icated impl icated in cachexia, from either c l in ica l or 
precl in ica l  studies, that were reproduced in  our  the present study on adipose t issue. 
7 . 3  C ha nges i n  G e n e  E x p ress i o n  i n  Bot h ;  M uscle a n d  Ad i pose Tissue 
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With two large organs in  the body,  there must be a cross-ta lk mediating the 
compensation or decompensation s ignals lead ing to wast ing .  Several a ltered genes 
were found to be common between these two t issues. Many of these genes are yet 
to be characterized wh i le others need to be investigated at the context of the 
pathogenesis of cachexia .  
7.4 C o n c l u s i o n  
Progress in  cancer cachexia research was,  up t i l l  now, he ld  back with poor progress 
due to the lack of re l iab le and representative sample that serve as a "point of 
reference" or a benchmark for future research .  Cancer  cachexia research cont inuum 
have either worked in  iso lated in vitro and in vivo models which outcomes rare ly  
been a true reflect ion of  what is seen in  the c l in ic .  I n  addit ion, studies conducted on 
cl in ical sam ples d idn't feed enough data reflect ing the t rue complexity of  the cl in ica l  
presentation .  
Our enthusiasm took us back to the c l in ic  to extract a mean ingfu l representative 
sample from cachect ic cancer patients exhibit ing early cachectic changes. We were 
able for the first t ime to reflect on the big p icture of the pathological changes in the 
two major organs affected by cachexia ( i . e .  m uscle and fat) .  This was achieved by 
combinat ion of factors that starts by looking at expression changes in  early stages of 
cachexia using s imple diagnostic criteria ,  bu i ld ing on  previous array studies where 
we learnt from their  l im itat ions, and fina l ly by ut i l iz ing the state-of-the-art technology 
for generating the h ighest qua l ity data . These stUdies confirmed that for a 
m ult ifactoria l  condit ion ,  genome wide transcriptome analysis is the method of choice 
to explore the d isease complexity. They expla in  some documented evidence i n  
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cachexia pathogenesIs, h igh l ight ambiguous data from an imal  models, and reveal 
unexpected changes in  gene expression that underl ie the pathophysiology of the 
cachectic state in  cancer. These resu lts bring rel iable,  representable ,  and consistent 
data from the c l in ic and back to the bench with more focused insights to be 
investigated and verified. 
Chapter 8 :  Limitations and Future Directions 
8 . 1  L i mitations 
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We were l ucky that couple of genome-wide array studies have been publ ished 
dUring the time we were col lecting our samples. We build part of our success by 
starting at where they have ended. However, no study is l im itation free. Due to 
feasib i l ity issues (t ime and accrual  rate) ,  the study cou ldn 't further restrict its 
inclusion criteria further ( i .e .  same age group ,  gender, d iagnoses, etc). This may 
have In  part question the homogeneity of samples. H owever, we don't bel ieve it is a 
major influence in the major target organ ( i .e .  skeletal muscle) as was evident i n  the 
m uscle heat map.  Functional  assessment of subjects was not a l l  done.  For example, 
none of the subjects were anorexic or malnourished at the t ime of obta in ing 
samples. On the other hand, other phenotypes (or symptoms) known to accompany 
cachexia were not assessed (e.g. weakness and fatigabi l ity) . Patients were 
general ly with good performance status. Thus, we bel ieve that such symptoms are 
on ly clear ly evident with advanced cachexia .  Our  data documented the i nvo lvement 
of many related genes which is a prerequ isite to an evident funct ional impa i rment .  
We were also not able to val idate the data for al l  the d ifferentia l ly  expressed genes. 
I t  wou ld have been wise if a larger separate g roup of samples is col lected and to get 
the data cross-va l idated , however, due to slow accrual rate, we restricted our 
findings to what in  hand.  
8.2 Future D i rections 
Sample col lection wi l l  continue using the same s imple criteria to identify cachectic 
patients in c l in ic using meticulous fol low-up a nd recording of weight changes to 
diagnose patients with cancer cachexia and separate them from non-cachectic 
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weight-stable controls .  After th is logical presentation of the complexity of cachexia 
pathogenesis, the second best step is to be able to verify these changes on a 
different and larger g roup of patients. Also, a l l  reproducible changes should be 
confirmed at prote in leve l using western blott ing and immunohistochemistry .  
Changes In m uscular morphology are also wort h  being investigated via electron 
microscopy. 
In future studies, we would measure circulating factors where changes were seen in 
the present study, including inflammatory cytokines, GAD 1 5 , leptin, mysotat in,  
proteolysis inducing factor, l ipid mobi l iz ing factor, etc. 
F inal ly ,  it would be hard to completely characterize the role of all of these factors in 
the development of cachexia un less we succeed in developing a re l iab le animal  
model  that tru ly reflects cachexia presentation in humans .  
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